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Disease-regulated local gene therapy for rheumatoid arthritis
Een uitgave over ziekte-gereguleerde lokale 
gentherapie voor reumatoïde artritis.
De dokter van binnenuit
De grote nadelen van de nieuwste generatie 
geneesmiddelen tegen reumatoïde artritis, 
zogenaamde biologicals, zijn een verhoog­
de kans op infectieziekten en hoge kosten.
Een langdurige en afgestemde lokale productie van 
biologicals in het ontstoken gewricht lijkt een goed 
alternatief om deze nadelen te ondervangen.
Gentherapie, het inbrengen van therapeutisch genetisch 
materiaal in cellen van de patiënt, heeft zich ontwikkeld 
tot een werkzame methode om dit doel te bereiken. 
In het ideale geval wordt de biological bovendien ge­
produceerd naar gelang de behoefte van het ont­
stoken gewricht en functioneert de virale vector zo als de 
"doktervan binnenuit"door te diagnoseren en daarop ge­
baseerd de gentherapeutische behandeling te doseren.
In dit proefschrift beschrijven we de ontwikkeling 
en toepassing van biologische sensoren bestaande 
uit gen promoters, welke gevoelig zijn voor 
gewrichtsontsteking. Ontstekingsgevoelige promoters 
werden geselecteerd met behulp van een muis- 
model van reuma. Deze bleken vervolgens, 
wanneer ingebracht in cellen van een muizenknie, 
aangezet te worden tijdens ontsteking en de sterkte 
bleek zelfs afhankelijk van de mate van ontsteking. 
Toepassing van deze ziekte-gereguleerde gentherapie 
in muizen bleek uiteindelijk net zo effectief, echter veel 
veiliger dan onafgestemde, continue productie.
De "dokter van binnenuit" zou in de nabije toekomst toe­
gepast kunnen worden voor gentherapeutische diag­
nostiek en behandeling van reuma.
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1. General introduction
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints and mainly 
targets the joint capsule, articular cartilage and bone. Key features of the disease include 
autoimmunity, chronic inflammation and connective tissue destruction. RA affects approximately 
1% of the adult population worldwide and is associated with an increased mortality [1]. While 
the exact etiology remains to be elucidated, several genetic loci and environmental factors have 
been associated with disease susceptibility and severity. Genome-wide association studies 
have identified at least 31 RA risk alleles of which many, i.e. HLA-DR1, PTPN22, CTLA-4 and STAT4, 
are related to immune system function [2]. Environmental susceptibility factors linked to RA 
include smoking and several infectious microorganisms such as bacteria and viruses [3]. Current 
treatments for RA aim at alleviating disease symptoms and halting its progression. Standard 
therapies include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic 
drugs, glucocorticoids and biologicals.
RA pathogenesis involves a complex interplay of various cell types of the immune system 
and resident cells of the joint [4-10] (Figure 1). After the clinical onset of disease the synovial 
membrane, consisting of synovial fibroblasts and macrophages, becomes hyperplastic and is 
infiltrated by immune cells such as monocytes, T- and B-cells, dendritic cells and neutrophils. 
Joint inflammation induces the release of pro-inflammatory mediators which promote cartilage 
destruction and bone erosion mediated by the activities of synovial fibroblasts, osteoclasts, and 
chondrocytes. The immune and destructive processes that take place in the rheumatic joint 
are governed by a complex and hierarchical network of cytokines, chemokines and proteolytic 
enzymes. In this vast network, interleukin (IL)-1 and tumor necrosis factor (TNF) have originally 
been identified as crucial mediators of RA pathogenesis in humans [11,12]. Extensive studies in 
experimental arthritis using TNF-/IL-1-deficient mice or blocking agents, such as antibodies and 
soluble receptors, have confirmed the pivotal roles of TNF and IL-1 in joint inflammation and 
destruction, respectively [13-19]. More importantly, these studies have revealed the therapeutic 
potential of TNF and IL-1 targeting for treatment of RA. Currently, TNF, IL-1 or IL-6 blockers are 
being applied as biologicals, while targeting alternative cytokines (e.g. IL-17) continues to be 
investigated in animal models and clinical trials [20]. Blocking TNFa using antibodies or soluble 
receptors represents the standard biological therapy for RA and shows efficacy in approximately 
seventy percent of the patients.
However, despite its efficacy systemic anti-TNF treatment suffers from several disadvantages. 
First and most prominently, the percentage of patients that fulfills more than seventy percent 
improvement of disease parameters (ACR70 criteria) is limited to only twenty percent
[21]. Second, the role of TNFa in anti-infectious pathways leads to a significantly increased
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Figure 1.1
Key players in jo in t pathology of rheumatoid arthritis
The healthy joint is lined by an thin inner membrane called synovium, which 
consists of synovial fibroblasts and macrophages. Its main function is secretion 
of synovial fluid, which serves to lubricate the joint and reduces friction between 
joints and bones. Chondrocytes, which reside in the cartilage, control the synthesis 
and turnover of the extracellular matrix. The hallmarks of RA include inflammation 
and irreversible joint destruction. The latter is mediated via several mechanisms 
including enhanced osteoclast activities, cytokine-induced chondrocyte 
catabolism, chondrocyte death and invasion of bone and cartilage by the inflamed 
synovium (pannus). Joint inflammation is characterized by infiltration of both 
joint cavity and synovial tissue by immune cells, such as B-/T-cells, dendritic cells, 
neutrophils, and monocytes. In addition, hyperproliferation of synovial fibroblasts 
induces synovial hyperplasia and pannus formation and is accompanied by 
induction of angiogenesis. These pathological processes are largely mediated via 
the actions of cytokines and chemokines.
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susceptibility to opportunistic infections upon systemic anti-TNF treatment [22-24]. Third, thirty 
percent of RA
patients fail to respond to TNF blockers suggesting alternative molecular pathways underlying 
pathogenesis in these patients. Fourth and last, the required continuous mode of treatment 
makes anti-TNF therapies relatively costly. To tackle these issues, local and sustained delivery of 
biologicals to arthritic joints appears an ideal treatment alternative. Over the last decade, gene 
therapy has emerged as a promising approach for achieving these goals.
Gene Therapy for RA
Gene therapy comprises the transfer of a gene product into a patient's cell in order to treat a 
disease. Monogenic diseases caused by single gene disorders were the first to be considered 
to be treated by insertion of a functional copy of the affected gene into target tissues [25]. 
Consecutively, transfer of therapeutic genes has been evaluated for a large number of lethal 
and non-lethal diseases including cancer, neurodegenerative diseases, diabetes and RA.
In terms of both safety and efficacy, the relatively confined joint space appears ideally suited 
for a local treatment based on gene therapeutic delivery of intracellular or secreted gene 
products such as short hairpin RNAs and proteins. Synovial fibroblasts make up the largest 
population of resident cells in the synovium (Figure 1) and are considered as the primary 
target cells for ex vivo and in vivo RA gene therapy. These are readily transducible by several 
viral vectors including retrovirus, adenovirus, adeno-associated virus, lentivirus and potentially 
sustain long-term transgene expression [26-31]. Initial proof of principle has been established 
by successful treatment of experimental arthritis based on local gene transfer of interleukin-1 
receptor antagonist (IL1 Ra) [26,32]. These encouraging studies were followed up by local 
delivery of IL-4 and IL-10 as cartilage-protective and anti-inflammatory cytokines, respectively 
[31,33-35]. Currently, a substantial number of gene therapy approaches has convincingly 
shown therapeutic efficacy in experimental arthritis, based on cytokine blocking, inhibition 
of angiogenesis, induction of synovial apoptosis and targeting of signal transduction 
pathways [36].
Recently, a Phase 1/2 clinical study of intra-articular adeno-associated virus serotype 2-mediated 
delivery of a human TNFa receptor-immunoglobulin Fc fusion gene has been completed [37]. 
The study demonstrated safety of local viral vector delivery and showed an improvement 
of clinical outcome measurements in treated patients. An alternative approach developed 
by Evans and coworkers [28,38], based on engraftment of autologous synovial fibroblasts 
retrovirally-transduced ex vivo with the IL-1 receptor antagonist gene, resulted in reduction of 
joint pain and swelling and prevented flares of joint inflammation [39]. Despite the optimistic 
results arising from these clinical studies, gene therapy for RA remains in its infancy and could 
still profit greatly from innovations in vector design and definition of novel targets.
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Regulated Transgene Expression in RA Gene Therapy
A major advantage of a local gene therapeutic treatment for RA is that it allows precisely 
regulated transgene expression using a transcriptional targeting strategy. This strategy is 
based on the application of promoters that display preferential activity in specific cell types 
or under specific conditions, such as inflammation. The rationale for using transcriptional 
targeting for RA gene therapy is twofold. First, the course of RA is fluctuating rather than 
continuous resulting in periods of increased disease activity or flares alternating with periods 
of relative quiescence. Ideally, the induction of transgene expression parallels these flares in an 
offer-meets-demand fashion. Second, with an emphasis on safety transgene expression should 
be turned off after having effectively suppressed arthritis. Munford and Varley were the first to 
develop a transcriptional targeting strategy for inflammation [40]. The strategy was based on a 
two-component expression construct in which the murine complement 3 promoter regulates 
production of HIV-Tat protein, which in turn stimulates expression of a transgene downstream  
of a HIV-LTR promoter (C3-Tat/HIV). Our group and Miagkov etal. simultaneously demonstrated 
therapeutic efficacy in experimental arthritis of intra-articular C3-Tat/HIV-driven expression of 
human IL1Ra or IL-10, respectively [41,42]. However, the immunogenicity of HIV-Tat protein and 
its transactivating potential of host genes [43,44] hampered its application for gene therapy. 
This has led to the development of alternative transcriptional targeting strategies using both 
synthetic and endogenous promoter constructs, such as the hybrid IL-1 enhancer/IL-6 promoter 
[45,46].
Promoters and Signal Transduction
A promoter is defined as the cis-regulatory DNA region upstream of a gene that regulates 
timing, spacing and the level of its transcription under given environmental conditions. 
Roughly, a promoter can be divided into a core-, proximal-, and distal-promoter region. The 
core-promoter encompasses the 80-100 base pair (bp) region surrounding the transcription 
start site (TSS) and is required for assembly of the pre-initiation complex that contains 
RNA polymerase II [47]. The proximal-promoter (up to 500 bp upstream) contains pivotal 
cis-regulatory elements that interact with trans-acting transcription factors (TFs) and largely 
determine cell- or context-specific gene expression [48,49]. The distal-promoter together 
with distal up/downstream enhancers/silencers (up to 100 kB) further regulate the complex 
expression patterns of genes in vivo.
In RA, numerous stimuli trigger intracellular signaling cascades leading to activation of a specific 
set of TFs that bind the promoter and induce expression of pro-inflammatory genes (Figure 2). 
Synovial fibroblasts are potently activated by cytokines, such as IL-1 and TNF , and exogenous 
and endogenous toll-like receptor (TLR) 2, 3 and 4 ligands [8,11,12,50-53]. After ligation of 
their respective receptors, expression and secretion of pro-inflammatory mediators including 
cytokines, chemokines and matrix metalloproteinases (MMPs) is induced through multiple 
signal transduction pathways including nuclear factor-KB (NF-kB) and the mitogen-activated
12
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Figure 1.2
Inflam m atory signal transduction leading to induction of gene transcription
Upon ligand binding receptor-associated kinases induce phosphorylation of 
MAP3Ks. Consecutively, these phosphorylate their respective targets including IKK 
and MAPKKs. IKK induces degradation of the inhibitor IkB, which enables nuclear 
translocation of transcription factor NF-kB. MAPKKs phosphorylate their downstream 
targets JNK, p38 and ERK ultimately leading to activation and nuclear translocation 
of several transcription factors. In the nucleus, these factors bind their cognate 
sequences in enhancer and promoter regions thereby inducing transcription of 
downstream genes.
P = phosphorylation, TF = transcription factor, TSS = transcription start site.
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protein kinase (MAPK) families: p38, c-Jun-N-terminal kinase (JNK) and extracellular-signal 
regulated kinase (ERK) [54]. The latter kinases are regulated through phosphorylation by their 
upstream MAPK kinases (MAPKK). NF-kB signaling is regulated through phosphorylation of the 
inhibitor of kappaB (IkB) by IkB kinase (IKK), which leads to proteasomal degradation of the prior. 
In turn, MAPKK kinases (MAP3Ks) control the activation of IKK and MAPKK and are activated 
through interactions with receptor-associated proteins, such as IL-1R-associated kinases (IRAKs) 
and TNFR-associated factors (TRAFs). The MAP3K family comprises numerous members of 
which MEK kinase-1, -2 (MEKK1,-2) and transforming growth factor-p activated kinase 1 (TAK1) 
are most abundantly expressed in RA synovial fibroblasts [55]. Ultimately, signal transduction 
pathways lead to activation of TFs that translocate to the nucleus and cooperatively induce 
transcription of their target genes. Pivotal TFs in pathogenesis of human and experimental 
arthritis include activator protein-1 (AP-1), CAAT/enhancer-binding proteins (C/EBPs), NF-kB 
and signal transducers and activators (STAT)-1 and -3 [56-58].
Outline of the thesis
Despite its potential for addressing safety and efficacy of gene therapy approaches for RA, 
transcriptional targeting strategies are only scarcely explored. Therefore, the aim of the present 
thesis was to rigorously design a transcriptional targeting strategy for RA and evaluate its 
applications in gene therapeutic treatment and diagnostics.
In Chapter 2 we have reviewed the status of vectors in RA gene therapy with an emphasis on 
targeting resident cells of the joint. Among the viral vectors reviewed were adenovirus and 
lentivirus, which we used as gene transfer vectors in Chapters 3-7.
In Chapter 3 we designed proximal-promoters for transcriptional targeting using a computational 
approach on a microarray study of murine collagen-induced arthritis. We found an enrichment 
of NF-kB, AP-1 and C/EBPp TF binding sites in the promoters of genes upregulated during 
arthritis. Nine identified promoters were responsive to pro-inflammatory stimuli in vitro and 
based on its excellent transcriptional properties the serum amyloid A3 (Saa3) promoter was 
selected as a promising candidate for transcriptional targeting.
In Chapter 4 we explored the application of the computed promoters as a diagnostic tool 
for assessing joint inflammation in experimental and human arthritis. Analyzing promoter 
responses in flares of streptococcal cell wall-induced arthritis and synovial fibroblasts of 
rheumatoid arthritis patients, we found that specifically a Saa3-promoter could distinguish 
between inflammatory subtypes.
In Chapter 5 we investigated the impact of transcriptional targeting on safety of RA gene 
therapy. To this end, we evaluated the effects of constitutive and transcriptionally-targeted 
IL-4 gene therapy in healthy and arthritic joints. Transcriptional targeting showed therapeutic
14
efficacy in arthritis while preventing transgene-induced side effects under healthy conditions, 
thereby providing proof-of-principle that it is a safer mode of gene therapy.
Chapters 6 and 7, describe two novel gene therapy approaches based on RNA 
interference-mediated knockdown of TNF receptor-1 and targeting multiple signaling cascades 
though inhibition of transforming growth factor-p-activated kinase 1 (TAK1).
Chapter8 reviews recent developments and future perspectives of transcriptional targeting in 
gene therapy approaches for autoimmune and inflammatory disease, in particular RA.
In the final chapter, the results described in this thesis are summarized and discussed.
---------------------------------------------------------------------------------------------------------------------------------------------  Disease-regulated local gene therapy for rheumatoid arthritis  —
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Abstract
Rheumatoid arthritis (RA) is a systemic disease with polyarticular manifestation of chronic 
inflammation in the knees and small joints of hand and feet. The current systemic anti-tumor 
necrosis factor (TNF)-a therapies with biologicals ameliorate disease in 60% to 70% of RA 
patients. However, biologicals must be given systemically in relatively high dosages to achieve 
constant therapeutic levels in the joints, and side effects have been reported. To this end, local 
gene delivery can provide an alternative approach to achieve high, long-term expression of 
biologicals, optimizing the therapeutic efficacy and minimizing systemic exposure. Evidence 
from animal models convincingly supports the application of local gene therapy in rheumatoid 
arthritis, but preclinical studies remain necessary to evaluate the merge of cell-specific 
targeting, viral vector development, and disease-regulated transgene expression to optimize 
efficacy and safety.
Introduction
For the title of this review, we have chosen a provocative remark sometimes raised by 
preclinical gene therapy (GT). We hope this shows the eagerness to proceed into humans. The 
implementation of GT in the clinic will be delayed until researchers can determine whether 
results from GT trials in experimental arthritis models is sufficient to turn this technology into 
the long-promised magic bullet.
In 1990, the first GT clinical trial was approved, and the technology rapidly emerged as an 
innovative form of treatment for inherited and acquired genetic disorders such as cancer [1]. 
The principles of GT as designed in the 1990s became the foundation of GT in preclinical practice 
of today. Originally, GT was used to transfer genes in order to supplement a gene product for 
several purposes: 1) to restore a deficiency; 2) to overcome, counteract, or correct a defect; or 3) 
to restore the normal physiology and function of cells and organs. The first phase l clinical trial 
in RA, initiated in Pittsburgh in 1995 by Evans et al. [2], used the ex vivo method. Autologous 
synovial fibroblasts from the metacarpophalangeal (MCP) joints were transduced in vitro with a 
derivative of the Moloney murine leukemia virus (MLV) encoding human lL-1Ra, and then they 
were transplanted back into the MCP joints. Nine patients underwent this treatment at the time 
of joint replacement. No adverse effects were reported, and 11 of 12 joints expressed IL-1Ra
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Figure 2.1
Gene transfer methods and targeted cells in experim ental arthritis
Schematic presentation of the various gene transfer methods and their targeted cells that are 
used in experimental models of rheumatoid arthritis. In the in vivo gene transfer approach 
(left panel), vectors are injected either locally (intra-articular, peri-articular) or systemically 
(intramuscular, intravenous). Fibroblast-like synoviocytes are most efficiently transduced in 
vivo by a large variety of viral vectors while other resident cells (e.g. macrophages or T-cells) 
require specific viruses or adaptor molecules for transduction. In the ex vivo gene transfer 
approach (right panel), autologous fibroblasts, antigen-presenting cells (i.e. dendritic cells, 
macrophages, or B cells) or T-cells (primary or hybridoma cells) are transduced virally and 
consecutively transferred in the animal intra-articularly (fibroblasts) or intravenously (adoptive 
cellular gene therapy). HTLV-1— human T-cell lymphotropic virus type 1; rAAV— recombinant 
adeno-associated virus.
one week after transplantation. However, this ex vivo method requires a laborious and costly 
procedure to obtain and culture autologous cells.
On the other hand, direct injection of genes into the inflamed joint is simple, and several viral 
and nonviral vehicles are applicable and under review. Using this direct approach, a phase I dose 
escalation study in RA patients started in 2003 examining the intra-articular administration of 
tgAAC94, a recombinant adeno-associated virus (AAV) containing the tumor necrosis factor 
receptor-Fc (TNFR:Fc) immunoglobulin fusion gene [3]. No significant safety issues were noted 
in the 14 RA patients treated in the first two cohorts, and a second phase I/II was approved and
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initiated in 2005. The completion of two phase I clinical trials of GT in RA in the past 16 years is 
not a success story.
The field of GT suffered a major setback in 1999, when 18-year-old Jesse Gelsinger died during 
a clinical trial to treat a genetic liver disorder. Then, approximately 2 years later, two of 10 
boys enrolled in a French GT trial to cure their X-linked severe combined immunodeficiency 
(SCID) syndrome developed leukemia after initial encouraging results [4]. (A third patient 
later developed the disease.) These events set the entire GT field back, especially in non­
life-threatening diseases such as RA. Meanwhile, the development of this sophisticated 
approach continued to show that GT in animal models of RA works.
Gene Therapy Approaches for Arthritis
In RA, the whole spectrum of inflammatory cells is present in the inflamed joint. These cells, 
together with the resident cells of the synovial membrane, are all potential targets for GT 
(Figure 1). For this application, local gene transfer into the inflamed joint is the most likely 
approach. Successes have been reported using different vectors (viral and nonviral), route (local 
and systemic), and mode of administration (injection, gene-gun, electroporation), and using a 
large arsenal of therapeutic transgenes. For cell-killing (also called suicide GT, gene scalpel, or 
genetic synovectomy), the emphasis is on cell-targeting depending on the receptor-binding 
characteristics of the vector, and only short-term expression is required. Whereas for modulation 
studies (e.g. restoring the cytokine balance), the emphasis lies on long-term transgene 
expression rather than cell-specificity. Since joint inflammation in RA patients often shows a 
relapsing course, transcriptional regulated transgene expression will be more efficacious.
Targeting Inflammatory Cells
Cells o f the adaptive immune system 
The ex vivo method of transplanting genetically modified immune cells into recipient mice is 
called adoptive cellular GT (ACGT). In this approach, isolated primary spleen cells, T-cells (T-cell 
hybridomas), and antigen presenting cells (i.e. dendritic cells [DCs], B-cells, macrophages) are 
virally transduced and transferred in the arthritic animal. Two adoptive transfer strategies have 
been shown to cause significant immune changes and ameliorate disease: 1) collagen-specific 
T-cell hybridoma transduced to express anti-TNF single chain antibodies or IL-12 p40, and 2) 
splenocytes from arthritic animals expressing soluble TNFR or transforming growth factor 
(TGF) G [5-8]. Adoptive transfer of antigen-specific T-cell hybridomas, antigen-pulsed B-cells, or 
macrophages transduced to express IL-4 home to the joint and exert a prophylactic effect that 
relies on the anti-inflammatory property of IL-4 [9,10].
An effective approach in the treatment of collagen-induced arthritis (CIA) is the eradication 
of antigen-specific T cells by transfer of antigen-pulsed DCs that overexpress TRAIL or FasL 
[11,12]. Since DCs do not migrate to the joint, they probably exert their effect in the spleen and 
lymph nodes. The most sophisticated approach came from Zhang et al. [13]. They developed 
a dual ACGT strategy, in which they transferred collagen type II pulsed antigen-presenting
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cells adenovirally transduced to express either 1) FasL to eradicate antigen-specific T-cells, or 
2) transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) 
to block antigen-specific B-cell activation. The dual ACGT completely prevented murine CIA, 
but a therapeutic regimen failed to affect established disease. Overall, the implementation of 
ACGT to treat early RA needs further preclinical investigation and more importantly requires 
knowledge of the putative autoantigen.
T-cells
In vivo targeting of T lymphocytes in the inflamed joint will be difficult, since they reside in the 
synovial sublining layer, often as lymphoid aggregates forming ectopic germinal centers that 
are less accessible to (viral) vectors. In vitro, vectors derived from oncoretroviruses such as the 
MLVs are frequently used as tools to transduce T cells. However, these viruses cannot transduce 
nonproliferating cells, probably due to post entry-block [14]. Activation of the T-cell receptor (TCR) 
by anti-CD3 and the CD28 coreceptor stimulates proliferation and renders these resting T cells 
permissive for retroviral transduction [15]. Lentiviral vectors (LV) can transduce both resting and 
dividing cells. However, costimulation is still needed, because T cells must enter the G1b phase of 
the cell cycle to facilitate transduction [15]. Maurice et al. [16] genetically engineered HIV-based 
lentiviruses that display a single chain of the anti-CD3 OKT monoclonal antibody on the surface, 
and this strongly increased transduction of T-lymphocytes.
Direct delivery of oncoretroviruses into the joint resulted in poor transduction of the synovium, 
which was greatly improved by lentiviruses; however, transduction of the infiltrating T cells was not 
demonstrated in these studies [17]. Even excessive amounts of adenoviruses or AAVs only achieve 
moderate transduction of T lymphocytes [18,19]. Human T-lymphotropic virus type 1 (HTLV-1) is 
related to deltaretroviruses and has a natural tropism for CD4+ T cells [20]. Furthermore, HTLV-1 
antigens and immunoglobulin (Ig) M antibodies are found in chronic inflammatory arthropathies, 
and transgenic mice carrying the env-Px region of HTLV-1 spontaneously developed inflammatory 
arthropathies [21]. For this, HTLV-1 can be a valuable vector tool for T-cell-specific gene delivery in 
the inflamed joint of RA.
Cells o f the innate immune system: Macrophages and neutrophils 
Macrophages are abundantly present in inflamed joints, and the type A synovial lining cells 
are tissue-specific macrophages. Macrophages are prime target cells of GT in arthritis, as they 
produce proinflammatory cytokines and cartilage destructive enzymes. Macrophages express 
constitutively high levels of the high-affinity Fcy receptor I. This receptor can be targeted selectively 
using a bispecific hybrid adapter protein consisting of the amino-terminal extracellular domain of 
the human CAR protein and the Fc region of the human IgG1 protein. Up to a 250-fold increase of 
transgene expression in CAR-negative human monocytic cell lines expressing the high-affinity Fcy 
receptor I (CD64) was achieved with adenoviruses in the presence of this adaptor molecule [22]. 
Therefore, adaptor molecule mediated targeting should be explored in experimental arthritis. 
Macrophages also express CD44, and the introduction of heparan sulfate binding moieties on
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fiber coat proteins facilitates adenoviral uptake via CD44. Intra-articular delivery of these modified 
adenoviruses into the rat ankle joint with adjuvant induced arthritis leads to enhanced transgene 
expression due to inflammation-induced upregulation of CD44 [23].
Large numbers of neutrophils are present in the RA synovial fluid, and they release large amounts 
of matrix-degrading enzymes and proinflammatory mediators. However, the lifespan of these cells 
is short due to apoptosis, making these cells poor targets for GT approaches. More importantly, 
these cells can scavenge viral vectors very efficiently due to their opsonization with antibodies 
and complement, thereby reducing the transduction of the synovium [24].
Targeting Resident Articular Cells
Synovial fibroblast-like cells 
The RA fibroblast-like synoviocytes (FLS) are resident cells that also produce proinflammatory 
cytokines and matrix-degrading enzymes, as exemplified by the invasive pannus tissue that 
destroys cartilage and bone. RA-FLS do not express CAR and are poorly permissive to adenoviruses 
for the most commonly used serotype 5 (Ad5). Adenoviruses from subgroup B (serotypes 11, 16, 
and 35) do not use CAR for infection of cells. Chimeric adenoviruses of serotype 5 but carrying 
fibers from subgroup B are superior in transducing human synoviocytes [25]. Interestingly, 70% to 
90% of RA patients have neutralizing antibodies against serotype 5 in their synovial fluid, whereas 
this is less frequent for serotype 35 [26].
CAR-independent cell entry of adenoviruses can be realized by modification of the fiberknob 
through introducing the arginine-glycine-aspartic (RGD) acid motif in the H1 loop. RGD-binding 
integrins such as aVp3 and aVp5 are expressed on FLS and other CAR-deficient cells as lymphocytes 
and macrophages [27]. We demonstrated that RGD-modified Ad5 were more efficient in 
transducing the murine synovial tissue, and that the higher IL-1Ra transgene expression results in 
a more efficacious treatment of CIA [28]. It is known that the members of adenovirus subgroup B 
have naturally short fibers. Hence, shortening the shaft of the adenoviral fiber from 22 to 7 fiber 
shaft repeats or ablating the fiberknob markedly enhanced (40- to 50-fold) the transduction of 
CAR-negative rheumatoid synovial fibroblasts, CD14+ macrophages, and CD3+ lymphocytes in 
vitro and murine synovial tissue in vivo [29]. Pro-inflammatory cytokines and joint inflammation 
further enhanced the transduction with these modified adenoviruses, due to upregulation of the 
integrins by inflammation. Furthermore, these shaft-modified adenoviruses partially escaped 
viral neutralization by human synovial fluid [29].
The adenoviral genome resides as episomal DNA in the nucleus and is lost during cell division, 
but under naive conditions it remains in the murine knee joint for over 12 weeks. However, with 
the conventional constitutive promoters the transgene expression was short-lasting. As a result, 
adenoviruses are more suitable for the delivery of pro-apoptotic ("killer") genes when genetic 
synovectomy is required and for proof-of-principle studies in animal models of RA.
In contrast to retroviruses, LV and AAV do not need cell proliferation for efficient transduction 
of the synovium. Most commonly used self-inactivating (SIN)-LV are derived from HIV type 1 
pseudotyped with vesicular stomatitis virus envelope glycoprotein (VSV-G). The advantage of
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VSV-G over other retroviral envelope proteins is its broad host range, enabling infection into a 
wide variety of cell types [30]. Direct injection of VSV-G pseudotyped SIN-LV into rat or mouse 
knee joint cavities results in transduction of the synovial lining cells, but transduction of all 
synovial cell layers was seen when injected into inflamed joints [31]. Transgene expression 
peaked at day five after injection and declined thereafter to approximately 30% at day 21 [17]. 
Human primary synoviocytes, rabbit HIG-82 synovial fibroblasts, rat skin fibroblasts, rat synovial 
fibroblasts, and mouse NIH-3T3 fibroblasts can efficiently be transduced by SIN-LV, whereas RAW
264.7 macrophages and EL4.NOB1 thymoma were poorly transfectable (unpublished data). This 
suggests some selectivity of VSV-G pseudotyped LV for fibroblasts-like cells.
Currently, AAV is the first choice for gene transfer in arthritis, since no AAV-based pathology is 
found in humans. AAV is a non-enveloped, single stranded (ss) DNA virus of the human parvovirus 
family. The 4.7 kilobase (kb) AAV genome contains two open reading frames, rep and cap, which 
are flanked by 145 base pair (bp) inverted terminal repeats (ITRs). These ITRs comprise the 
origins of replication and the packaging signal, and they serve as cis elements for chromosomal 
integration. The recombinant AAV vector is devoid of viral genes and only possesses the ITRs, 
thereby becoming replication incompetent and non-immunogenetic, an advantage over other 
viral vectors used in GT. Twelve human and nonhuman primate AAV serotypes are known to 
exist, and their heterogeneity in capsid proteins determines their different host range and tissue 
tropism: muscle (AAV1/2/10), liver (AAV7/8), and retina (AAV4) [32]. Most studies in experimental 
arthritis are done with AAV2, and the main cell-type transduced by local application is the synovial 
lining cells with conflicting reports on chondrocyte transduction. AAV vectors provide long-term 
expression after local application in the inflamed joint.
Interestingly, the AAV-IL-1Ra transgene expression in naïve rat knees was undetectable, but even 
100 days later, it could be upregulated by lipopolysaccharide-induced joint inflammation [33]. 
The transduction ability of AAV is species specific. AAV can enter mouse fibroblasts but is retained 
in the early endosomes due to impaired viral trafficking to the nucleus [34]. Goater et al. [35] found 
that the low AAV transduction of the synovium was significantly enhanced in the TNF-transgenic 
mice and correlated with joint damage. Direct injection of the AAV virus into the arthritic joint 
showed considerably higher expression of the IL-4 transgene than injection into a naïve joint [36]. 
Thus, recombinant AAV vectors are even more attractive for GT, because they give rise to low 
basal levels of transgene that increase with inflammation. The clinical efficacy of local GT with 
rAAV-sTNFR has been demonstrated in both spontaneous arthritis in TNF-transgenic mice and in 
streptococcal cell wall (SCW) arthritis in rats [37,38].
Eighty percent of humans have antibodies directed against AAV2, and 30% express neutralizing 
antibodies, which may hamper its therapeutic application in RA patients. The capsid protein of 
AAV5 shares the lowest homology (60%) with all the other AAV serotypes, and antibodies against 
AAV5 are rarely found in humans.
Apparailly et al. [39] compared the efficiency of AAV2 with a chimeric AAV2/5 (i.e. an AAV2 
pseudotyped with capsids of AAV5) for transduction of the murine arthritic joint. In knees with 
CIA, both AAV2 and AAV2/5 infected the synovial lining tissue and adjacent bone marrow but not
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the cartilage, bone, or muscle. Quantitative analysis of transgene expression showed markedly 
enhanced expression with the cross-packaged AAV2/5. The same investigators also examined 
this apparent difference in transduction efficiency between AAV2 and AAV2/5 in a rat adjuvant 
arthritis model after local delivery in the inflamed ankle joints [40]. Again, the synovial tissue was 
the dominant transduction site using AAV2/2 and AAV2/5, in particular the fibroblasts. In addition, 
AAV2 pseudotyped for capsids of AAV1, 3, and 4 failed to transduce the joint.
Strikingly, both studies showed similar transduction efficiencies in vitro between AAV2 and AAV2/5 
for different human cell-types: chondrocytes, osteocytes, myoblasts, and primary synoviocytes 
[39,40]. This finding was unexpected, since AAV2 uses heparan sulfate proteoglycans, integrins, 
and fibroblast growth factor receptor-1, whereas AAV5 uses N-linked sialic acid and the platelet 
growth factor receptor for cell binding and internalization. Furthermore, it does not explain the 
profound improved transduction properties of AAV2/5 in mice. Species differences could be 
the underlying reason, and Gao et al. [32] found that AAV2/5 raised higher titers of neutralizing 
antibodies than AAV2/2 in the rabbit. This finding warrants further investigation in humans.
Chondrocytes
Cartilage pathology is striking in RA, and chondrocytes play a pivotal role in the underlying 
processes. Therapeutic options include either reducing the synthesis of cartilage catabolic 
cytokines (eg, IL-1) and destructive enzymes (eg, metalloproteinases) or enhancing the anabolic 
capacity of chondrocytes in an attempt to counteract the matrix loss. Therefore, targeting the 
chondrocytes with GT is a valid option.
In vitro, isolated articular chondrocytes are easy to transduce with all viral vectors known today. 
In vivo, these cells are sealed in a complex and dense pericellular matrix. Based on their physical 
size, it is highly unlikely that AAV, adenoviruses, and LV with respective diameters of 20 nm, 80 nm, 
and 100 nm can transduce chondrocytes. Controversially, it was reported that AAV can transduce 
chondrocytes, probably related to the extent of cartilage damage [35,41,42]. To overcome this 
barrier effect, Grossin et al. [43] injected naked plasmid DNA into the rat knee joint, and they 
were able to transduce 30% to 50% of chondrocytes in the patella at all depths of cartilage using 
electroporation.
Vascular endothelium
Angiogenesis is an ongoing process in the deeper layers of the inflamed synovium, and it plays a 
central role in the perpetuation of chronic synovitis. The vascular endothelial growth factor (VEGF) 
promotes angiogenesis. Intravenous injection of adenoviruses expressing human soluble VEGF 
receptor 1 at the onset of murine CIA significantly reduced paw swelling and disease severity 
[44]. TNF is a proangiogenic cytokine, and direct injection of a LV expressing endostatin, an 
antiangiogenic peptide derived from collagen XVIII, into the joints of huTNF-transgenic mice 
before arthritis onset reduced vascularization and overall arthritis index 8 weeks later [45]. 
Transplantation of retroviral transduced NIH3T3 cells expressing angiostatin gene, an internal
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fragment of plasminogen, into the knee joint of DBA1/J mice before onset of CIA dramatically 
prevented angiogenesis. As a result, pannus formation and cartilage erosion are reduced [46]. 
The enzyme plasmin is essential in endothelial cell migration, and systemic adenoviral-mediated 
overexpression of urokinase plasminogen activator receptor molecule also prevents angiogenesis 
and as a result ameliorates CIA [47]. The vascular endothelium of new blood vessels expresses high 
levels of aVp3 and aVp5 integrins, which can be targeted by adenoviruses with RGD-modified 
fiberknobs [27]. Recombinant AAV1 and AAV5 efficiently transduce vascular endothelial cells 
via 2,3-linked sialic acid, which is their high affinity receptor on endothelial cells. White et al. [48] 
changed the AAV2 capsid by introducing phage display selected vascular endothelium binding 
peptides. The capsid-modified AAV showed a different tropism with reduced hepatic uptake and 
enhanced uptake by the vena cava after systemic delivery. This study showed proof of principle, 
but at present, no published data exists showing the targeting of newly formed blood vessels in 
arthritis.
Fine Tuning GT in Arthritis by Regulated Gene Expression 
Clearly, different cell-types/organs involved in arthritis can be targeted, but the stringency of 
vector choice will depend on the therapeutic approach, the safety of the vector, and the route 
of application. The major challenge is a disease-regulated expression of a recombinant protein 
to meet the variable demands during RA (i.e. high expression during relapse and low expression 
during disease remission). Target cells must remain transduced for a long period of time to avoid 
frequent readministration.
Several vectors allow long-term expression because of either integration into the host genome or 
the formation of self-replication genomic particles [22]. The disadvantage of integration vectors, as 
with retroviruses, is the random integration into the host genome with the potential for activating 
oncogenes (called insertional mutagenesis). This risk became painfully apparent in the French 
GT trial for SCID-X1, in which three patients to date have developed cancer [49]. Wild-type AAV2 
integrates at a specific locus on chromosome 19 in human cells through the activity of a specific 
replicase/integrase protein (Rep) of AAV. However, recombinant AAV2 is devoid of Rep and only 
integrates into the host genome at low frequencies. Recombinant AAV2 integration in mouse 
liver and cultured human cells was favored in actively transcribed genes, which can lead to small 
deletions of host chromosomal DNA [50]. This is worrisome and may have consequences for risk/ 
benefit considerations, especially with the reported enhanced liver metastasis in 18-month-old 
mice that received a single AAV injection early in their lives [51]. Stable transgene expression 
primarily results from extrachromosomal localization of the genome of either circular or linear 
concatemers. A recent advantage is the creation of self-complementary duplex strand structures 
of the AAV genomes. These self-complementary AAV genomes do not need second strand 
synthesis and support stable and long-term transgene expression in vivo [52].
Excessive production of the transgene and spill-over to the system may cause serious side 
effects, as seen in some patients receiving anti-TNF biologicals. Ideally, gene transfer vectors must 
auto-regulate transgene expression in relation to the disease activity, turned on by relapse and
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turned off when in remission. Varley et al. [53] showed that the promoters of the acute phase 
proteins C3 and serum amyloid A (Saa) are particularly attractive candidates for transcriptional 
regulation of cytokine inhibitors. A two-component expression system was created, in which 
the C3-promoter regulates the production of the HIV transactivator of transcription (Tat) protein, 
which in turn regulates the HIV long terminal repeat (LTR) promoter to express the transgene of 
interest [54]. Miagkov et al. [55] and we [56] independently demonstrated the feasibility of this 
two-component system in adenoviral vectors for auto-regulated expression of IL-10 and IL-1Ra 
in two different experimental arthritis models. In a prophylactic regimen, we demonstrated 
a superior effect of this two-component IL-1Ra expression system in murine CIA. These two in 
vivo studies showed proof of principle of the efficacy of a disease-regulated expression system in 
arthritis.
However, this promoter may not be suitable for RA, because the Tat is a foreign immunogenic 
protein and may have undesirable effects by transactivating host genes [56]. For future clinical 
application, novel disease-regulated promoters will be developed based on the expression of 
endogenous genes at the site of injury/inflammation. We demonstrated that a hybrid promoter 
consisting of the human IL-1 enhancer region in front of the human IL-6 promoter fulfills the criteria 
of a disease-inducible promoter: low basal transcriptional activity that is highly upregulated during 
acute joint inflammation and the flare-up of SCW arthritis [57]. This system was used successfully 
to auto-regulate expression of cartilage protective levels of IL-4 in mouse CIA (unpublished data). 
This showed that controlled transcriptional regulation is a feasible GT approach for 
auto-regulated protein drug treatment in experimental arthritis. In the future, a combined system 
of disease-inducible/drug-regulated transgene expression will provide auto-regulation with 
the possibility to intervene from the outside as an extra safety measure. Gould et al. (personal 
communication) are exploring so-called hybrid promoters (e.g. a minimal CMV promoter with 
seven upstream tetO elements combined with four hypoxia responsive elements) to obtain a dual 
responsiveness to both pharmacological and pathophysiological regulation.
The non-immunogenic recombinant AAV vectors also show an attractive transgene expression 
profile even with constitutively active promoters, as reviewed earlier. The autonomously regulated 
transgene expression in AAV-transduced human RA-synovial fibroblasts was studied in more 
detail by Traister et al. [58]. To bypass the second-strand synthesis, they used double-stranded AAV 
vectors and consistently obtained higher transgene expression as compared to single stranded 
AAV2. Nevertheless, they found that with RA-synovial fluid or cytokines, the expression of different 
transgenes (sTNFR-Ig, IL-10, or GFP) was upregulated stimulated even when constitutive viral and 
non-viral promoters (CMV or chicken p-actin) were used for driving the transgene expression. 
The transgene expression returned to basal levels upon withdrawal and could be reinduced by 
re-exposure to these cytokines in a phosphatidylinositol 3-kinase dependent manner. Evidence 
shows that this could be due to either viral uncoating and trafficking or increased mRNA stability. 
However, a more likely explanation for this inducible expression is the favored integration site of 
AAV into active and potentially regulated genes. The observed slow response to cytokines and
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arthritis (3-7 days to turn on or off) and the unknown long-term effects of AAV integration into 
the host genome are features that must be investigated in more detail before its application in GT 
for arthritis.
Conclusions
The field of vector development is ongoing. Recent novelties include the hybrid vectors of LV 
genome in an adenoviral backbone and the integration cassette of AAV in the helper-dependent 
adenoviral vector [59,60]. These hybrid vectors combine the efficient gene transfer and large 
packaging capacity of an adenoviral vector with stable integration from LV or AAV. The random 
integration of LV into the host genome can be dangerous. To avoid insertional mutagenesis, 
researchers have developed novel integrase-defective LVs that remain episomal as circular 
double-stranded viral DNA [61]. In cells that are essentially post-mitotic (eg, muscle, liver, brain, 
and retina), the episomal DNA does not need to replicate for long-term expression. Artificial 
chromosomes are advantageous in that they are non-integrating, have mitotic stability and can 
host multiple genes. Until now, the in vivo transfer of these large DNA strands (1 -2  microns) is 
inefficient but can be used in the ex vivo gene delivery approach, as has been demonstrated 
recently in experimental arthritis [62].
Drug- and/or disease-regulated transgene expression will increase the efficacy and safety of 
local GT. Many strategies have demonstrated efficacy in preclinical studies: several transgenes, 
constitutive or regulated promoters, viral or nonviral vectors, and local or systemic delivery 
routes. However, no standardized side-by-side comparisons of different delivery systems 
have been performed. No consensus exists on the models used in reviewed studies, but the 
transplantation of synovial tissue biopsies into SCID mice could be a relevant model [63].
Gene therapists are considerably optimistic on the clinical approval of two GT cancer drugs 
in China based on the adenoviral delivery of the tumor suppressor gene p53 [64]. In contrast, 
rheumatoid arthritis is a more complex autoimmune disease, and the success of GT will not 
only depend on our understanding of the pathophysiological processes underlying this disease 
but also on extensive preclinical research to test suitable transgene delivery and expression 
systems. The recent mouse study revealing the development of T-cell lymphomas in 33% of 
animals treated with the IL-2RG (as used in the French SCID trial) 1.5 years post-transplantation 
underlines the necessity of proper preclinical GT studies [65].
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Abstract
The promoter region of genes that are differentially regulated in the synovial membrane 
during the course of rheumatoid arthritis represent attractive candidates for application in 
transcriptionally targeted gene therapy. In this study, we applied an unbiased computational 
approach to define proximal-promoters from a gene expression profiling study of 
murine experimental arthritis. Synovium expression profiles from progressing stages of 
collagen-induced arthritis were classified into six distinct groups using k-means clustering. Using 
an algorithm based on local over-representation and comparative genomics, we identified 
putatively functional transcription factor binding sites in TATA-dependent proximal-promoters. 
Applying a filter based on spacing between TATA box and transcription start site combined with 
the presence of over-represented nuclear factor-KB (NF-kB), AP-1, or CCAAT/enhancer binding 
protein ß (C/EBPß) sites, 382 candidate murine and human promoters were reduced to 66, 
corresponding to 45 genes. In vitro, nine out of ten computationally defined promoter regions 
conferred cytokine-inducible expression in murine cells and human synovial fibroblasts. Under 
these conditions, the serum amyloid A3 (Saa3) promoter showed the strongest transcriptional 
induction and strength. We applied this promoter for driving therapeutically efficacious levels 
of the interleukin-1 receptor antagonist (Il1rn) in a disease-regulated fashion. These results 
demonstrate the value of bioinformatics for guiding the selection of endogenous promoters 
for transcriptional targeted gene therapy.
Introduction
Selective spatial and temporal expression of a therapeutic transgene has a major impact on the 
safety and efficacy of gene therapeutic treatments for human disease. This can be accomplished 
by transcriptional targeting using endogenous or synthetic cis-regulatory DNA regions, which 
facilitate tissue/cell-specific or physiologically-regulated expression. Predominantly in cancer
34
gene therapy, numerous tumour/tissue-specific or drug/radiation-inducible promoters have 
been developed and applied [1].
With emphasis on the discontinuous clinical course of rheumatoid arthritis (RA), which 
is characterized by spontaneous remissions and exacerbations of joint inflammation, 
transcriptionally targeted gene therapy appears ideally suited. The few endogenous 
promoters that have been tested in RA thus far were empirically derived. Efficacious 
inflammation-responsive expression in experimental arthritis has been accomplished using the 
promoter elements of the murine acute-phase response gene complement factor 3 (C3) [2,3] 
and the human cytokine gene interleukin-6 (IL6) [4]. While IL6 and C3 promoters showed high 
specificity towards inflammation, they only conferred weak transcriptional activity that had to 
be enhanced artificially using a interleukin-1 enhancer region [5] or a recombinant HIV-1-taf 
transcriptional activator [6], respectively. However, the application of the latter approach is 
hampered due to the immunogenic properties of HIV-1-tat.
The promoter of a gene is defined as the cis-regulatory DNA region that drives transcription in 
response to environmental signals. Roughly, a promoter can be divided into a core-, proximal- 
and distal-promoter region. The core-promoter encompasses the 80-100 bp region surrounding 
the transcription start site (TSS) and is required for assembly of the pre-initiation complex [7]. 
Bioinformatic analyses of mammalian core-promoters have revealed that the spacing between 
the TATA box and TSS affects the transcriptional specificity of the downstream transcript and the 
highest specificity has been observed for TATA-TSS distances between -32 and -29 [8]. In mouse, 
the most common TATA-TSS spacings are 30 and 31 bp [9] and most functional TATA boxes reside 
in a window ranging from positions -34 to -27 relative to the TSS [8]. The proximal-promoter 
(-500/+200 relative to the TSS) contains modules of transcription factor binding sites (TFBS) 
that confer tissue- and context-specific expression [10]. Several bioinformatics tools have been 
developed for computational identification of these TFBS in eukaryotic promoters (reviewed 
in [11]). The accuracy of prediction of TFBS that are functional in vivo has been significantly 
enhanced using the combination of phylogenetic footprinting with sets of co-regulated genes 
[12]. These methods have been used to successfully identify cartilage- [13] or muscle-specific 
[14] cis-regulatory elements in mammals.
In this study, we computationally designed and verified endogenous proximal promoters from 
a gene expression profiling study of murine collagen-induced arthritis (CIA) for transcriptionally 
targeted gene therapy for RA. The 201 genes that were significantly regulated during advancing 
CIA severity stages, were divided in clusters of distinct expression profiles using k-means 
clustering. Next, over-represented TFBS per cluster were calculated in proximal-promoter 
sequences of the genes and their human orthologs that contained a putative TATA box within 
the -44 to -17 bp region relative to the TSS. We investigated the transcriptional properties of 
ten computationally identified proximal-promoter regions in vitro using lentiviral luciferase 
reporter. Nine out of ten promoters drove gene expression in a cytokine-inducible fashion. 
The serum amyloid A3 (Saa3) proximal-promoter conferred high transcriptional specificity and
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activity towards inflammation and we demonstrated that this promoter improved the efficacy 
of transcriptionally targeted adenoviral gene therapy using interleukin-1 receptor antagonist 
(Il1rn) as a transgene.
Results
K-means clustering o f CIA gene expression profiles 
In local gene therapy for RA the synovial tissue, a thin layer of connective tissue consisting of 
fibroblast- and macrophage-like cells, is transduced by viral vectors [15]. To elucidate candidate 
genes whose proximal-promoter might confer inflammation-inducible expression, we analyzed 
gene expression profiles in inflamed synovium of mice with CIA. Whole genome expression 
profiles were obtained from synovial tissue biopsies of knee joints from both naive and DBA/1J 
mice at day 30 of CIA using the Mouse Genome 430 2.0 array (Figure 1a). Prior to isolation, we 
semi-quantitatively scored the degree of joint inflammation and subdivided samples in four 
advancing stages of disease severity. For each stage, hybridization experiments were performed 
in triplicate and data normalized using MAS 5.0 software. Using Expander 4.1 software [16] 
we obtained 234 Affymetrix probes that correspond to 201 unique Ensembl genes whose 
expression was at least tenfold upregulated in at least three severity stages compared to naive 
conditions. Next, the standardized (mean 0 and variance 1) expression profiles were partitioned 
into distinct clusters using the k-means algorithm. Partitioning into six clusters resulted in the 
most optimal average separation (0.913) and homogeneity (0.938) of clusters. The average 
standardized expression levels of the clusters are plotted in Figure 1b. The annotation of the 
probe identities per cluster is documented in Table S1.
AP-1, C/EBPp and NF-kB binding sites are over-represented in TATA proximal-promoters 
To filter for promoters with high transcriptional specificity towards inflammation, we analyzed 
the murine and human orthologous proximal-promoters (-500/+200 region) for the presence of 
a putative TATA box within a -44 to -17 bp window relative to the TSS. The promoter sequences 
of 191 murine and human orthologs (Table S2) were retrieved from the Cold Spring Harbor 
Promoter database [17] and putative TATA box binding sites were searched with the program 
PATSER [18] using TATA_01 (M00252) and TBP_01 (M00471) position weight matrices (PWMs) in 
the TRANSFAC 7.0 database [19]. For 37 genes a putative TATA box was predicted in both murine 
and human promoter sequences. Additionally, a single TATA TFBS was predicted in promoter 
sequences 21 murine and 12 human genes (Table 1). The TATA proximal-promoters were used 
for subsequent identification of over-represented cis-regulatory elements. For this, we used 
Transcription Factor Matrix-Explorer software since it combines motif over-representation with 
comparative genomics and takes spatial conservation of cis-regulatory elements into account. 
Per cluster, over-represented TFBS were searched using PWMs corresponding to human or 
mouse binding factors in the public TRANSFAC and JASPAR databases [20]. Proximal-promoters 
from clusters 1 and 2, were significantly (P<10-6) enriched for PWMs corresponding to the 
transcription factor Rel/nuclear factor-KB (NF-kB). In clusters 2,4,5 and 6 several PWMs for the 
transcription factor activator protein-1 (AP-1) were over-represented. In contrast, promoters of
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Figure 3.1
Clusteranalysis of gene expression profiles from collagen-induced arthritis
(a) Schematic overview of the collagen-induced arthritis model. DBA/1J mice were immunized 
at day 0 by intradermal injection of bovine collagen type II (bCII). Immunized mice received 
an intraperitoneal booster injection of bCII at day 21 which triggers arthritis onset. After 10 
days of arthritis progression knee joints were macroscopically scored and divided in the four 
indicated severity stages. Representative hematoxylin & eosin stained tissue sections of knee 
joints from the four advancing severity stages are shown. M = muscle, S = synovium (dotted 
rectangle), F = femur. (b) Mean expression profiles of the eight clusters obtained with k-means 
clustering in EXPANDER 4.1. The Y-axis represents standardized expression levels. Error bars 
represent the ± 1 standard deviation of the members of each cluster about the mean of the 
particular severity stage.
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Table 1. Putative TATA-dependent murine and human orthologous genes
Gene Posa Scoreb Ortholog Pos Score Gen e Pos Score Ortholog Pos Sco re
Clust er 1 Cluster 5
ADAMTS4 -30 5.29 N i l  3 -24 8.70
Argl -30 4.58 ARGl -32 6.36 Ccll2 -30 5.19
Ccl20 -44 7.58 CCL20 -30 9.21 Clec4e -30 5.69
Clcal -32 5.32* CLCAl -30 5.01* Cxcl5 -32 6.41 CXCL6 -33 4.16
Cxcll -36 8.70 CXCLl -32 7.64 EVI2B -29 3.46*
Cxcl2 -32 7.8(5 CXCL2 -44 7.64 Hasl -28 4.93
CXCLl4 -35 5.28 I llb -33 7.08 IL lB -33 7.64
Il4ra -31 6.22 Illrn -34 7.68 IL lR N -40 4.32*
M srl -29 5.38* Il4ra -31 6.22
NCAPG -23 5.41* Lcn2 -30 9.39 LCN2 -31 7.71
OLFM4 -32 7.39 Lcpl -44 6.20* LCPl -43 6.20*
Rrm2 -30 8.12 RRM2 -38 5.58* Lox -30 3.84*
SULFl -40 8.61 MS4A7 -29 5.93*
Tnfaip6 -36 5.98* TNFAIP6 -30 5.98* NCAPG -23 5.41*
PAPPA -30 4.98
Cluster 2 Rassf5 -34 7.82
Ccl2 -33 6.88 CCL2 -31 4.33 Timp l -31 4.06* TIMPl -30 5.49*
Ccl7 -30 9.34 CCL7 -17 9.75 Tnc -36 8.9.31 TNC -34 9.38
Cxcll -36 8.70 CXCLl -32 7.64 Wwox 2-13-5 6.71
Gpr84 -38 4..4(85 GPR84 -34 3.95*
Il6 -30 5.28* IL6 -34 3.79* Cluster 6
Ptgs2 -30 3.67 PTGS2 -30 7.52 Chi3l l -23 5.68 CHI3Ll -31 7.63
Rrad -33 7.12 RRAD -31 6.47 Crabp2 -27 8.50
Serpbinla -31 7.38 SERPINBl -40 8.08 Hdc -30 4.38* HDC -30 5.70
Socs3 -39 5.41 I llr ll -23 5.98* IL lR L l -29 3.46*
Ltb -29 6.73 LTB -30 6.41
Cluster 3 Ltbp2 -29 6.73
Ankrdl -32 8.41 ANKRD1 -35 7.43 Mmp 3 -34 7.89 MMP3 -33 6.95
Uhrfl -31 7.67 UHRFl -20 5.96 Mmp9 -31 4.65* MMP9 -35 4.82
Mxdl -31 4.72*
Cluster 4 PLEK -31 6.44
Clqtnf3 -32 7.29 Cl QTNF3 -30 7.67 Sl00a8 -30 9.83 Sl00A8 -29 8.97
Clec4n -31 4.76* Sl00a9 -30 8.31 SI 00A9 -31 9.81
Cxcl3 C -33 9.13 Saa3 -33 5.47
Ibsp -30 5.28* IBSP -30 5.38* Slpi -30 3.78* SLPI -31 4.99
IR R C l5 -31 7.33 Snai2 -3(5 4.61
M m pl3 -31 5.53 M M Pl3 -31 7.50 Sox4 -30 5.38* SOX4 -21 5.38*
Pbk -25 4.27* Sppl 330 4.76* SPPl -32 5.83*
Pmaipl -30 5.48
Rspo2 -37 5.67*
Tnfsfll -33 4.32*
Putative TATA-box binding sites were identified by searching promoter sequences with TRANSFAC 
PWMs for TBP_01 (M00471) and TATA_01 (M00052) using the PATSER program. Sequences with 
scores higher than the cutoff calculated by PATSER were considered as putative binding site. 
Promoters with binding sites within the -44/-17 window relative to the TSS are displayed. 
a Start position of the core TATA-motif
b Putative TFBS based on scores above the numerically calculated cutoff scores for TATA_01 
(range: 4.36-11.76) and TBP_01 (range: 3.45-7.53)
* Hits for TBP_01 PWM
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Table 2. Over-represented transcription factor binding sites in k-means clusters
P W M L o catio n P -v a lu e n h a n sb P W M L o catio n P -v a lu e n h ns
Cluster 1 Cluster 4
NFKAPPAB65_01 -0095 -0049 8,53x10'15 14 47% FREAC-7 -0273 / -0029 2,62x10-10 32 76%
p65 -0095 -0050 4,06x10'12 12 42% F0XD3_01 -0428 / -0026 1,08x10'“ 42 84%
MEF2 -0048 -0019 5,67x10'12 15 66% MEF2 -0445 / -0028 1,53x10'°8 34 92%
CREL_01 -0095 -0049 6,55x10'12 12 38% AP1_C -0276 +0185 4,83x10'°8 24 76%
c-REL -0095 -0049 1,10x10'“ 12 38% FREAC7_01 # -0438 / -0020 1,01x10'°7 40 84%
NFKB_C -0156 -0048 7,25x10'“ 15 52% 0C T 1_02 -0247 / -0098 1,30x10'°7 16 61%
NRSF_01 * +0008/+0171 6,55x10-09 23 61% AP1_Q6 -0050 / -0004 9,81x10-07 8 53%
IK_01 * -0119 -0046 3,82x10J08 12 38%
FREAC-7 -0060 /  -0029 4,24x10J08 13 47% Cluster 5
NF-kappaB -0096 / +0061 1,02x10-07 13 52% CEBPB_01 -0238 / -0044 1,31x10'07 25 50%
FREAC7_01 # -0051 / -0020 3,30x10'07 14 50%
Cluster 2 GR_Q6 -0377 / -0035 4,15x10'07 36 57%
NFKAPPAB65_01 -0168 -0053 6,21x10'“ 14 58% AP1_Q6 -0239 / -0047 4,41x10-07 22 57%
p65 -0186 -0053 6,22x10-10 14 64% HLF -0098 / +0050 5,73x10-07 19 53%
CREL_01 -0165 -0053 1,06x10"°8 12 52% SPI-B -0138 / -0036 8,70x10'07 15 42%
c-REL -0165 -0053 1,79x10"°8 12 52%
NF-kappaB -0168 -0067 9,46x10J08 10 52% Cluster 6
NFKB_Q6 -0170 -0057 1,29x10J07 11 58% cEBP -0454 / -0052 3,32x10-11 39 64%
NRSF_01 * +0026 / +0102 1,48x10J07 13 52% CEBPB_02 -0493 / -0041 1,75x10'10 43 71%
c-Fos -0284 /  -0037 6,41x10J07 19 76% NF1_Q6 -0491 / -0047 1,60x10'09 30 60%
SRF -0145 -0018 7,75x10J07 10 47% SPI-1 -0273 / -0066 4,91x10-09 47 78%
NFKAPPAB_01 -0168 -0070 8,10x10J07 9 52% CEBPB_01 -0183 / -0078 2,12x10'08 20 50%
AP1_C -0198 / -0072 1,14x10'07 18 35%
PAX4_04 # +0120 / +0167 3,50x10'07 17 50%
Gfi -0228 / -0051 3,56x10-07 22 53%
CEBPA_01 -0282 / -0078 3,78x10-07 27 50%
S8_01 # -0236 / -0162 4,13x10-07 16 39%
Abbreviations: PWM, position weight matrix; TFBS, transcription factor binding sites. 
Over-representation of hits for TRANSFAC and JASPAR PWMs in promoters sequences with a 
putative TATA-box between positions -44/-17 (Table 1), was calculated using TFM-Explorer. Hits 
with a P-value < 10-6 are regarded as significant. 
a Total number of hits for PWM within promoter sequences 
b Percentage of promoter sequences containing at least one hit for PWM
* TFBS for which only murine binding factors have been described.
* TFBS for which only human binding factors have been described.
39
—  Disease-regulated local gene therapy for rheumatoid arthritis
Table 3. Significant transcription factor binding sites for N F -!  B, AP-1 and C/EBP" in 
TATA-dependent genes
NFkappaB65_ 01a A P 1_ 01b C E B P B _ 01c 
Gene_____ Pos. lnQF) Gene_____ Pos. lnQF) Gene______ Pos. lnQF)
Cxcl2 -70 -14.07 CXCL14 -96 -13.23 IL6 -158 -15.90
Cxcll -71 -14.07 Rrad -143 -12.74 Has1 -198 -12.83
CXCL1 -79 -14.07 Mmp9 -90 -12.63 Il6 -158 -12.35
Cxcl5 -89 -14.07 M MP9 -79 -12.51 Cxcl1 -131 -11.94
CXCL2 -90 -14.07 Il1rn -137 -12.13 Saa3 -79 -11.86
CXCL6 -92 -14.07 MMP13 -52 -11.80 Saa3 -154 -11.28
LTB -86 -12.96 IL6 -286 -11.62 LCN2 -146 -11.11
Ltb -89 -12.96 LRRC15 -52 -11.54 PLEK -52 -10.91
NCAPG -65 -12.35 Il6 -279 -11.37 MMP3 -115 -10.81
Cxcl3 -74 -12.24 MMP3 -75 -11.35 Arg1 -233 -10.19
RRAD -112 -12.17 Mmp13 -52 -11.31 CXCL14 -110 -10.02
Rrad -163 -12.17 OLFM4 -140 -10.71 MMP9 -166 -9.91
Il6 -71 -11.75 Wwox -200 -10.63 Chi3l1 -160 -9.53
IL6 -73 -11.75 TNFAIP6 -132 -10.52 LCN2 -85 -9.51
CCL20 -79 -11.68 Tnfaip6 -138 -10.52 S100A8 -136 -9.06
Ccl20 -96 -11.68 Chi3l1 -125 -10.37 Ccl12 -79 -9.02
Wwox -100 -11.28 Timp1 -98 -9.90 IL1B -95 -8.98
SOX4 -99 -10.59 TIMP1 -105 -9.90 Lcn2 -188 -8.86
Rspo2 -119 -10.34 Ccl2 -58 -9.73 SLPI -96 -8.74
Il1rl1 -138 -10.13 Socs3 -201 -9.29 ARG1 -81 -8.68
Ccl2 -154 -9.83 Lcn2 -277 -8.83 Il1b -95 -8.66
Il1b -230 -8.79 Has1 -144 -8.62
Ptgs2 -279 -8.78
LCP1 -449 -12.71 EVI2B -401 -11.95 ANKRD1 -304 -13.92
Ptgs2 -403 -12.17 Ccl2 -456 -10.93 Wwox -422 -13.79
PTGS2 -449 -12.17 CHI3L1 -367 -10.84 Ccl7 -460 -12.86
LCN2 -175 -10.79 Mmp9 -488 -10.37 Wwox -400 -12.56
Lcn2 -229 -10.79 Il4ra -416 -10.06 Ankrd1 -301 -11.79
IL1B -296 -10.71 Arg1 -410 -10.04 MMP9 -269 -11.05
Il1b -303 -10.64 CXCL6 -323 -9.81 Slpi -458 -10.97
TNC -222 -10.57 Slpi -490 -9.81 Serpinb1a -408 -10.60
CCL7 -306 -10.38 IL6 -490 -9.58 Slpi -281 -10.34
PLEK -337 -10.27 TIMP1 -359 -9.56 Chi3l1 -356 -9.85
MMP9 -329 -10.20 Cxcl5 -417 -9.56 MMP9 -446 -9.65
MS4A7 -494 -9.83 UHRF1 -468 -9.49 Tnfaip6 -444 -9.41
Putative binding siteswere identifiedbyPATSER using TRANSFAC matrices for 
aNF-KB (M00052), bAP-1(M00517) and cC/EBPp (M00117). Hitsarerankedaccordingtotheir 
ln(P)values and separatedintohitslyingwithin (upper panel)oroutside(lowerpanel)the 
conserved windows identified byTFM-Explorer (Table2).
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Figure 3.2
Schematic map of promoter regions with putative cis-regulatory elements
Indicated promoter regions were inserted upstream of the firefly luciferase cDNA in a SIN 
lentiviral backbone. The position of putative binding sites for TATA, NF-kB, AP-1 and C/EBPP 
identified by PATSER (Table 1, 3) are indicated. Promoter regions were derived from the murine 
genes CXC ligand 1/5 (Cxcl1/5), chitinase 3-like 1 (Chi3l1), hyaluronan synthase 1 (Has1), 
interleukin-1 beta (ILIfi), matrixmetalloproteinase 3/13 (Mmp3/13), serum amyloid A3 (Saa3), 
tissue inhibitor of metalloproteinase 1 (Timpl) and TNF alpha-induced protein 6 (Tnfaip6).
cluster 5/6 genes, whose transcriptional activity correlates most closely with disease severity, 
were enriched for binding sites CCAAT/enhancer binding protein p (C/EBPP). The majority of 
over-represented cis-regulatory elements were spatially conserved in a narrow 200-100 bp 
window upstream (NF-kB -170/-50, AP-1 -290/-30, C/EBPP -240/-45) of the putative TATA box 
binding site (Table 2).
Target genes of these transcription factors were identified using PATSER with high quality 
TRANSFAC PWMs, compiled from more than twenty experimentally verified binding sites,
41
—  Disease-regulated local gene therapy for rheumatoid arthritis
NFkappaB65_01 (M00052) , AP1_01 (M00517) and CEBPB_01 (M00109). Bona fide hits 
(P<10-8) were ranked according to the log ratio of their P values (In P) (Table 3). From the 97 
TATA-dependent promoters, 66 contained a spatially conserved NF-kB, AP-1 or C/EBPP TFBS. 
Without taking spatial conservation into account, 81 promoters contained a putative binding 
site. This strategy, has narrowed down the number of candidate proximal-promoters for 
transcriptional targeting in arthritis and provides useful information for rational selection of the 
promoter region.
Construction and validation o f transcriptionally targeted SIN lentiviral vectors 
We developed ten transcriptionally targeted lentiviral vectors, in which the firefly (Photinus Pyralis) 
luciferase cDNA expression is under control of computationally identified proximal-promoters. 
All promoters comprised the upstream region containing the identified over-represented 
TFBS, the TSS and a part of the 5'UTR-exon (Figure 2). To evaluate the basal transcriptional 
activity of the cloned promoter regions, murine NIH-3T3 fibroblasts were co-transfected with 
promoter constructs and as internal control reporter pRL-TK encoding constitutively active 
Renilla Reniformis luciferase. Cells were transfected with a promoterless or constitutively active 
cytomegalovirus immediate early (CMV) promoter construct as negative and positive control, 
respectively. Assessment of the relative luciferase activity at two days after transfection revealed 
that the basal transcriptional activity of all generated constructs was approximately three- to 
tenfold lower than obtained with the CMV promoter (1141 ±48). The strongest and lowest 
basal activity in murine fibroblasts was observed for the promoter regions of Cxcl5 (332±12), 
Il1b (331±10), Mmp13 (398±26), Tnfaip6 (342±8) and Saa3 (96±3), Mmp3 (112±10), respectively 
(Figure 3a). Next, we determined the responsiveness and kinetics of promoter activities to a 
pro-inflammatory stimulus. Murine RAW 264.7 macrophages (Figure 3b) or NIH-3T3 fibroblasts 
(Figure 3c) were transduced with lentiviral promoter-luciferase vectors and after two days 
challenged with lipopolysaccharide (LPS, 50 ng/ml). Luciferase activity was consecutively 
measured at two-hour intervals (0-6 hours) and twenty four hours. With exception of the 
Tnfaip6 (-499/+63) promoter, all constructs showed induction of promoter activity in response 
to toll-like receptor 4 (TLR4) triggering by LPS in macrophages. In contrast, a clear promoter 
response in fibroblasts was only observed for Saa3 (-314/+50), Cxcll (-455/+43), Cxcl5(-319/+31), 
Il1b (-350/+53) promoters. Since our computational analyses included the promoter regions of 
human orthologs (Table 1) and the majority of over-represented TFBS were conserved between 
species (Table 3), we investigated whether the murine promoters would be responsive in 
synovial fibroblasts isolated from RA patients (RASF). Primary synovial fibroblasts (n=4) were 
transduced with lentiviral vectors containing the Saa3, Cxcll, Cxcl5 or Mmp13 promoter. Two 
days after transduction RASF were stimulated for twenty four hours with either recombinant 
human IL-1P (0.25 ng/ml) or hTNFa (1 ng/ml) alone, or the combination of the two cytokines 
(Figure 3d). The Saa3 promoter activity was most strongly induced by stimulation with hIL-1P 
(17±2) or hTNFa (15±2) and the induction was less than additive for the combination of stimuli 
(22±3). As in murine fibroblasts, the Cxcl5 and Mmp13 were modestly and nonresponsive,
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Figure 3. 3
Experimental verification of transcriptionally targeted vectors
(a) Dual luciferase assay of basal promoter activity in NIH-3T3 fibroblasts. Cells were 
co-transfected with 500 ng transcriptional targeted vector and 50 ng pRL-TK. Promoterless 
(empty) and CMV-promoter vectors (black bars) served as negative and positive controls, 
respectively. Promoter activity is expressed as relative (firefly/renilla) luciferase activity +SEM 
(n=3). Kinetics of promoter induction by TLR4 triggering in murine RAW 264.7 macrophages
(b) and NIH-3T3 fibroblasts (c). Two days after transduction with lentiviral vectors, cells were 
stimulated for indicated time points with lipopolysaccharide (50 ng/ml). Luciferase activities 
are represented as fold induction over unstimulated conditions. (d) Induction of promoter 
activity in rheumatoid arthritis synovial fibroblasts (n=4 donors). Fibroblasts were transduced 
with lentiviral vectors and stimulated for twenty four hours either recombinant human IL-1p 
(0.25 ng/ml) or hTNFa (1 ng/ml) alone, or the combination. Luciferase activities are expressed 
as fold induction +SEM.
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respectively. Strikingly, the Cxcl1 promoter activity was induced by hIL-1P (4.0±0.3) but only 
marginally by hTNFa (1.6±0.2), while the combination of cytokines synergistically activated the 
Cxcll promoter (7.0±0.8).
Saa3 promoter drives therapeutically efficacious Illrn  in a disease-regulated fashion 
Previously, we have demonstrated therapeutic efficacy of transcriptionally targeted IL-4 gene 
therapy in CIA using a hybrid promoter consisting of the enhancer region of IL1B (-3690/-2720) 
fused to the proximal promoter of IL6 (-163/+12) (IL1E/IL6P) [4]. However, when the IL-4 
cDNA was replaced for the Il1rn cDNA we failed to prevent the development and progression 
of CIA (data not shown) as described for constitutive overexpression of this transgene 
[2,21]. We sought to address this efficacy issue by substituting the IL1E/IL6P promoter for a 
computationally identified promoter. Based on in vitro validations of promoter strength and 
responsiveness (Figure 3), the Saa3 promoter was selected as the most promising candidate 
for such a substitution. Firstly, we compared the promoter strength under arthritic conditions in 
vivo. Knee joints of C57Bl/6 mice were transduced by lentiviral vectors and after seven days an 
acute arthritis was induced by intra-articular injection of zymosan A (180 ^g). Twenty four hours 
after challenge we assessed luciferase activity ex vivo (Figure 4a). To control for amplification of 
transgene expression by inflammation-induced proliferation of lentivirally transduced synovium
[22], knee joints were transduced with a vector encoding phosphoglyceratekinase-1 (PGK) 
promoter-driven, constitutively expressed luciferase. Under naive conditions transcriptionally 
targeted vectors exhibited equal and low luciferase activities, approximately a log-fold lower 
compared to PGK-driven expression. One day after induction of arthritis, we measured a two-fold 
upregulation of PGK-driven luciferase expression. In contrast, under arthritic conditions Saa3 
and IL1E/IL6P promoter activities were twenty five- and eight-fold upregulated, respectively, 
and Saa3 promoter strength was approximately six fold higher compared to IL1E/IL6P. Next, 
we generated adenoviral vectors encoding Saa3 or IL1E/IL6P-driven Il1rn and measured the 
Il1rn protein levels under basal and stimulated conditions. HeLa cells were transduced (MOI 
10) at day one and the day thereafter left untreated or stimulated for twenty four hours with 
hTNFa (10 ng/ml). Basal and induced levels were 152.9±34.2 vs. 325.0±50.8 ng/ml (CMV) and 
2.8±0.2 vs. 49.6±8.1 ng/ml (Saa3) (n=4). Protein levels for IL1E/IL6P-driven Il1rn were around the 
detection limit of the ELISA (1 ng/ml). Next, we tested therapeutic efficacy of these vectors in an 
in vitro assay system (Figure 4b). NIH-3T3 fibroblasts stably transfected with the luciferase gene 
downstream of 5 tandem repeats of NF-kB binding sites were transduced (MOI 10) at day one 
with adenovirus encoding transcriptionally targeted Il1rn and at day two with constitutively 
expressed Il1b. As a positive and negative control, cells were transduced at day one with 
adenovirus encoding constitutively expressed Il1rn (CMV) or non-encoding adenovirus (del). 
At day three, we assessed 111 rn protein levels by ELISA and IL-1p-induced NF-kB activation 
by luciferase assay at day three. As expected, CMV-driven Il1rn expression (56.8±11.8 ng/ml) 
completely suppressed IL-1p-induced NF-kB activation (P<0.01). Empty control virus and IL1E/ 
IL6P-driven Il1rn expression (undetectable) failed to significantly inhibit NF-kB activation. In
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Figure 3.4
Saa3-promoter drives therapeutically efficacious I l lrn
Comparison of therapeutic efficacy using Saa3 versus IL1E/IL6P promoter for disease-regulated 
Il1rn expression. (a) Promoter activity in transduced synovium of naive and arthritic C57Bl/6 
mice. Knee joints were injected with 300 ng p24gag equivalents lentivirus encoding PGK, Saa3 
or IL1E/IL6P-luciferase. Seven days after transduction, arthritis was induced by intra-articular 
injection of 180 pg zymosan A. After twenty fours luciferase activity was assessed ex vivo. Data 
are represented as individual relative luciferase activities; horizontal bars indicate the means 
per group. (b) Efficacy of transcriptionally targeted adenoviral vectors expressing Il1rn. NIH- 
3T3-5xNF-kB-Luc were transduced at MOI 10 with control vector (del) or adenovirus encoding 
CMV, Saa3, IL1E/IL6P-driven Il1rn. After twenty four hours cells were transduced at MOI 10 
with control vector (del) or Ad5.CMV-Il1b. The day thereafter, IL-1p-induced NF-kB activation 
was assessed by luciferase assay. Data are represented as relative luciferase activities +SEM 
(n=4) and differences were determined using ANOVA with Dunnett's post-test. ** P<0.01.
contrast, Saa3-driven Il1rn expression (11.1±1.7 ng/ml) led to a significant (P<0.01) reduction 
(~56%) of IL-1p-induced NF-kB activation. These results indicate that the promoter strength 
and responsiveness of Saa3 might be sufficient to provide therapeutically efficacious protein 
levels in a transcriptionally targeted Il1rn gene therapy approach for experimental arthritis.
Discussion
Endogenous proximal-promoters that confer a range of transcriptional activities in an 
inflammation-specific fashion are of great value towards tailor-made transcriptionally targeted 
gene therapy for RA. To this end, we used a gene expression profiling study of CIA for elucidating 
disease-regulated genes and performed computational analyses on the proximal-promoter 
regions to define DNA regulatory elements that can be applied for transcriptional targeting. 
Using this approach we narrowed down the number of candidate murine and human promoters 
from 382 to 66, corresponding to 45 unique genes.
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In our approach we took the spacing between TATA box and TSS as a filtering parameter for 
transcriptional specificity. The rationale for this was derived from recent studies [8,9] showing 
the association of TATA-dependent transcription with tissue/context-specific gene expression. 
Moreover these studies demonstrate that the TATA-TSS spacing affects the transcriptional 
specificity of the downstream transcript. We predicted putative bona fide TATA boxes in using 
matching of PWM models. Generally, the score of a predictive PWM model is highly correlated 
with the strength of the protein-DNA interaction [23]. However, a genome-wide characterization 
of the interaction between the TATA box and the pre-initiation complex has revealed the 
absence of a global correlation between PWM score and tissue specificity [8]. These findings are 
reflected in our computations in which we could not establish any correlation between PWM 
score and spacing. Accordingly, in the experimental verifications using promoter-luciferase 
constructs we did neither find an apparent correlation between TATA box scores and basal 
promoter activity in a murine fibroblast cell line.
Apart from the TATA-TSS spacing, the identification of putative TFs that govern a particular 
expression profile was the second key determinant for selection of promoter regions. 
As demonstrated in similar approaches [13,14], the combination of co-regulated genes 
with phylogenetic footprinting proved fruitful for identification of over-represented TFBS. 
Supporting evidence for the functional relevance of the predicted over-represented TFBSs in 
RA is substantial. The over-representation of NF-kB and AP-1 binding sites corresponds to the 
pivotal role that has been implied for these factors in human RA, CIA and immunity [24-27]. 
Enhanced expression and DNA binding activity of C/EBPp in synovial tissue of RA patients 
has been implicated in the pathology [28] and chronicity [29] of disease. The latter coincides 
with the enrichment of C/EBPp binding sites in the CIA clusters in which the gene expression 
profile was closely correlated with disease severity. The additional enrichment of Spi-1 (Pu.1) 
and C/EBPa binding sites in cluster 6, is expected to arise from the increasing infiltration of 
the inflamed joint in CIA by myeloid (monocytes, dendritic cells, neutrophils) and lymphoid 
(T and B cells) cells. Pu.1 and C/EBPa are key factors in development of myeloid and B cells 
[30]. Interestingly, promoters of myeloid and B-cell-specific genes often contain a regulatory 
module consisting of a C/EBPa motif in close proximity (<60 bp) of the Pu.1 motif [31]. Indeed, 
the conserved locations of Pu.1 (-273/-66) and C/EBPa (-282/-78) in our analyses indicate the 
presence of such myeloid-specific modules. Since synovial fibroblasts represent the target cells 
for local gene therapy [15,32], the identification of myeloid-specific modules might be exploited 
to further refine the number of candidate promoters. Besides aforementioned TFs, we expect 
an contribution of the TFs signal transducers and activators of transcription-1/3 (STAT-1/3) 
[33] and interferon regulatory factor-1 (IRF-1) [34] in synovial inflammation. Indeed, scanning 
TATA-dependent promoters with corresponding PWMs (STAT_01 and IRF1_01) we found 15 
and 36 promoters with a putative binding site, respectively (data not shown). However, these 
hits were evenly dispersed over the clusters on a wide range (-500/-100) of positions, which 
explains the absence of over-representation for these TFBS in our analyses. The accuracy of 
the approach for inferring functional cis-regulatory elements is not only demonstrated by our
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experimental verifications but also by literature confirming the functionality of computational­
ly-identified top-ranking TFBS in several promoters such as Il1b [35], Cxcl1 [36], Saa3 [37], Timp1 
and Mmp3/13 [38].
The strength of our approach lies in the combination of gene expression profiling for 
identification of candidate genes with computational prediction of functional endogenous 
proximal promoters. These are expected to contain evolutionarily conserved and by natural 
selection optimal combinations of and spacings between TFBSs. This represents a major 
advantage over recent efforts that aim at tailoring gene expression using genetic engineering 
of synthetic promoters [25,39,40]. While these studies have demonstrated encouraging 
results for modulating transgene expression in prokaryotes, the extrapolation to eukaryotic 
transcriptional regulation by modules proves far more complex and the screening of hundreds of 
randomly assembled synthetic promoters is laborious and time-consuming. Still, the identified 
over-represented TFBS and their distance constraints might be useful for guiding the rational 
design of a synthetic promoter. For example, it was demonstrated for RA gene therapy that a 
synthetic promoter consisting of six tandem repeats of NF-kB consensus sites drives efficacious
[41] expression of anti-TNFa. The functionality of this promoter might be explained by the fact 
that the construct consists of a TFBS that is over-represented in inflammation-induced genes 
and positioned within the evolutionary conserved -170/-50 region upstream of the TSS.
The pitfall of using Il1rn as a transgene lies in the fact that it needs to be present in at least 
100-fold molar excess in order to block the effects of IL-1p on synoviocytes and chondrocytes
[42]. However, using Saa3-driven Il1rn expression we obtained a more than 50% inhibition 
of an CMV-driven, exaggerated and non-physiological amount of IL-1 p. The relatively high 
transcriptional strength of the Saa3 proximal promoter has been demonstrated by Varley 
and coworkers [43]. In their study, Saa3-driven luciferase expression exceeded that of the 
CMV promoter in response to cytokine-rich conditioned medium prepared from the culture 
supernatant of LPS stimulated human peripheral blood monocytes. In combination with 
our computational analyses and verifications, the Saa3 promoter is the most appropriate 
endogenous promoter for transcriptionally targeted Il1rn gene therapy for arthritis.
For the panel of inflammation-responsive promoters we envisage two major applications. First, 
these promoters can be applied in non-invasive imaging approaches of joint inflammation or 
activation of particular transcription factors, e.g. AP-1 (Mmp13) versus NF-kB (Cxcl1), in human 
and experimental arthritis. Whether these proximal promoters confer differential expression 
patterns during experimental arthritis will be investigated using an in vivo imaging approach. 
Second, differential transcriptional activities can be exploited for gene therapy tailored to 
transgene properties, e.g. a promoter with strong transcriptional activity for generating the 
required excess of Il 1 rn expression and a promoter with low basal activity for minimizing 
Il4-induced side effects.
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Materials and methods 
Animals
Male 10-12 week old DBA/1J mice were obtained from Janvier (Le Genest Saint Isle, France). 
C57BI/6 mice were obtained from Charles River (Sulzfeld, Germany). During viral experiments, 
mice were housed in low-pressure isolator cages. The animals were fed a standard diet with food 
and water ad libitum. All in vivo studies complied with national legislation and were approved 
by the local authorities of the Care and Use of Animals.
Induction of collagen-induced arthritis
Bovine collagen type II (bCII) was dissolved in 0.05 M acetic acid to a concentration of 2 
mg/ml and was emulsified in equal volumes of Freund's complete adjuvant (2 mg/ml of 
Mycobacterium tuberculosis strain H37Ra, Difco Laboratories, Detroit, MI, USA). DBA-1/J mice 
were immunized intradermally at the base of the tail with 100 ^l of emulsion (100 ^g of bCII). 
On day 21, the mice were given an intraperitoneal booster injection of 100 ^g bCII dissolved 
in PBS. Mice were sacrificed on day 30 by cervical dislocation. Prior to biopsy, knee joints were 
scored visually using four grades: nondiseased, mild (minor swelling, color change due to 
infiltration), moderate (marked swelling) and severe (severe swelling, patella tendon structure 
not visible). Synovial tissue samples from the lateral and medial sites (n=24, 12 knee joints per 
severity stage) were isolated in a standardized manner using a 3 mm biopsy punch (Stiefel, 
Wächtersbach, Germany), as described previously [44]. Samples were pooled in a randomized 
fashion to generate triplicates consisting of eight biopsies.
RNA isolation
Total RNA from biopsy punches was prepared by TRIzol extraction (Invitrogen Life Technologies), 
and purified on an affinity resin (RNeasy Kit, Qiagen) according to the manufacturer's 
instructions. Quantity and purity were assessed by the absorbance at A = 260 nm (A260nm) and 
the ratio A260nm/A 280nm . Integrity of the RNA was confirmed by non-denaturing agarose gel 
electrophoresis. Total RNA was stored at -80 °C until further processing.
Oligonucleotide array
1 ^g of total RNA was used as starting material for cDNA preparation. Generation of biotinylated 
cRNA and subsequent hybridization, washing and staining of MOE 430_2 oligonucleotide 
arrays (Affymetrix, Santa Clara, CA) were performed according to the Affymetrix Expression 
Analysis Technical Manual for one-cycle amplification. The arrays were then scanned using a 
laser scanner GeneChip®Scanner (Affymetrix) and data were analyzed and normalized using 
Affymetrix Microarray Suite (MAS) 5.0 software according to the manufacturer's instruction. The 
gene expression data were deposited in the GEO database under accession number GSE13071.
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Clusteranalysis
Filtering, standardization and cluster analysis were performed using Expression Analyzer and 
Displayer (EXPANDER) software version 4.1 [16]. The mean (n=3) expression values calculated 
from the normalized microarray data using Excel served as input. After filtering for tenfold 
regulated probes, the expression values were standardized using the mean 0 and variance 
1 algorithm. Cluster analyses were performed using k-means clustering with the number of 
clusters set to 6.
Promoter sequence retrieval
Affymetrix probe identifiers were converted into ENSEMBL gene identifiers (NCBI m37 mouse 
assembly) and RefSeq DNA identifiers (mm8) using BioMart (http://www.biomart.org). Human 
orthologs were retrieved from the Mouse Genome Database (MGB) [45]. We extracted the 
proximal promoter regions of these genes (-500/+200) from the Cold Spring Harbor Laboratory 
mammalian promoter database [17] using RefSeq identifiers. When multiple promoters existed 
for a gene, we selected either a promoter from the Eukaryotic Promoter Database (EPD) or 
Database of Transcription Start Sites (DBTSS). When the prior two were unavailable, we selected 
the promoter with the shortest distance to the gene.
Identification of transcription factor binding sites
The PATSER program [18] at the Regulatory Sequence Analysis Tools server (http://rsat.ulb.ac.be/ 
rsat) [46] was used to search position weight matrix models collected from the public TRANSFAC 
7.0 database [19]. Both strands of the promoter sequences were scanned in our analyses. 
Sequences with scores higher than the cutoff calculated by PATSER were considered as putative 
TFBS [47].
Identification of over-represented TFBS
Promoter sequences with a putative TATA binding site were scanned, per cluster, for 322 
vertebrate matrices from the TRANSFAC 7.0 and JASPAR [20] databases using TFM Explorer 
(http://bioinfo/lifl.fr/TFM-Explorer) [12]. The ratio parameter, indicating the minimal average 
density of hits in the cluster relative to the reference model, was set to 4.0. PWMs with a P-value 
< 10-6 were regarded as significantly over-represented.
Cell culture
Mouse embryonic fibroblasts (NIH-3T3), macrophages (RAW 264.7) and human HeLa cells were 
cultivated in DMEM with 1 mM pyruvate, 40 pg/ml gentamycin, and 5% or 10% fetal calf serum 
(FCS), respectively. Early-passage rheumatoid arthritis synovial fibroblasts (kind gift from R.W. 
Kinne, Universital Hospital Jena, Eisenberg, Germany) were maintained in DMEM supplemented 
with 1 mM pyruvate, 80 pg/ml gentamycin, and 10% FCS. Cells were kept at 37 °C in a humid 
atmosphere containing 5% CO2.
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Plasmids
Renilla luciferase vector pRL-TK was obtained from Promega (Madison, WI, USA). For generation 
of recombinant lentiviral vectors we made use of the third-generation self-inactivating transfer 
vectors pRLL-cPPT-PGK-mcs-PRE-SIN containing the human phosphoglyceratekinase (PGK) 
promoter and the promoterless pRLL-cPPT-mcs-PRE-SIN (kind gift from J. Seppen, AMC Liver 
Center, Amsterdam, The Netherlands). For cloning we used Pfu DNA polymerase (Stratagene, 
La Jolla, CA, USA) and T4 DNA Ligase (New England Biolabs, Ipswich, MA, USA). All generated 
constructs were verified by sequencing. The firefly luciferase cDNA from pGL3b (Promega, 
Madison, WI, USA) was transferred as an NheI/XbaI fragment into the multiple cloning site 
generating pRLL-cPPT-PGK-Luc-PRE-SIN and pRLL-cPPT-Luc-PRE-SIN. The plasmid pRLL- 
cPPT-CMV-Luc-Pre-SIN was generated by PCR cloning the CMV promoter from pShuttle-CMV 
(Stratagene) into SalI/HpaI sites using primers FW 5' GTCGACTAGTAATCAATTACGGGG-3' and 
RV 5'GTTAACGGATCTGACGGTTCAC-3'. The murine promoter sequences were PCR cloned from 
liver genomic DNA into SalI/NheI sites of pRLL-cPPT-mcs-Luc-PRE-SIN using primers in Table 
S3. The IL-1E/IL-6P promoter was transferred as a SalI/NheI fragment from pGL3-IL-1E/IL-6P [5] 
into pRLL-cPPT-mcs-Luc-PRE-SIN. The cDNA of the mouse Il1rn gene was transferred as a SalI/ 
XbaI fragment from pShuttle-CMV-Il1rn [48] into pRLL-cPPT-PGK-mcs-PRE-SIN. For constructing 
pRLL-cPPT-Saa3-Il1 rn-PRE-SIN, Il 1 rn was amplified from pShuttle-CMV-Il1rn using primers 
FW 5'-GCTAGCGCCACCATGGAAATCTGCTGGGGAC-3' and RV 5'-TCTAGACTATTGGTCTTCCT- 
GGAAG-3' introducing a 5' NheIand 3' XbaI site and blunt ligated into the SrfI site of pCR-Script 
Amp SK(+) (Stratagene, La Jolla, CA, USA). The luciferase cDNA was removed from pRLL-cPPT- 
Saa3-Luc-PRE-SIN by restriction with NheI/NsiI and religated with a NheI/PstI fragment from 
pPCR-Script-Il1rn (-). A SalI/XbaI fragment from pRLL-cPPT-Saa3-Il1rn-PRE-SIN containing the 
Saa3 promoter and Il1rn cDNA was transferred to pShuttle-polyA to give pShuttle-Saa3-Il1rn- 
polyA. The cDNA of mouse interleukin-1 beta (Il1b) was PCR cloned from reverse transcribed 
C57Bl/6 synovial tissue RNA into the KpnI/XhoI sites of pShutlle-CMV using primers FW 
5'-AAAGGTACCGCTATGGCAACTGTTCC-3' and RV 5'-TTTCTCGAGTTAGGAAGACAC-3'.
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was performed by transient 
transfection of 293T cells. The day prior to transfection, 293T cells were seeded in a T75 flask at 
1x105 cells/cm2 in DMEM supplemented with 10% FCS, 1 mM pyruvate, 40 pg/ml gentamycin and 
0.01 mM water-soluble cholesterol (Sigma). Cells were co-transfected with 19 pg transfer vector, 
14 pg gag/pol packaging plasmid (pMDL-g/p-RRE), 4.7 pg rev expression plasmid (RSV-REV) and
6.7 pg VSV-G expression plasmid (pHIT-G) by calcium phosphate precipitation. Transfections 
were performed in 6 ml DMEM without antibiotics and cholesterol and proceeded for 16 hours. 
Thereafter medium was replaced with fully supplemented DMEM and supernatant harvested 
after 24 and 48 hours. Cell debris was removed by centrifugation at 1500 rpm for 5 minutes 
at 4 °C, followed by passage through a 0.45 pm pore PVDF Durapore filter (Millipore, Bedford, 
MA, USA). For concentration by ultracentrifugation 28 ml supernatant was layered on 4 ml 20%
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sucrose solution and centrifuged at 25.000 rpm in a Surespin 630 rotor (Sorvall). Pelleted viruses 
were resuspended in sterile PBS and stored at -80 °C. Viral titers were determined by assaying 
p24gag values with a commercial enzyme-linked immunosorbent assay (ELISA) kit (Abbott, Il, 
USA) and expressed as ng p24gag/pl.
Adenoviral vectors
Replication-deficient adenoviral vectors (E1/E3 deleted) Ad5.Saa3-//1rn, Ad5.IL-1E/IL-6P-//7rn, 
Ad5.CMV-//7rn, Ad5.CMV-//7b and Ad5.del were prepared according to the AdEasy system 
(Stratagene), with the exception that replication-competent recombinant free viral particles 
were produced in E1 transformed N52E6 amniocyte cells [49]. Viruses were purified by two 
consecutive CsCl2 gradient purifications and stored in small aliquots at -80 °C in buffer containing 
25 mM Tris, pH 8.0, 5 mM KCl, 0.2 mM MgCl2, 137 mM NaCl, 730 pM Na2HPO4, 0.1% (w/v) 
ovalbumin and 10% (v/v) glycerol. The infectious particle titer (ffu) was determined by titrating 
vector stocks on 911 indicator cells and measuring viral capsid protein immunohistochemically 
20 hours after transduction.
Luciferase measurements
For in vitro  reporter studies, cells were seeded at 5 x 104 cells per well in a Krystal 2000 
96-wells plate (Thermo Labsystems, Brussels, Belgium). The day after, cells were transduced 
with 50 ng p24gag equivalents lentivirus in 50 pl medium supplem ented with 8 pg/m l 
polybrene (Sigma) for 4 hours at 37 °C. Cells were serum starved (1% FCS) for tw o days and 
subsequently stimulated with recombinant human IL-1ß (R&D Systems Europe, Oxford, UK), 
TNFa (Abcam, Cambridge,UK) or E. Coli LPS (Sigma) for indicated hours and subsequently 
lysed in ice-cold lysis buffer (0.5% NP-40, 1 mM DTT, 1 mM EDTA, 5 mM M gCl2, 100 mM KCl, 
10 mM Tris-HCl pH 7.5). Luciferase activity was quantified using the Bright-Glo luciferase 
assay system (Promega, Madison, WI, USA) by adding an equal volum e of Bright-Glo to 
the cell lysate. Luminescence was quantified in a lum inom eter (Lumistar, BMG, Offenburg, 
Germany), expressed as relative light units (RLU) and normalized to total protein content 
of the cell/tissue extracts. For transient transfection experiments, cells were seeded at 70%  
confluency in a 24-wells plate and co-transfected with 500 ng firefly luciferase reporter 
and 50 ng renilla luciferase reporter (pRL-TK) using Arrest-In (Open Biosystems, Huntsville, 
AL, USA) according to the  m anufacturer's instructions. Cells w ere serum starved (1%  
FCS) for tw o days and firefly  and renilla luciferase activities w ere quantified  using the  
Dual Luciferase Reporter Assay System (Prom ega). For in vivo  studies, knee jo ints were  
in jected w ith  300 ng p24gag equivalents lentivirus in a to ta l vo lum e o f 6 pl. Seven days 
after transduction, knee jo ints w ere in jected w ith 180 pg zymosan A /6  pl PBS (Sigma). 
A fter one day patellae w ith surrounding tissue w ere dissected, put in 250 pl cell culture  
lysis buffer (Prom ega) and snap frozen in liquid n itrogen. Supernatant was centrifuged  
at 13.000 rpm  for 5 m inutes and luciferase activ ity  assayed as described above.
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In vitro  Il1rn-efficacy assay system
NIH-3T3 fibroblasts stably transfected with a 5xNF-kB luciferase reporter were seeded at 5 x 104 
cells per well in a Krystal 2000 96-wells plate (Thermo Labsystems, Brussels, Belgium). The day 
thereafter, cells were transduced at a multiplicity of infection (MOI) of 10 with Il1rn-encoding 
or control non-encoding adenovirus (Ad5.del) in DMEM for 4 hours at 37 °C. After twenty four 
hours medium was aspirated, cells were rinsed and transduced at MOI 10 with Il1b-encoding or 
Ad5.del virus in DMEM for 4 hours at 37 °C. The day after the second transduction, IL-1p-induced 
NF-kB activation was measured by assessing the luciferase activity as described above.
Il1rn ELISA
White high-binding flat bottom 96-well plates (Greiner Bio-One, Alphen a/d Rijn, The 
Netherlands) were coated with the capture antibody rat anti-murine 111 rn (MAB480, R&D 
Systems, Minneapolis, Minnesota, USA) at 3 pg/ml in 0.1 M carbonate buffer pH 9.6 and 
incubated overnight at 4 °C. Non-specific binding sites were blocked with 1% BSA in PBS for 
1 hour at room temperature. Between subsequent incubations, wells were rinsed three times 
with 0.1% Tween-20 in PBS. Twenty four hour culture supernatants (100 pl) from 3 x 105 HeLa 
cells transduced with adenoviral Il1rn-expressing vectors at a MOI 10 were added to coated 
wells and incubated for 3 hours at room temperature. The plates were then incubated with 
the biotinylated goat anti-murine Il1rn (BAF 480, R&D Systems) at 0.2 pg/ml in 0.1 % BSA/PBS 
for 2 hours, followed by a 30 minute incubation with streptavidin-conjugated horseradish 
peroxidase (Dako, Glostrup, Denmark) at 0.25 pg/ml in PBS. Antibody complexes were detected 
by incubation with the Supersignal ELISA Pico Chemiluminescent Substrate (Pierce, Rockford, 
Illinois, USA) and luminescence quantified in a luminometer.
Statistics
Data are represented as means+s.e.m. and significant differences were calculated using one-way 
analysis of variance (ANOVA) followed by Dunnett's Multiple Comparison test (GraphPad Prism 
5.02, San Diego, CA, USA). P-values less than 0.05 were regarded significant.
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Abstract
Objective: To evaluate the applicability of a lentiviral (LV) Saa3-promoter luciferase (Luc) 
reporter for assessing inflammation subtypes in experimental arthritis and synovial fibroblasts 
(SF) from osteoarthritis (OA) and rheumatoid arthritis (RA) patients.
Methods: Lentiviral transduction of murine synovium and human SF was optimized using a 
cholesterol-additive during LV production. In mice, synovium was transduced in vivo and two 
flares of acute joint inflammation were induced by intra-articular injection of streptococcal cell 
wall (SCW) material into the knee joint cavity. The time course of synovial inflammation was 
assessed using ex vivo luciferase assays, 99mtechnetium (Tc) uptake and histological analysis. 
SF (n=12) of RA and OA patients were stratified by hierarchical clustering of whole genome 
expression profiles. Relative Saa3-promoter responses were determined in cytokine- or toll-like 
receptor-stimulated SF subgroups.
Results: Saa3-promoter activity was transiently and strongly upregulated at one and two 
days after first and second SCW challenge, respectively. Promoter activities during acute 
inflammation correlated with Tc uptake measurements and histological assessments, whereas 
only the Saa3-promoter activity correlated with histological changes during the relapse stage 
of the disease. Saa3-promoter reporter, but not Tc uptake, responded to SCW challenge in a 
dose-dependent fashion. Molecular stratification defined two inflammatory SF subtypes, 
unrelated to disease classification. Relative Saa3-promoter responses to IL-1 p, TNFa and 
TLR4 agonist were significantly increased in OA/RA SF with a high (n=3) compared to a low 
inflammatory subtype (n=3).
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Conclusion: A transcriptional Saa3-promoter reporter demonstrates a robust and feasible 
method for assessing the course and severity of experimental arthritis and to distinguish 
molecularly distinct inflammatory SF subtypes from a heterogeneous patient population.
Introduction
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease that mainly affects the 
synovial joints that ultimately leads to joint destruction. Prior to and during joint inflammation 
the synovial lining tissue, consisting of synovial fibroblasts (SF) and macrophages, becomes 
activated. In both experimental and human arthritis, SF have been identified as cells that 
actively drive inflammation and joint destruction [1-3]. Moreover, transmigration of activated 
RASFs has been implicated in mediating the spreading of destructive arthritis to unaffected 
joints [4]. Due to their key role in RA pathogenesis, SF are regarded not only as major target 
cells for treatment, but also for diagnostic assessment of disease activity or phenotype. 
Non-invasive assessment of disease activity is frequently performed using radiographic agents 
such as 99mtechnetium pertechnetate (99mTc) [5]. Histological and immunohistochemical analyses 
of synovial tissue comprise the classic ex vivo methods for assessing the grade of inflammation 
and molecular pathology in human and experimental arthritis and have evidently pointed out 
that RA is a heterogeneous disease [6,7]. These findings have been corroborated by various 
gene expressing profiling studies of synovial membranes and isolated SF using microarrays 
[8-13]. Moreover, these have shown that disease heterogeneity is stably imprinted in SF and 
molecularly distinct inflammatory subtypes can be discerned.
Gene expression is regulated at multiple levels including epigenetic, transcriptional and 
translational control. Transcriptional control is exerted by the differential activation of 
transcription factors (TF) and pivotal TFs implied in RA pathogenesis include nuclear factor-KB 
(NF-kB), activator protein-1 (AP-1) and CCAAT/Enhancer binding protein p (C/EBPp) [14-16]. 
Activity of TFs can be dynamically assessed using transcriptional assays based on expression 
of luminescent, fluorescent or enzymatic reporter genes driven by a promoter containing 
TF-response elements. Until now, the diagnostic potential of transcriptional reporters in RA has 
not been extensively investigated.
Recently, we have designed a number of promoter-luciferase reporters, using gene 
expression profiling data of inflamed synovium in murine collagen-induced arthritis (CIA), 
that demonstrated responsive to experimental arthritis and inflammatory stimuli in human SF 
[17]. These reporters contained composite elements of AP-1, NF-kB and C/EBPp binding sites. 
Notably, we found an enrichment of C/EBPp-binding sites in the promoters of genes whose 
expression correlated with disease severity in CIA, in particular the promoter of serum amyloid 
A3 (Saa3). This led to the hypothesis that a Saa3-promoter reporter might serve as a novel 
diagnostic tool for assessing inflammatory subtypes in arthritis.
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Therefore, we performed kinetic analyses of Saa3-promoter activity in SCW arthritis 
and compared this novel method with 99mTc uptake and histological assessment of joint 
inflammation. In addition, we evaluated whether Saa3-promoter responses in SF would be able 
to discriminate between SF of low and high inflammatory expression profiles, as deduced by 
gene expression profiling.
Results
Optimal transduction efficiency of synovial fibroblasts using cholesterol-optimized lentivirus. 
HIV-1 recombinant lentiviruses (LV) have been demonstrated to efficiently transduce murine SF 
in vivo [17,18]. To establish a novel LV vector-based method for assessing synovial inflammation, 
we determined optimal transduction efficiency of murine synovium using cholesterol-optimized 
LV particles (Figure 1a) [19]. Cholesterol addition during LV production resulted in maximally 
six-fold increased functional titers (P<0.001) at a cholesterol concentration of 0.01 mM. Using 
conventionally-produced LV, maximal transgene expression in vivo was reached at 300 ng of 
LV p24gag equivalents per joint (Figure 1b). In contrast, cholesterol-optimized LV showed a 
four-fold increase in transgene expression at the same particle titer (Figure 1c). Fluorescence 
microscopy of tissue sections demonstrated that increased transgene expression resulted from 
an enhanced transduction efficiency of the synovial lining layer (Figure 1d).
Next, we determined optimal transduction efficiency of human SF isolated from tissue biopsies. 
The fibroblast phenotype of isolated cells was confirmed by the abundant surface expression of 
Thy-1 (Figure 2a). Transduction efficiency reached approximately 98% of the starting from 100 
ng of p24gag LV per 1.6x105 cells and the optimum was reached at 200 ng, respectively (Figure 
2b,c)
Saa3-promoter activity correlates with histological assessment of joint inflammation in SCW
arthritis
Using optimal transduction parameters described in the previous section, we investigated 
the kinetics of Saa3-promoter activity during two consecutive flares of SCW-induced arthritis. 
Histological analysis revealed a large inflammatory infiltrate at one day post-challenge, which 
was most prominently located in the joint cavity (exudate, score: 2.05±0.37) and marginally in 
the synovium (infiltrate, score 0.30±0.11) (Figure 3a). At six days after SCW challenge exudate 
was resolved (0.06±0.13), whereas the infiltrate remained and showed an increase compared 
to day one (1.19±0.37) (Figure 3b). In line with these results, the induction of Saa3-promoter 
activity peaked at day one after challenge (35.3±6.8-fold), declined significantly at 2,4 and 6 
days (~12-fold), but did not return to basal levels (Figure 3c). A second SCW injection strongly 
reactivated Saa3-promoter activity at one (23.3±6.8-fold) and three days (40.3±8.7-fold) after 
challenge. To assess whether these results are specific for the Saa3-promoter, we performed 
the same experiment using a Cxcl1-promoter reporter. Our previous computational analyses 
demonstrated that, unlike Saa3, expression of Cxcl1 does not correlate with disease activity in 
CIA and its promoter contains two strong NF-kB motifs. Cxcl1-promoter activity showed peak
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Figure 4.1
Enhanced transduction efficiency of murine synovium using cholesterol- 
optimized LV
Enhanced transduction efficiency of murine synovium using cholesterol-optimized 
LV. (a), 5x104 NIH-3T3 fibroblast were transduced with 50 ng p24gag equivalents 
LV-PGK-Luc. Viral particles were produced in the presence of indicated amounts 
water-soluble cholesterol. Two days post-transduction luciferase expression was 
quantified using a luciferase assay. Data are expressed as RLU/pg protein +SEM 
(n=3). (b-d), Analysis of transduction efficiency of murine synovial tissue in vivo. 
Knee joints of naïve C57Bl/6 mice were transduced with 300 ng p24gag equivalents 
LV-PGK-Luc (b,c) or LV-PGK-GFP (d) produced in absence (b) or presence (c,d) of 
cholesterol. Five days post-transduction joints were dissected and transgene 
expression was quantified using a luciferase assay (b,c) or fluorescence microscopy 
(d). Luciferase expression is expressed as RLU corrected for protein content of 
samples +SEM (n=3). (d), Analysis of GFP expression in synovium using immunof­
luorescence microscopy of tissue sections. Statistical differences were determined 
using ANOVA with Bonferroni's post-test. ** P<0.01, *** P<0.001.
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Figure 4.2
Transduction efficiency of human SF by cholesterol-optimized LV
Fibroblasts were isolated from the synovial tissue by consecutive digestion of the tissue with 
trypsin and collagenase p, followed by negative CD14 MACS isolation [48]. (a) Strongly positive 
immunohistochemical staining of CD14 MACS negatively isolated RA SF for the surface marker 
Thy-1 (CD90) confirms a fibroblast phenotype. (b,c), 1.6x105 SF were transduced with the 
indicated p24gag equivalents LV-PGK-GFP. After two days, GFP expression was evaluated using 
fluorescence microscopy, a representative picture is shown (b). The optimal transduction 
efficiency was deduced using FACS analysis of the percentage GFP-positive cells (% GFP+) and 
the protein expression level (MFI) (c).
induction (6.9±2.5-fold) at day one and returned to nearly basal levels (~2-fold) from day two 
through six. However, a second SCW challenge failed to induce reactivation of Cxc/7-promoter 
reporter. These results suggest a unique correlation between Saa3-promoter activity in 
synovium and joint inflammation.
Saa3-promoter reporter provides increased sensitivity for detecting joint inflammation
compared to 99mTc uptake 
Bioluminescent imaging has shown potential for non-invasive assessment of inflammation in 
arthritis [20]. Therefore, we compared the performance of Saa3-promoter reporter with 99mTc 
uptake measurement, which is an well-established method for non-invasive quantification
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Figure 4.3
Saa3-promoter activity correlates with histological assessment of joint 
inflammation
(a,b) Knee joints of naïve C57BI/6 mice were challenged with 25 pg SCW and mice were 
sacrificed at one (a) or six (b) days thereafter. Joint inflammation was assessed by evaluation 
of hematoxylin and eosin-stained tissue sections, representative pictures are shown. Filled 
and open arrowheads mark inflammatory infiltrate in the synovial cavity and synovial lining, 
respectively. Inlays show the synovial lining at a higher magnification. (c) Knee joints of naïve 
C57Bl/6 mice were transduced with 300 ng p24gag LV-Saa3-Luc, LV-Cxcll-Luc or constitutively- 
active LV-PGK-Luc. Four and ten days post-transduction (days 0 and 6) acute arthritis was 
induced by intra-articular injection of 25 pg SCW (arrows). Luciferase activities were evaluated 
ex vivo at indicated time points, normalized versus PGK-driven luciferase, and represented as 
fold-induction+SEM (n=5) over naïve conditions.
of joint inflammation [5]. Both Soo3-promoter activation (15.0±1.5-fold) and 99mTc uptake 
measurement (1.84 ±0.02), revealed strong joint inflammation at day one after SCW challenge 
(Figure 4a). In addition, we observed a strong and significant correlation between both 
methods at this time point (P<0.0005, Pearson r 0.82) (Figure 4b). At day seven, in line with 
the observations from the previous section, Soo3-promoter reporter remained significantly
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Figure 4.4
Saa3-promoter reporter vs. 99mTc uptake for assessing joint inflammation
Comparison of Saa3-promoter reporter versus 99mTc uptake for assessment of joint 
inflammation. (a) Both knee joints of naïve C57BI/6 mice were transduced with 300 ng p24gag 
equivalents LV-Saa3-Luc. Seven days post-transduction, unilateral arthritis was induced by 
intra-articular injection of 25 pg SCW fragments (right joint). 99mTc uptake was assessed at 
indicated days and immediately thereafter joints were dissected and luciferase activities 
assessed. Bars represent means+SEM (n=4) of luciferase (black) and 99mTc uptake (white) ratios 
(right/left joint). (b) Correlation between Saa3-promoter reporter and 99mTc uptake ratios from 
non-inflamed and SCW-challenged knee joints. Data are collected from two independent 
experiments. (c) Sensitivity of Saa3-promoter reporter versus 99mTc uptake. Right knee joints 
were transduced with LV-Saa3-Luc and after 6 days challenge with indicated amounts SCW 
fragments. Bars represent means+SEM (n=3) of luciferase activity (black, fold induction over 
naïve conditions) and 99mTc ratios (white).
activated (6.3±2.4-fold) during relapse of joint inflammation. However, joint inflammation was 
not detectable at this time point using 99mTc uptake measurement (1.01±0.02).
These results prompted us to investigate the sensitivity of both methods by measuring the 
dose-response to SCW fragments (1, 5 and 25 pg) (Figure 4c). Whereas 5aa3-promoter reporter 
showed a clear response for all doses and a trend towards stronger responses at higher dose 
(5.5±0.8, 6.5±1.3, 7.9± 1.6-fold), joint inflammation as measured by 99mTc uptake was only 
evident (1.62±0.17) at highest SCW-dose. These data suggest that 5aa3-promoter reporter is a 
more sensitive read-out for joint inflammation than 99mTc uptake.
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Figure 4.5
Hierarchical clustering of RA and OA SF gene expression profiles
(a,b) Hierarchical clustering of the expression of 7705 cDNAs in SF from patients with RA 
(n=6) or OA (n=6). Each row represents a single gene; each column represents an individual SF 
sample. Black, red and green bands indicate relative expression equal to, greater or lower than 
the median of all samples. Gray bands indicate the absence of expression of the corresponding 
cDNA. Color intensities indicate the magnitude of the deviation from the median (bottom, b). 
Subgroups are labeled I, II and III. Gene clusters with a related expression profile are labeled A 
through E (a). (b) Detailed cluster diagram of subcluster A. Gene symbols are indicated.
Molecular stratification of inflammatory subtypes in OA/RA SF using gene expression profiling 
Since Saa3-promoter reporter in murine synovium could discriminate the grade of inflammation 
in experimental arthritis, we hypothesized that this method might discriminate between 
high and low inflammatory synovial tissues from arthritis patients. Molecular stratification 
of inflammatory subtypes was performed using complete-linkage hierarchical clustering 
of whole-genome expression profiles of RA and OA SF (n=6 for each) (Figure 5a). Based on 
expression profiles, RA and OA SF were completely intermingled and three subgroups could be 
discerned. To define low and high inflammatory subtypes, we analyzed gene identities in the
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Figure 4.6
Saa3-promoter reporter distinguishes low and high inflammatory SF
(a) Low (n=3) and high (n=3) inflammatory SF were transduced in quadruplo with 
LV-Saa3-Luc and serum-starved for two days. Cells were stimulated for 6 hours with human 
IL-ip (1 ng/ml), TNFa (10 ng/ml), LPS or Pam3Cys (both 1 |jg/ml). Luciferase activities are 
given as fold-induction and represented as box plots indicating the sample minimum, 
lower quartile, median, upper quartile and sample maximum of low and high subgroups.
(b) IL-ip-induced Saa3-promoter activation in individual SF of a healthy control, or SFs 
from low and high inflammatory subtypes. Data are represents as means+SEM. Statistical 
differences were determined using ANOVA with Bonferroni's post-test. * P<0.05,
subclusters (A through E) displaying clearly differential gene expression between subgroups 
(Figure 5b). Consistent with prior studies, group III could be classified as a high inflammatory 
subtype based on significantly increased expression of genes involved in chemotaxis, 
angiogenesis and TGFp/activin A pathways [10,21,22].
Increased Saa3-promoter response in stimulated SF with high inflammation profile 
Next, we evaluated Saa3-promoter responses in SF from low and high inflammation synovial 
tissue. Irrespective of the subtype, Saa3-promoter activity could be significantly induced by 
TNFa, IL-ip, LPS, but not Pam3Cys (Figure 6a). Whereas basal promoter activity was equal 
between groups (data not shown), we observed significant higher induction of Saa3-promoter 
reporter in high inflammatory SF stimulated with IL-1 p (10.1±1.4 vs. 18.3±1.4, P<0.01), 
TNFa (5.5±1.0 vs. 11.8±1.1, P<0.01), or LPS (2.6±0.4 vs. 7.1±0.7, P<0.05). Since IL-1p-induced 
Saa3-promoter response provided the largest readout window, we evaluated whether this 
response could discriminate inflammatory subtype in individual samples (Figure 6b). Within 
subgroups, individual Saa3-promoter responses did not differ significantly. Two out of 
three high inflammatory SF showed significantly increased (P<0.05) responses over all low
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inflammatory SF, while the third revealed a clear trend towards a higher response that failed to 
reach significance. These results suggest that Saa3-promoter reporter might have a diagnostic 
value for classification of molecularly distinct low and high inflammatory synovial tissues.
Discussion
Regarding the significant role of activated SF in the local inflammatory processes within the 
arthritic joint, methods that allow quantitative measurement of inflammation through assessment 
of the degree of activation of these cells are of great value toward diagnostics of disease activity 
and treatment efficacy. In experimental arthritis, a number of methods has been developed 
for ex/in vivo assessment of synovial inflammation including histological analysis, 99mTc uptake, 
magnetic resonance imaging and ultrasound biomicroscopy [5,23,24]. In our study, we have 
introduced a lentiviral bioluminescent Saa3-promoter reporter as a novel, sensitive and feasible 
tool for discriminating between inflammatory subtypes in experimental arthritis and human SF. 
A bioluminescent promoter-reporter has several prominent advantages over the aforementioned 
methods.
First, the versatility of luciferase as a reporter gene enables quantitative analysis at several levels of 
resolution. We have assayed transgene expression in synovium ex vivo by performing a luciferase 
assay on a lysate from homogenized tissue. Alternatively, luciferase expression can be revealed and 
semi-quantitatively scored in histological tissue sections using standard immunohistochemical 
analysis. Most importantly, luciferase activity can readily be assessed non-invasively and in real-time 
using in vivo imaging systems. These offer high sensitivity and ease of use and have been successfully 
been applied for monitoring zymosan-induced arthritis [25,26], angiogenesis [27], and stem cell 
transplantations [28]. In a pilot experiment we were able to monitor inflammation knee and ankle 
joints of collagen-induced arthritis (CIA) mice using real-time imaging (unpublished observations). 
Second, using standard molecular cloning it is possible to generate a diverse range of 
promoter-luciferase reporters that allow imaging of the activity of individual transcription factors, 
genes-of-interest or the specific processes with which they correlate, e.g. chemotaxis, cartilage 
destruction, inflammatory infiltration. Zhang and co-workers utilized this approach to create a 
number of transgenic luciferase-reporter mice for monitoring diverse cellular processes including 
DNA damage (Gadd45 promoter), angiogenesis (Vegfr2 promoter), and NF-kB signaling (Ikba 
promoter) [27,29,30].
Gouze and co-workers have demonstrated that intra-articular injection of lentivirus leads to 
predominant transduction of synovial fibroblasts, but not macrophages [31]. This means that our 
findings with Saa3-promoter reporter have to be interpreted within a synovial fibroblast-specific 
context. Acute SCW arthritis is initiated via a TLR2- and MyD88-dependent macrophage-driven 
mechanism [32,33], which suggests that activation of the promoter reporter most likely does not 
arise directly from SCW-induced TLR2 activation in synovial fibroblasts. In support of this hypothesis, 
we found only marginal induction of Saa3-promoter in human synovial fibroblasts upon TLR2 
triggering.
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Histological analyses of joint inflammation revealed a predominant exudate, consisting of 
polymorphonuclear neutrophils [34,35], at the peak of promoter induction. An outstanding 
question remains therefore whether correlation of Saa3-promoter in synovium with joint 
inflammation arises from a response to neutrophil-secreted molecules, synovial-derived 
cytokines, or both. In favor of the latter, the cytokine profile of IL-ip in SCW arthritis appears 
to coincide with Saa3-promoter activity, showing a peak of induction within 24 hours and 
declining thereafter [36]. Notably, upon repeated SCW challenge IL-ip protein was present 
at an increased level compared to the first flare, which corresponds to our findings that 
Saa3-promoter reporter was stronger induced after SCW restimulation. In addition, we have 
shown that IL-ip is a potent inducer of Saa3-promoter reporter in human SF. Recent studies 
have shown that a Saa3-promoter can be induced by Si00A8 in macrophages, mononuclear 
cells and a tumor cell line [37]. Si00A8 is highly expressed and secreted by activated neutrophils 
[38] and has been shown regulate joint inflammation in antigen-induced arthritis [39]. This 
might represent a mechanism that specifically links neutrophil infiltration with Saa3-promoter 
activation, although it remains to be verified if Si00A8 can induce pro-inflammatory signaling 
in SF.
The observation that Saa3-promoter reporter in stimulated human SF could distinguish 
low and high inflammatory phenotypes, was our most clinically relevant finding. This 
phenomenon was observed for IL-ip, TNFa and TLR4 stimulation. Based on these findings it 
can be hypothesized that increased Saa3-promoter activation in SF results from differential 
receptor expression or a downstream protein that is common between pathways. However, in 
our gene expression profiling the respective receptors ILiR i, TNFRi or TLR4 were absent from 
subclusters showing differential expression between low and high inflammatory groups. In 
contrast we did detect an increased expression of transcription factor CEBPB, which is a strong 
inducer of Saa3-promoter activity [40,4i]. Previous studies have demonstrated enhanced 
expression and DNA binding of C/EBPp in RA SF [42]. Additionally, Pope and co-workers have 
established a correlation between nuclear staining of C/EBPp in synovial lining and the grade 
of inflammation [i6]. Moreover, the correlation was not a disease-specific since it could be 
observed both in RA and OA. This corresponds to our finding that RA and OA expression 
profiles were not distinct but intermingled.
A recent study by van Baarsen etal. has shown that high inflammatory synovial gene expression 
profile correlates with higher disease activity, C-reactive protein (CRP) levels, erythrocyte 
sedimentation rates (ESRs), increased platelet numbers and a shorter disease duration in 
RA patients [i2]. This indicates that there is a diagnostic value of determining low and high 
inflammatory subtypes of synovial tissue. We failed to observe a correlation with these clinical 
parameters in our study (data not shown), which is most likely caused by the intermingling of 
RA with OA samples, since the latter showed an overall shorter disease duration, lower CRP 
levels and ESRs. On the other hand, intermingling of RA and OA tissues corresponds with 
recent to recent findings of the involvement of synovial inflammation in the pathogenesis of 
OA and a change in the dogma that OA is not an inflammatory disease [43-45].
66
Our findings have demonstrated that lentiviral Saa3-promoter reporter is a novel and feasible 
tool with a potential diagnostic value in experimental and human arthritis. In the future, it 
seems valuable to explore the potential of real-time bioluminescent imaging of Saa3-promoter 
activity in vivo as a non-invasive molecular imaging approach in animal models. Apart from 
its potential in identifying inflammatory subtypes, elucidation of the molecular mechanism 
causing differential induction of Saa3-promoter activity in SF could provide valuable insight 
into pathogenesis of arthritis.
Materials and methods 
Animals
C57Bl/6 mice were obtained from Janvier (le Genest-Saint-Isle, France). During viral experiments, 
mice were housed in HEPA filtered individually ventilated cages. The animals were fed a standard 
diet with food and water ad libitum. All in vivo studies complied with national legislation and 
were approved by the local authorities of the Care and Use of Animals.
SCW preparation and induction of SCW arthritis
Streptococcus pyogenes Ti2 organisms were cultured overnight in Todd-Hewitt broth. Cell 
walls were prepared as described previously [46]. Uni- or bilateral arthritis was induced by 
intra-articular injection of 25 ^g of streptococcal cell wall (SCW) fragments (rhamnose content) 
in 6 l^ of phosphate buffered saline (PBS), respectively, into both or only the right knee joints 
of naive mice.
Assessment of joint inflammation by 99mTc-uptake
Joint inflammation was quantified by 99mTc uptake in knee joints as described previously [5]. 
Briefly, animals were sedated by intraperitoneal administration of chloral hydrate. Approximately 
20 ^Ci 99mTc in 200 l^ saline was injected subcutaneously and after i5 minutes the accumulation 
of the isotope was determined by external gamma counting. The severity of inflammation is 
expressed as the ratio gamma counts of the inflamed (right) over the contralateral joint. Ratios 
larger than i.i are considered as inflammation.
Histology
Whole knee joints were isolated at day one or six after SCW challenge and fixed in 4% 
paraformaldehyde for 4 days. After decalcification in 5% formic acid, specimens were processed 
for paraffin embedding. Tissue sections (7 ^m) were stained with haematoxylin and eosin. 
Histological changes were scored in the patella/femur region on five semi-serial sections of the 
knee joint, spaced 70 ^m apart. Scoring was performed by two observers without knowledge 
of the group. Infiltration of cells was scored on a scale of 0-3, depending on the amount of 
inflammatory cells in the joint cavity (exudate) or synovial tissue (infiltrate).
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Patients and samples
Synovial tissue was obtained from open joint replacement surgery or arthroscopic synovectomy 
at the Clinic of Orthopedics, Waldkrankenhaus "Rudolf Elle" (Eisenberg, Germany). Patients 
with RA or OA were classified according to the ACR criteria, as described previously [47]. SF 
were purified from synovial tissue as previously published [48]. Briefly, the tissue samples were 
minced, digested with trypsin/collagenase p (Sigma, St. Louis, MO), and the resulting single cell 
suspension cultured for seven days. Non-adherent cells were removed by medium exchange. 
SF were negatively purified using Dynabeads M-450 CDi4 (Invitrogen, Carlsbad, CA).
Oligonucleotide arrays and clusteranalyis.
Second passage SF were used for oligonucleotide arrays as described in detail previously. 
Briefly, SF were serum starved in DMEM/i% FCS for 72 hours and RNA was isolated using the 
RNeasy kit (Qiagen, Hilden, Germany). Gene expression analysis was performed using the U95A 
oligonucleotide arrays (Affymetrix, Santa Clara, CA) and data were analyzed and normalized 
using MAS 5.0 software according to the manufacturer's instruction. The gene expression 
data were deposited in the GEO database under accession numbers GSE7669 and GDS293i. 
Complete-linkage hierarchical clustering was performed using the algorithm available at the 
Gene Expression Omnibus server [49].
Plasmids
For generation of recombinant lentiviral vectors we made use of the third-generation 
self-inactivating transfer vectors pRLL-cPPT-PGK-mcs-PRE-SIN containing the human 
phosphoglyceratekinase (PGK) promoter, pRLL-cPPT-PGK-GFP-PRE-SIN, and the promoterless 
pRLL-cPPT-mcs-PRE-SIN (kind gift from J. Seppen, AMC Liver Center, Amsterdam, The 
Netherlands). Construction of promoter-luciferase constructs is described in detail in Chapter 3.
Lentiviral vector production
VSV-G pseudotyped recombinant LV particles were produced as described in Chapter 3 with 
following modifications: Preceding calcium phosphate-based co-transfection of packaging 
plasmids and during virus production, HEK293T cells were cultured in medium supplemented 
with 0.0i, 0.03 or 0.i mM water-soluble cholesterol (Sigma). Viral particles were purified from 
supernatant by ultracentrifugation. Viral particle titers were determined by assaying p24gag 
values with an enzyme-linked immunosorbent assay (ELISA) kit (Abbott, IL, USA) and expressed 
as ng p24gag/ l^.
Luciferase measurements
For in vitro reporter studies, cells were seeded at 5 x i04 cells per well in a Krystal 2000 96-wells 
plate (Thermo Labsystems, Brussels, Belgium). The day after, cells were transduced with 50 
ng p24gag equivalents of lentivirus in 50 l^ medium supplemented with 8 ^g/ml polybrene 
(Sigma) for 4 hours at 37 °C. Cells were serum-starved (i%  FCS) for two days and subsequently
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stimulated with recombinant human IL-1ß (R&D Systems Europe, Oxford, UK), TNFa (Abcam, 
Cambridge,UK), E. Coli lipopolysaccharide (LPS, Sigma) or Pam3Cys (EMC Microcollections, 
Tübingen, Germany) for the indicated hours and subsequently lysed in ice-cold lysis buffer. 
Luciferase activity was quantified using the Bright-Glo luciferase assay system (Promega, 
Madison, WI, USA) by adding an equal volume of Bright-Glo to the cell lysate. Luminescence 
was quantified in a luminometer (Lumistar, BMG, Offenburg, Germany), expressed as relative 
light units (RLU) and normalized to the total protein content of the cell/tissue extracts. For in 
vivo studies, knee joints were injected with 300 ng p24gag equivalents LV in a total volume of
6 l^. Four or seven days after transduction, knee joints were challenged with SCW fragments. 
At indicated time points, patellae with surrounding tissue were dissected, put in 250 l^ cell 
culture lysis buffer (Promega) and snap frozen in liquid nitrogen. Supernatant was centrifuged 
at 13.000 rpm for 5 minutes and luciferase activity assayed as described above.
Statistics
Data are represented as means+SEM. and significant differences were calculated using one-way 
analysis of variance (ANOVA) followed by Bonferroni's Multiple Comparison test (GraphPad 
Prism 5.02, San Diego, CA, USA). P-values of less than 0.05 are regarded as significant.
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Abstract
The application of disease-regulated promoters in local gene therapy for rheumatoid 
arthritis potentiates the development of a sophisticated treatment that relies on a restricted 
and fine-tuned supply of biologicals. Although several studies have investigated regulated 
promoters for achieving effective transgene expression during arthritis, none have explored 
their potential for minimizing deleterious effects arising from constitutive overexpression 
of transgenes under naïve conditions. Using naïve and collagen-induced arthritic mice, we 
examined the applicability of a hybrid interleukin-1 enhancer/interleukin-6 proximal promoter 
for achieving efficacious murine interleukin-4 gene therapy under arthritic conditions, while 
minimizing interleukin-4-induced inflammation under naïve conditions. We found strong 
upregulation of luciferase expression in virally transduced knee joints under arthritic conditions 
compared to levels in naïve animals. Besides its responsiveness, the promoter strength proved 
sufficient for generating therapeutically efficacious levels interleukin-4, as demonstrated by the 
successful protection against cartilage erosion in collagen-induced arthritis. Most importantly, 
promoter-mediated restriction of the potent chemotactic interleukin-4 in naïve animals 
strongly reduced the amounts of inflammatory cell influx. This study suggests the suitability of 
the interleukin-1 enhancer/interleukin-6 promoter hybrid for the development of a local gene 
therapy strategy for rheumatoid arthritis that requires fine-tuned and restricted expression of 
transgenes with a pleiotrophic nature.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that mainly affects synovial joints 
and which is characterized by inflammatory synovitis, ultimately leading to invasion and 
destruction of articular cartilage and bone [1,2]. Rather than a continuous clinical course, RA 
displays variable disease activity in a considerable fraction of patients resulting in spontaneous 
remissions and exacerbations of joint inflammation [3]. Although the etiology of RA remains 
to be elucidated, it is recognized that the proinflammatory cytokines tumor necrosis factor 
alpha (TNF-a) and interleukin-1 (IL-1) are central mediators of inflammation and cartilage 
destruction, respectively [4]. Conventional treatments for RA are predominantly based on
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systemic delivery of biologicals that target these proinflammatory cytokines, e.g. anti-TNF-a 
[5]. Although these treatments have shown to be therapeutically efficacious, the safety of the 
systemic mode of treatment is under dispute [6,7]. Local intra-articular gene therapy represents 
a promising alternative for coping with side effects and improving therapeutic efficacy. The 
joint resident cells, primarily synovial fibroblasts, are readily transduced by several viral vectors 
and potentially sustain long-term gene expression from both integrating and non-integrating 
vectors [8-10]. As demonstrated in animal models, the relatively confined joint space appears 
ideally suited for treatments relying on secretion of anti-inflammatory proteins such as IL-4, 
IL-10 or IL-1 receptor antagonist [11]. A strong advantage of gene therapy is the possibility to 
transcriptionally control transgene expression and effectuating protein supply that is restricted 
to arthritic conditions [12-15]. Moreover, by minimizing transgene expression under naïve 
conditions, a safer mode of gene therapy could be generated that allows the application of 
biologicals which have deleterious effects when expressed constitutively, such as IL-4. 
Intra-articular IL-4 gene therapy has been demonstrated to prevent cartilage and bone 
erosion in experimental arthritis [16-19]. The anti-inflammatory capacity of IL-4 arises from its 
capacity to downregulate the production of proinflammatory and Th1 cytokines by inducing 
mRNA degradation and upregulating expression of inhibitors of proinflammatory cytokines. 
Reduction of Th1 cytokines results in suppression of macrophage activation and production of 
IL-1, IL-6, IL-8 and TNF-a [20]. In contrast to the annotated anti-inflammatory properties, IL-4 is 
also potent proinflammatory and chemotactic factor for fibroblasts and macrophages [20,21]. 
This is illustrated by the fact that overexpression of IL-4 in a naïve knee joints results in a severe 
joint inflammation that is characterized by synovial cell influx [18]. In this study we investigate 
whether controlled and temporal expression of IL-4 minimizes these side effects.
Results
IL-1E/IL-6P promoter is responsive to collagen-induced arthritis 
Previously, we have shown that the hybrid IL-1E/IL-6P promoter, composed of the human 
interleukin-1 enhancer region (-3690/-2720) upstream of the human interleukin-6 proximal 
promoter (-163/+12), responds to a broad range of proinflammatory cytokines in vitro as well as 
to an acute joint inflammation induced by zymosan or streptococcal cell wall material [13,14]. 
Alternatively, we investigated the responsiveness of this hybrid promoter to collagen-induced 
arthritis, which is an animal model of arthritis that is characterized by immune-mediated 
polyarticular joint inflammation and irreversible cartilage damage. To this end, adenovirus (107 
ffu) expressing IL-1E/IL-6P-driven luciferase was injected into either nonaffected or arthritic knee 
joints of collagen type II immunized DBA/1J mice. Luciferase activities in the synovium were 
measured at two or seven days after virus injection. Under naïve conditions, the basal promoter 
activities were low (1.0x103 RLU, not shown), in line with previous observations [13,14]. When 
arthritis developed at two and seven days after virus injection, luciferase activity was strongly 
increased (3.0x104 RLU) (Figure 1). As we described previously, the transduction efficiency of the 
synovial tissue in arthritic joints was hampered [22]. Still, luciferase activities were significantly
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Figure 5.1
IL-1E/IL-6P promoter activity in collagen-induced arthritis
Collagen type II-immunized DBA/1J mice were injected intraarticularly with 107 ffu Ad5.IL-1E/ 
IL-6P-Luc. Knee joints were scored macroscopically for inflammation at the time point of viral 
injection: negative (Day 0 Neg) or positive (Day 0 Pos). At day 2 and 7 post injection, arthritic 
joints were isolated. Luciferase activity in the synovium was assessed and expressed as 
relative light units (RLU). Squares and triangles represent individual luciferase measurements; 
horizontal bars indicate the mean per group; the dotted line indicates the mean expression 
level under naïve conditions.
increased over basal levels at day two and seven, although five- to six fold lower (5-6x103 RLU) 
than activities observed in joints that were non-inflamed at transduction. This shows a strong 
response of the IL-1E/IL-6P promoter to an immune-mediated inflammation. Furthermore, the 
IL-1E/IL-6P promoter activity was to the same extent at day two and seven, which illustrates 
that the promoter is not shut down when disease persists. This marks a strong advantage over 
the conventionally applied constitutively active viral promoters, such as the cytomegalovirus 
(CMV) immediate early promoter, which gives rise to a short expression peak at two days after 
transduction that is strongly declined after seven days [13,14].
Murine IL-4 does not influence IL-1E/IL-6P promoter activity in vitro 
It has been reported that IL-4 synergizes with IL-1 in the release of several factors, e.g. IL-6, 
from fibroblasts,[23-25] but there is also evidence pointing to a suppressive effect of IL-4 on
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Figure 5.2
IL-4 does not influence IL-1E/IL-6P promoter activity in vitro
IL-4 effects on basal or cytokine-induced IL-1E/IL-6P promoter activity in vitro. NIH-3T3 
fibroblasts were transduced at MOI 50 with Ad5.IL-1E/IL-6P-Luc and after one day stimulated 
for 24 hours with two concentrations IL-4 (5 or 50 ng/ml) alone, or in the presence of IL-1a (10 
ng/ml) or LPS (2 pg/ml). Luciferase activity was assessed and given as relative expression (ratio 
x 100) as compared to unstimulated cells. Data are presented as means +SEM (n=4).
IL-1 induced secretion of matrix metalloproteinases [26,27]. From previous studies it was 
determined that IL-1 and lipopolysaccharide (LPS) strongly upregulate IL-1E/IL-6P promoter 
activity [13], therefore we sought to investigate whether expression of murine IL-4 might 
interfere with the inducibility of IL-1E/IL-6P promoter activity. To this end, murine 3T3 fibroblasts 
were infected with Ad5.IL-1E/IL-6P-Luc at a multiplicity of infection of 50. The day thereafter, 
cells were stimulated for 24 hours with recombinant murine IL-4 (5 or 50 ng/ml) in the absence 
or presence of IL-1a (10 ng/ml) or LPS (2 pg/ml) (Figure 2). IL-4 alone did not affect promoter 
activity; relative expression levels were 97±3 and 104±5 for 5 and 50 ng/ml IL-4, respectively. 
The proinflammatory stimuli IL-1a or LPS alone increased promoter activity approximately four 
to five fold, expression levels were 524±16 and 455±21, respectively. Addition of IL-4 resulted 
in neither additive nor suppressive effects on LPS-induced promoter activity. IL-4 showed a 
slightly suppressive, but non-significant, effect on IL-1a-induced promoter activity.
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Figure 5.3
Disease-regulated IL-4 expression prevents cartilage erosion in CIA
Disease-regulated IL-4 expression prevents cartilage erosion in collagen-induced arthritis. (a) 
Safranin-O-stained tissue sections of arthritic knee joints, 7 days after injection with 107 ffu 
control vector (Dl70-3) or adenovirus encoding the murine IL-4 gene (IL-1E/IL-6P, and CMV). 
Arrowheads mark the sites of erosion. (b) Cartilage erosion was scored separately for the 
patella and femur on a 0-3 scale. Data are represented as means + SEM (n=10, IL-1E/IL-6P 
and CMV, n=6, Dl70-3) and differences determined using the Mann-Whitney U test. * P<0.05. 
P = patella, F = femur.
These results indicate that IL-4 does not influence basal or induced IL-1E/IL-6P promoter 
activity. It is expected that IL-1E/IL-6P-driven IL-4 expression in vivo will depend primarily on the 
presence of proinflammatory mediators rather than IL-4 itself.
Disease-regulated IL-4 expression prevents cartilage erosion in collagen-induced arthritis 
Previously, we have shown that intraarticular overexpression of murine IL-4 provides protection 
against progression to major cartilage erosion in collagen-induced arthritis, presumably by 
suppression of IL-1 p expression and nitric oxide synthesis [18]. To demonstrate that IL-1E/ 
IL-6P-driven mIL-4 expression levels are therapeutically efficacious, 107 ffu Ad5.CMV-mIL-4 
(positive control, constitutive IL-4 expression), Ad5.dl70-3 (negative control, no IL-4 production),
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Figure 5.4
A disease-regulated promoter strongly reduces IL-4-induced inflammation in 
naive mice
(a) Haematoxylin and eosin-stained tissue sections of inflamed knee joints, 7 days after 
injection with 107 ffu control vector (Dl70-3) or adenovirus encoding the murine IL-4 gene 
(IL-1E/IL-6P and CMV). (b) Inflammatory infiltrate and exudate in the patella/femur region 
were scored on a 0-3 scale. Data are represented as means + SEM (n=10) and differences 
determined using the Mann-Whitney U-test. * P<0.05. P = patella, F = femur, S = synovium, I 
= infiltrate, E = exudate.
or Ad5.IL-1E/IL-6P-mIL-4 were injected in the knee joints of collagen type II immunized DBA-1/J 
mice, two days after they received a collagen booster injection. At day 30, incidence of arthritis 
was 100% in both IL-4 groups and 80% in the control group. As described previously for this 
vector dose [18], there were no significant differences between IL-4 treated and control groups 
in macroscopic clinical score of arthritis and histological score of inflammation (data not 
shown). Consecutively, histological knee joint sections were scored for cartilage depletion and 
cartilage surface erosions in the patella and femur region (Figure 3a). Profound proteoglycan 
depletion was observed in all groups, sustaining evidence that mIL-4 has no protective effect 
on cartilage proteoglycan depletion (data not shown). However, mIL-4 expression led to a 
significant decrease in erosion of patellar and femoral cartilage as compared to the control
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group (Figure 3b). Whereas femoral cartilage was severely eroded (mean 2.6±0.3) in the 
control group, constitutive or disease-regulated expression of mIL-4 in arthritic mice revealed 
non- (CMV) or mildly eroded femoral cartilage (IL-1E/IL-6P: 0.6±0.2). Patellar cartilage was less 
severely eroded than femoral cartilage in the control group (1.1±0.2 out of 3.0), however the 
same trend of cartilage protection was observed in both IL-4 treated groups (CMV: 0.03±0.03, 
IL-1E/IL-6P: 0.3±0.1). This experiment proved that the IL-1E/IL-6P promoter activity in arthritic 
animals is sufficient to provide therapeutically efficacious mIL-4 levels.
IL-1E/IL-6P-driven IL-4 expression results in marginal inflammation in naive mice 
Previously, it was demonstrated that constitutive intra-articular overexpression of mIL-4 for
7 days leads to substantial joint inflammation, characterized by massive infiltration of cells 
into the synovial cavity (exudate) and synovial tissue (infiltrate).[18] We hypothesize that 
disease-regulated mIL-4 expression will lead to low levels of mIL-4 under naïve conditions, 
thereby substantially reducing cell influx in naive mice. To verify this hypothesis, Ad5.IL-1E/ 
IL-6P-mIL-4, Ad5.CMV-mIL-4 or Ad5.dl70-3 (107 ffu) was injected in the knee joints of naïve 
C57Bl/6 mice. Eight days after viral transduction mIL-4 levels were measured in patella washouts. 
Production of mIL-4 in mice treated with control adenovirus was below the detection limit 
(<5 pg/ml), which demonstrates that endogenous IL-4 levels in the joint are low. Driving IL-4 
expression by the IL-1E/IL-6P promoter resulted in low basal levels (8.4±3.0 pg/ml) as compared 
to those obtained with the CMV promoter (>1000 pg/ml). Next, histological knee joints sections 
at day 7 were inspected for the presence infiltrate and exudate (Figure 4a). As expected, 
constitutive expression of IL-4 for seven days generated massive joint inflammation and 
treatment with control virus showed no signs of inflammation seven days after transduction. 
The IL-1E/IL-6P group showed only marginal amounts of inflammatory exudate. In line with 
the markedly reduced IL-4 levels, the extent of inflammatory infiltrate was profoundly reduced 
by putting IL-4 expression under control of a disease-regulated promoter (Figure 4b). Both 
infiltrate (0.63±0.13) and exudate (0.30±0.12) were strongly reduced in the IL-1E/IL-6P group 
compared to the CMV group (2.20±0.17 and 1.35±0.17 for infiltrate and exudate, respectively). 
These results show that the IL-1E/IL-6P promoter activity under naïve conditions is sufficient to 
maintain IL-4 expression at a minimal level.
Discussion
The concept of applying disease-regulated promoters in gene therapy for arthritis is a scarcely 
explored field. Nevertheless, this strategy contains a large potential since it might provide a 
fine-tuned supply of therapeutic proteins in an offer meets demand fashion. Perhaps even 
more importantly, tight control of transgene expression potentially minimizes the risk of 
deleterious effects under non-diseased conditions, such as toxicity or immune responses. 
This however, has not been investigated so far; similar studies focused rather on effective 
transgene expression under arthritic conditions [12,28-30]. In this study we demonstrate for 
the first time that disease-regulated mIL-4 expression by the IL-1E/IL-6P promoter provides not
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only therapeutically efficacious protein levels under arthritic conditions, but also sufficiently 
low activity under naïve conditions. Minimizing the undesired effects of biologicals, in this 
case the potent proinflammatory and chemotactic properties of IL-4, requires promoters 
with low basal activity under naïve conditions. Promoter regions from acute phase proteins 
(APP) [28-33], inducible nitric oxide synthase (iNOS) [34], proinflammatory cytokines [13,14], 
and a nuclear factor-KB (NF-kB) responsive promoter [12] have been predominantly explored 
for their potential to effectuate arthritis-induced transgene expression. Although several of 
these appeared applicable for disease-regulated gene therapy, intrinsic properties limit their 
suitability for minimizing transgene expression under naïve conditions. Promoters from APP are 
in general well-suited for inflammation-induced gene expression, however absolute amounts of 
transgene expression are far lower than obtained with strong constitutive promoters [30,32]. To 
overcome this disadvantage, APP promoters were incorporated in a two-component enhancer 
system. This system relied on APP-regulated expression of the human immunodeficiency 
(HIV) transactivator of transcription (Tat) that consecutively stimulated protein expression 
from genes inserted downstream of a HIV long terminal repeat (LTR) promoter. Indeed, this 
resulted in a gain of transgene expression. However, APP promoter demonstrated leakiness 
under naïve conditions, which led to relatively high background luciferase expression that was 
equal to [13], or even surpassed CMV-driven expression [28]. An additional downside of this 
approach, is the use of the Tat protein, which possesses a large immunogenic potential due 
to its capacity to regulate numerous host genes involved in cell signaling and translation [35]. 
An NF-KB-responsive promoter showed strong upregulation by proinflammatory cytokines in 
vitro and in adjuvant arthritis in rat [12]. Strikingly, absolute expression levels exceeded those 
provided by a constitutive CMV promoter by far, both in vitro and in vivo. Moreover, the same 
phenomenon was observed for basal levels, indicating that there are substantial amounts of 
active nuclear NF-kB present under naïve conditions. Thus, turning off transgene expression 
under naïve conditions by transcriptional control via an NF-KB-responsive promoter appears 
not very feasible. Our results show that the hybrid human IL-1 enhancer/IL-6 promoter emerges 
as the most likely candidate thus far to achieve low expression under naïve conditions in 
combination with efficacious disease-regulated expression in arthritis [13,14]. The promoter 
regions of these interleukin genes were selected based on their crucial role in early onset 
and development of experimental arthritis [36,37]. Additionally, microarray analysis of 
collagen-induced and streptococcal cell wall arthritis revealed a strong correlation of both 
genes with disease severity and very low expression in naïve knee joints (unpublished data). 
In contrast, APP genes e.g. complement 3, were originally selected based on the acute phase 
response in the liver rather than arthritis models. Although these proteins also show induced 
production by inflamed RA synovial tissue [38], they are constitutively expressed under naïve 
conditions in synovial fibroblasts [39]. The latter also holds for NF-kB [40], which explains the 
relatively high basal levels obtained with these promoters under naïve conditions.
An important feature for the development of technologies for arthritis gene therapy 
would be long-term stable expression in the joint. Recently, it was reported that synovial
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fibroblasts transduced with lentiviral or adenoviral vectors lost transgene expression in a 
promoter-independent fashion within 21 days [10], suggesting that transcriptional control 
of transgenes would not be beneficial. In our hands, however, we frequently experience 
rapid loss of transgene expression from constitutively active viral promoters, probably due 
to in vivo silencing caused by methylation of CpG motifs [41], histone modifications [42], 
cytokine-mediated promoter silencing [43] and vector clearance [44,45]. Strikingly, knee joints 
transduced with an IL-1E/IL-6P-Luc vector showed a robust response to inflammatory stimuli 
up to 90 days after viral transduction (unpublished data). Previously, we demonstrated that 
there is no significant difference in reduction of viral DNA from transduced synovium using the 
viral CMV or cellular IL-1E/IL-6P promoters [13]. It is our hypothesis that cellular promoters are 
less susceptible to promoter silencing and in fact support long-term expression in synovium as 
described by others [8,9].
Our data suggest that disease-regulated transcriptional control of transgene expression is a 
safer mode of local gene therapy for RA. The therapeutic potential of transgenes under arthritic 
conditions is retained, while undesirable effects under healthy conditions are effectively 
minimized. This enables the possible application otherwise disputable biologicals, such as IL-4. 
Currently, the IL-1E/IL-6P promoter seems very suitable for the development of gene therapy for 
RA that is based on fine-tuned and restricted expression of therapeutic genes of pleiotrophic 
nature.
Materials and methods 
Animals
Male 10- to 12-weeks old DBA-1/J mice were obtained from Janvier (Le Genest Saint Isle, 
France). C57Bl/6 mice were obtained from Charles River (Sulzfeld, Germany). During adenoviral 
experiments, mice were housed in low-pressure isolator cages. The animals were fed a standard 
diet with food and water ad libitum. All in vivo studies complied with national legislation and 
were approved by local authorities of the Care and Use of Animals with related codes of practice.
Plasmids
Generation of the plasmid pShuttle-IL-1 E/IL-6P-Luc, containing the hybrid IL-1 enhancer/ 
IL-6 promoter sequence (IL-1E/IL-6P) was described previously [13]. For cloning, Pfu DNA 
polymerase (Stratagene, La Jolla, CA) was used. All generated plasmids were verified by 
sequencing. The plasmid pShuttle-IL-1E/IL-6P-mIL-4-polyA was prepared as follows: the IL-1E/ 
IL-6P promoter was PCR-cloned from pUC 18-IL-1E/IL-6P in the XbaI/EcoRV restriction sites 
of pShuttle (Stratagene, La Jolla, CA). The SV40 polyadenylation signal was PCR-cloned from 
pShuttle-CMV (Stratagene) in the BglII restriction site of pShuttle-IL-1E/IL-6P. Subsequently, the 
cDNA of mIL-4 was amplified from the recombinant adenoviral vector Ad5E1mIL-4 (Kind gift 
from C.D. Richards, McMaster University, Hamilton, Ontario, Canada) by using the primers (sense 
5'-GATATC GCCACC ATGGGTCTCAACCCCC-3'; antisense 5'- GTCGAC CTACGAGTAATCCATTTGC-3')
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introducing a Kozak sequence for enhanced translation [46] and inserted in the EcoRV / Sal\ 
sites of pShutlle-\L-1E/\L-6P-polyA generating pShuttle-\L-1E/\L-6P-m\L-4-polyA.
Adenoviral vectors
Replication-deficient adenoviral vectors (E1/E3 deleted) Ad5.\L-1 E/\L-6P-Luc, Ad5.\L-1E/ 
\L-6P-m\L-4, and Ad5.dl70-3 were prepared according to the AdEasy system (Stratagene), with the 
exception that recombinant viral particles were produced in E1 transformed N52E6 amniocyte 
cells [47]. Replication deficient (E1 deleted) Ad5.CMV-m\L-4 was produced by infection of N52E6 
cells with Ad5E1m\L-4. Viruses were purified by two consecutive CsCl2 gradient purifications 
and stored in small aliquots at -80 °C in buffer containing 25 mM Tris, pH 8.0, 5 mM KCl, 0.2 
mM MgCl2, 137 mM NaCl, 730 ^M Na2HPO4, 0.1% (w/v) ovalbumin and 10% (v/v) glycerol. The 
infectious particle titer (ffu) was determined by titrating vector stocks on 911 indicator cells and 
measuring viral capsid protein immunohistochemically 20 hours after transduction.
Luciferase measurements
For in vitro evaluation of the effect of m\L-4 on \L-1E/\L-6P promoter activity, NIH-3T3 cells were 
seeded at 3x104 cells per well in a Krystal 2000 96-wells plate (Thermo Labsystems, Brussels, 
Belgium) and maintained in Dulbecco's modified Eagle medium containing 5% fetal calf serum, 
1% pyruvate and 40 ^g/ml gentamycin at 5% CO2/37 °C. The day after, cells were transduced 
with Ad5.IL-1E/IL-6P-Luc in serum-free medium at multiplicity of infection (MOI) 50 in a total 
volume of 50 l^ for 3 hours at 37 °C. Thereafter, medium was replaced for serum-containing 
medium. After 24 hours, cells were stimulated with recombinant mouse IL-1a (10 ng/ml, R&D 
Systems, Minneapolis, MN) or lipopolysaccharide (2 ^g/ml, Sigma, St. Louis, MO) in the presence 
or absence of recombinant murine IL-4 (5 or 50 ng/ml, kind gift of S. Gilles, Immunex, Seattle, 
WA) for 24 hours. Luciferase activity was quantified using the Bright-Glo luciferase assay system 
(Promega, Madison, WI) by adding an equal volume of Bright-Glo to cells lysed in aquadest. 
Luminescence was measured on the Polarstar Galaxy (BMG, Offenburg, Germany) and expressed 
as relative light units (RLU) and normalized to total protein content of the cell/tissue extracts.
Induction of collagen induced arthritis (CIA)
Bovine collagen type II (CII) was dissolved in 0.05 M acetic acid to a concentration of 2 mg/ml 
and was emulsified in equal volumes of Freud's Complete Adjuvant (2 mg/ml of M. Tuberculosis 
strain H37Ra, Difco laboratories, Detroit, MI). The mice were immunized intradermally at the 
base of the tail with 100 l^ of emulsion (100 ^g of bovine CII). On day 21, mice were given an 
intraperitoneal booster injection of 100 ^g bovine CII dissolved in PBS.
Study protocol and histology
To determine the response of the IL-1E/IL-6P promoter to an immune-mediated inflammation, 
107 ffu/6 l^ PBS luciferase-encoding adenoviruses were encoding were injected into the knee 
joints of immunized DBA-1/J mice, one day after they received a CII booster injection. Knee joints
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were qualitatively scored for inflammation (negative or positive) at the time point of injection. 
At day 2 and 7 after virus injection, knee joints were qualitatively scored for inflammation and 
patellae with surrounding tissue were isolated in a standardized manner [48]. For luciferase 
measurements, patellae were put in 250 l^ cell lysis buffer (Promega) and snap frozen in liquid 
nitrogen. Samples underwent four freeze-thaw cycles and were subsequently centrifuged for 
10 minutes at 13000 rpm. Luciferase activity in the supernatant was determined as described 
above.
To evaluate effects of mIL-4 expression in naïve animals, 107 ffu/6 l^ PBS adenovirus expressing 
mIL-4 (Ad5.IL-1E/IL-6P-mIL4 and Ad5.CMV-mIL-4) or an empty control (Ad5.dl70-3) was injected 
into the knee joints of C57Bl/6 mice. At day 8, mice were sacrificed by cervical dislocation. 
From four knee joints, patellae washouts were prepared for assessment of mIL-4 levels. 
Remaining whole knee joints were removed and fixed in 4% paraformaldehyde for 4 days. After 
decalcification in 5% formic acid, specimens were processed for paraffin embedding. Tissue 
sections (7 ^m) were stained with haematoxylin and eosin (cell influx) or safranin-0 (cartilage 
proteoglycan depletion). Histological changes were scored in the patella/femur region on 
five semi-serial sections of the knee joint, spaced 70 ^m apart. Scoring was performed by 
two observers without knowledge of the group as described before [49]. Histopathological 
changes were scored using the following parameters. Cartilage depletion, defined as the loss 
of proteoglycan content, was scored on a scale ranging from 0-3 per region, depending on the 
intensity of staining in the cartilage. Infiltration of cells was scored on a scale of 0-3 (0 = no cells, 
1 = mild cellularity, 2 = moderate cellularity, 3 = maximal cellularity) , depending on the amount 
of inflammatory cells in the synovial cavity (exudate) or synovial tissue (infiltrate) [50]. Cartilage 
erosion was graded on a scale of 0-3, ranging from no damage to compete loss of articular 
cartilage.
To assess the therapeutic efficacy of disease-regulated mIL-4 expression, 107 ffu/6 l^ PBS 
adenovirus encoding IL-1 E/IL-6P-mIL-4, CMV-mIL4 (positive control), or empty control (viral 
control) was injected at day 23 (onset arthritis) in knee joints of immunized DBA-1/J mice 
without macroscopic signs of arthritis in the paws. Development of arthritis in front and hind 
paws was macroscopically monitored (scores between 0-2) until day 30 (day 7, after intraarticular 
injection) Consecutively, whole knee joints were removed for histological analysis and cartilage 
erosion and depletion evaluated as described above.
Murine IL-4 ELISA
Patellae were incubated in RPMI 1640 (Gibco, 200 ^l/patella), supplemented with 0.1% bovine 
serum albumin (Sigma), gentamycin (40 ^g/ml) and 1% pyruvate for 1 hour at room temperature. 
Subsequently, supernatant was harvested and centrifuged for 5 minutes at 1000g. Murine IL-4 
levels were determined using the Luminex multianalyte technology, using the BioPlex system 
in combination with BioPlex Mouse IL-4 Assay (Bio-Rad, Hercules, CA). Cytokines were measured 
in 50 l^ washout medium. The sensitivity of the IL-4 assay was 5 pg/ml.
8 4
Statistical analysis
Data values are given as means+SEM and significant differences were determined using 
Student's f-test or Mann-Whitney U-test, unless stated otherwise. P values of less than 0.05 were 
regarded as significant.
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Abstract
Introduction
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. 
Biologicals directed against tumor-necrosis-factor (TNF)-a are efficacious in the treatment ofRA However, 
the role of TNF receptor-1 (TNFR1) in mediating the TNFa effects in RA has not been elucidated and 
conflicting data exist in experimental arthritis models. The objective is to investigate the role of TNFR1 
in the synovial lining cells (SLC) and the reticuloendothelial system (RES) during experimental arthritis.
Methods
Third generation of adenovirus serotype 5 were either injected locally in the knee joint cavity or 
systemically by intravenous injection into the retro-orbital venous sinus to specifically target SLC 
and RES, respectively. Transduction of organs was detected by immunohistochemistry of the 
eGFP transgene. An adenoviral vector containing a short hairpin (sh) RNA directed against TNFR1 
(HpTNFR1) was constructed and functionally evaluated in vitro using a nuclear factor-KB (NF-kB) 
reporter assay and in vivo in streptococcal cell wall-induced arthritis (SCW) and collagen-induced 
arthritis (CIA). Adenoviruses were administered before onset of CIA, and the effect ofTNFR1 targeting 
on the clinical development of arthritis, histology, quantitative polymerase chain reaction (qPCR), 
cytokine analyses and T-cell assays was evaluated.
Results
Systemic delivery of Ad5.CMV-eGFP predominantly transduced the RES in liver and spleen. Local 
delivery transduced the synovium and not the RES in liver, spleen and draining lymph nodes. In 
vitro, HpTNFR1 reduced the TNFR1 mRNA expression by three-fold resulting in a 70% reduction 
of TNFa-induced NF-kB activation. Local treatment with HpTNFR1 markedly reduced mRNA and 
protein levels of interleukin (IL)-1P and IL-6 in SLC during SCW arthritis and ameliorated CIA. Systemic 
targeting of TNFR1 in RES of liver and spleen by systemic delivery of Ad5 virus encoding for a small 
hairpin RNA against TNFR1 markedly ameliorated CIA and simultaneously reduced the mRNA 
expression of IL-1beta, IL-6 and Saa1 (75%), in the liver and that of Th1/2/17-specific transcription 
factors T-bet, GATA-3 and RORyT in the spleen. Flow cytometry confirmed that HpTNFR1 reduced 
the numbers of interferon (IFN)y (Th1)-, IL-4 (Th2)- and IL-17 (Th17)-producing cells in spleen.
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Conclusion
TNFR1-mediated signaling in both synovial lining cells and the reticuloendothelial system 
independently played a major pro-inflammatory and immunoregulatory role in the 
development of experimental arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that mainly 
affects synovial joints and is characterized by inflammatory synovitis, ultimately leading 
to the destruction of cartilage and bone. The central role for tumor necrosis factor a (TNFa) 
in RA pathogenesis has been extensively demonstrated in experimental arthritis, such 
as successful treatment of murine collagen-induced arthritis (CIA) with TNFa-antibodies 
[1,2] and development of arthritis in transgenic mice overexpressing human TNF [3]. Most 
importantly, TNFa has been identified as a key cytokine in human RA [4], which has led 
to the development of effective treatment of disease by administration of neutralizing 
TNF-antibodies [5,6].
TNFa signaling is mediated via two distinct receptors encoded by the genes Tnfrsfla 
(TNFR1) and Tnfrsf1b (TNFR2). The TNF receptors are single transmembrane glycoproteins 
and share only 28% homology, predominantly between their extracellular domains. Both 
TNFR1 and TNFR2 activate a wide range of pro-inflammatory signal pathways, leading to 
activation of nuclear factor-KB (NF-kB) and c-Jun N-terminal kinase, via recruitment of TNF 
receptor-associating factors (reviewed in [7]). Attenuation of CIA in TNFR1-deficient mice 
has demonstrated a dominant role of this receptor in disease [8,9]. Recent investigations 
on the cell-specific contribution of TNFR1-mediated signaling in RA pathogenesis, have 
revealed remarkably different functions of TNFR1 in mesenchymal or hematopoietic 
compartments. Cells from the prior compartment, in particular synovial fibroblasts (SF), 
have been identified as the primary targets for TNFa in the development of arthritis 
[10]. In contrast, TNFR1-mediated signaling in cells from the latter compartment, such as 
leukocytes, exerts an anti-inflammatory function [11,12].
This cell-specificity of TNFR1 function is highly relevant to the safety and efficacy of 
treatments that target TNFa signaling. Scintigraphic imaging of the biodistribution 
of radiolabeled anti-TNF after systemic administration in RA patients has shown that, 
apart from inflamed joints, antibodies accumulate in liver and spleen [13]. However, the 
function of TNFR1 expression in these secondary lymphoid organs and its contribution to 
RA pathogenesis remains to be elucidated.
In this study, we investigated the effects of TNFR1-mediated signaling in synovial lining 
cells (SLC) and the reticuloendothelial system (RES) during experimental arthritis. To this 
end, we used cell-specific RNA interference-mediated (RNAi) silencing of TNFR1 based on 
adenoviral delivery of a short hairpin RNA (shRNA)-expressing construct.
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Figure 6.1
Biodistribution after local and systemic administration of adenovirus in mice
One day after collagen booster, non-arthritic DBA/1J mice were injected intra-articularly with 
107 ffu or intravenously with 3x108 ffu Ad-eGFP. After administration, eGFP was assessed by 
immunohistochemistry in lung (a-b), liver (c-d), spleen (e-f), lymph nodes (g-h), synovium 
(i-j) after local (b-d-f-h-j) or systemic (a-c-e-g-i) treatment. Sites of eGFP positive cells are 
indicated by arrows. The expression of eGFP mRNA levels (k) in each organ, blood and BMC. 
Draining lymph nodes were negative on IHC and qPCR (not detected). Data are represented 
as the difference in ACt values compared to the housekeeping gene GAPdH. mRNA levels that 
could not be detect are noted by 'nd' (not detectable). Background mean mRNA levels of eGFP 
are as low as the negative control. Bars represent means±SEM and statistical differences were 
determined using Student's t-test. * P<0.01.
Results
Biodistribution after local and systemic administration of adenoviruses in mice.
Ad5.CMV-eGFP was injected intravenously or intraarticularly one day after the bCII 
booster-immunization in mice that had no clinical signs of arthritis. One day later, liver, 
spleen, lung, blood, BMCs and synovium of the knee joints was isolated and prepared for 
immunohistochemistry (IHC) or processed for mRNA isolation. As expected, the systemically 
administered adenoviruses were scavenged by the reticuloendothelial system primarily in liver 
and spleen. IHC detection of eGFP transgene expression showed that in liver the Kupffer cells 
were predominantly transduced [14] and in the spleen the marginal metallophilic macrophages 
around the white pulpa [15] (Figure 1a,c,e,g,i). The synovium, draining lymph nodes and lung
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Figure 6.2
In vitro validation of HpTNFR1
Validation of hairpin construct targeting TNFR1 in vitro. (a) NIH-3T3-5xNF-KB-luciferase cells 
were transduced at indicated MOI HpTNFR1 or HpNS and, after two days, stimulated with 10 
ng/ml mTNFa for 6 hours. NF-KB-driven luciferase activity is represented as means+SEM (n=4) 
of percentages compared to the HpNS group. The production of HpNS transduced cells (doses 
MOI 10) with or without TNFa stimulation was 164.232±864 and 21.555±864 relative light 
units (RLU)/mg protein, respectively. (b) Expression of TNFR1 in NIH-3T3-5xNF-KB-luciferase 
cells transduced at indicated MOI with HpTNFR1. Data are represented as the mean (n=10) 
of the difference in TNFR1 ACt values compared to HpNS-treated group (AACt). (c) NIH-3T3- 
5xNF-KB-luciferase cells were transduced at MOI 10 with HpTNFR1 or HpNS or left untreated. 
After two days, untreated cells were pre-incubated for 1 hour with 10 ^g/ml Enbrel and 
thereafter all groups were stimulated with 10 ng/ml mTNFa or mIL-p for 6 hours. Luciferase 
activity is represented as means+SEM (n=4). Statistical differences were determined using 
ANOVA with Bonferroni's post-test. *** P<0.001.
remained negative on IHC. A more sensitive detection method is RT-qPCR and at the mRNA level 
the spleen, liver, but also blood and BMCs were positive for eGFP, whereas the synovium remained 
negative (Figure 1k). One day after i.a. injection only synovial lining cells, probably type B cells 
(based upon their morphology), were transduced as shown by RT-qPCR and IHC, while lung, liver, 
spleen, draining lymph-nodes, blood and BMCs were negative on IHC (Figure 1b,d,f,h,j).
HpTNFR1 expression decreased TNFR1 mRNA expression and TNFa signaling in vitro 
RNAi-mediated downregulation of gene expression involves both translational repression 
and accelerated mRNA turnover [16]. To investigate the efficiency of TNFR1 gene silencing by 
shRNA-expression, we transduced murine NF-kB luciferase reporter fibroblasts with adenoviral 
vector encoding a hairpin construct targeting TNFR1 (HpTNFR1) or a scrambled control sequence 
(HpNS). After two days, cells were stimulated with TNFa for 6 hours and TNFa-induced NF-kB 
activation and TNFR1 expression were quantified using a luciferase assay or qPCR, respectively 
(Figure 2a,b). At MOI 1 and 10, we observed a strong reduction of NF-kB activation (70%) in
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Figure 6.3
Effects of silencing TNFR1 in synovial lining cells during SCW arthritis
Knee joints of naïve C57BL/6 mice were injected with 107 ffu HpTNFRI or HpNS and, two 
days post-transduction, joints were challenged with 5 pg SCW fragments. (a) Expression of 
indicated genes in synovial tissue at 24 hours after SCW challenge. Data are represented as 
means+SEM (n=3-6) of the difference in ACt values compared to the HpNS-group (AACt). (b) 
Cytokine protein levels in one hour cultures of synovial tissue explants isolated at 24 hours 
after challenge. Bars represent means+SEM (n=7) and statistical differences were determined 
using Student's t-test. * P<0.05.
the HpTNFRI-treated group as compared to the HpNS group. This was accompanied by a two- 
and three-fold reduction (2AACt) of TNFR1 mRNA levels at MOI 1 and 10, respectively. Next, we 
investigated the specificity of the TNFR1-targeting construct (Figure 2c). NF-kB luciferase reporter 
fibroblasts were either transduced with HpTNFR1 or pre-incubated with a specific TNF antagonist 
(Enbrel) and then stimulated with TNFa or IL-1p. Both HpTNFR1 and Enbrel showed a strong 
reduction (90%) of TNFa-induced NF-kB activation. In contrast, HpTNFR1 treatment did not 
affect IL-1P-induced NF-kB activation indicating the specific targeting of TNFR1-mediated signal 
transduction.
TNFR1 silencing in synovial lining cells ameliorated arthritis 
Previously, it was demonstrated that TNFR1 in SFs is essential to development of strictly TNF-driven 
arthritis [10]. Therefore, we sought to investigate whether this mechanism also holds for arthritis 
models that are known to be partly TNF-dependent including streptococcal cell wall (SCW) [17] and 
CIA [1]. Synovial lining cells from knee joints of naïve C57BL/6 were transduced by i.a. injection with 
adenoviral vectors encoding HpTNFR1 or HpNS. One day thereafter, joints were challenged with 
5 pg SCW fragments and after twenty four hours synovial cytokine mRNA expression and protein 
levels were measured by qPCR and Luminex, respectively (Figure 3a,b). TNFR1, but not TNFR2, 
mRNA level was decreased (two-fold) in synovial tissue explants from the HpTNFR1-treated group. 
In addition, we observed a strong reduction (more than threefold) in mRNA levels of IL-1P, IL-6 and 
TNFa. Corresponding with these results, protein levels of IL-1P and IL-6 were significantly reduced
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Figure 6.4
Silencing of TNFR1 in synovial lining cells ameliorates CIA
One day after collagen booster, knee joints of CIA negative mice were injected with 107 ffu 
HpTNFRI or HpNS. (a) Expression of indicated genes in synovial tissue at day 26 of CIA. Data are 
represented as means+SEM (n=6) of the difference in ACt values compared to the HpNS-group 
(AACt). (b) Appearance of arthritis in fore and hind paws was monitored at indicated time 
points and scored for severity. (c) Histological analysis of inflammation (infiltrate, exudate) 
and proteoglycan depletion in patellar and femoral cartilage (PG loss) from knee joints 
isolated at day 31. Data are represented as means±SEM (n=9 mice) and statistical differences 
were calculated using Mann-Whitney U-test. * P<0.05, ** P=0.01.
in the HpTNFRI compared to HpNS group. Next, knee joints of CIA negative mice were transduced 
with HpTNFRI or HpNS at day one after booster (day 22). RT-qPCR analysis at day 26 showed a strong 
(more than fourfold) reduction in synovial mRNA levels of IL-1P, IL-6 and TNFa (Figure 4a). Arthritis 
development was monitored until day 31 (Figure 4b). While CIA incidence was equal between 
treatments, TNFR1 silencing clearly reduced macroscopic arthritis severity. Histology taken at day 
31, revealed protection against cartilage destruction and a significant reduction in the amount of 
synovial inflammatory cell infiltrate and joint space inflammatory cell exudate (Figure 4c).
TNFR1 silencing in the reticuloendothelial system prevented collagen-induced arthritis
development
Recently, it was shown that TNFR1 silencing in the radiosensitive hematopoietic compartment 
aggravates disease in CIA [12]. Secondary lymphoid organs, such as liver and spleen, are rich in 
mature and functional cells of hematopoietic origin, such as lymphocytes, monocytes and APCs. 
To delineate the function of TNFR1 in hepatic and splenic cells during arthritis, CIA negative mice 
(collagen type II immunized mice without macroscopic signs of arthritis) were injected i.v. with 
HpTNFR1 or HpNS at day one after booster injection (day 22). We monitored arthritis development 
until day 31 (Figure 5a). Up to day 30, incidence of arthritis in the paws of mice treated with 
HpTNFR1 (40%) was considerably reduced compared to HpNS treatment (83%) (data not shown). 
In addition, macroscopic arthritis scores were significantly reduced in the TNFR1 group. Histology
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Figure 6.5
TNFR1 silencing in hepatic and splenic APCs ameliorates CIA
One day after collagen booster, CIA negative mice were injected intravenously with 
3x108 ffu HpTNFRI or HpNS. (a) Appearance of arthritis in fore and hind paws was 
monitored at indicated time points and scored for severity. (b) Histological analysis 
of inflammation (infiltrate, exudate) and proteoglycan depletion in patellar and 
femoral cartilage (PG loss) from knee joints isolated at day 31. Data are represented 
as means±SEM (n=6 mice) and statistical differences were calculated using 
Mann-Whitney U-test. * P<0.05, ** P<0.005. (c) Representative picture of Safranin- 
O-stained tissue sections of knee joints from mice treated systemically with HpNS 
or HpTNFRI. Original magnification 40x. C=cartilage, P=patella, JS=joint space, 
S=synovium, F=femur.
of knee joints taken on day 31, confirmed a significant reduction in joint inflammation and 
revealed a strong suppression of cartilage proteoglycan depletion (Figure 5 b,c).
TNFR1 silencing in antigen-presenting cells reduced the number of T helper cells in spleen and
dampened the acute-phase response in liver 
To elaborate on the mechanisms behind HpTNFRI-mediated prevention of CIA, we analyzed 
pro-inflammatory gene expression in liver at disease-endpoint by qPCR (Figure 6a). This qPCR 
analyses on the splenocytes (Figure 6b,c) and cytokine measurements on the APC fraction 
(Figure 6d), respectively. FACS analysis showed a significant reduction in the number of CD4+/ 
TCRP+T-cells, stained intra-cellularly for Th1 (IFNy), Th2 (IL-4) or Th17 (IL-17) cytokine expression. 
This was accompanied by a strong decrease (more than fourfold) in mRNA expression of their 
respective transcription factors (T-bet, GATA-3 and RoRyT). Since both IL-1 and IL-6 have been 
described as crucial cytokines T-cell expansion and differentiation [18,19], we measured their 
production by TNFa-stimulated APCs in HpTNFR1 and HpNS-treated groups. Indeed, secreted 
IL-6 protein levels were significantly reduced in HpTNFR1 as compared to HpNS treated 
groups. Together, these data demonstrate a clear pro-inflammatory role of TNFR1 in SFs and 
splenic APCs.
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Figure 6.6
Effects of TNFR1 silencing in hepatic and splenic reticuloendothelial system
One day after collagen booster, CIA negative mice were injected intravenously with 3x108 
ffu HpTNFRI or HpNS. (a) Expression of indicated genes in liver isolated at day 26. Data are 
represented as means (n=5) of the difference in ACt values compared to the HpNS-group 
(AACt). (b) Analysis of intra-cellular cytokine expression in T-cells isolated from spleen at day
26. Data are represented as mean+SEM (n=4) of the percentage positive cells compared to the 
HpNS-group. (c) Expression of indicated genes in isolated splenic T-cells. Data are represented 
as means (n=5) of the difference in ACt values compared to the HpNS-group (AACt). (d) 
Secreted cytokine levels from splenic APCs stimulated for 24 hours with 10 ng/ml mTNFa. 
Data are represented as means+SEM (n=5). Statistical differences were calculated using 
ANOVA with Bonferroni's post-test. * P<0.05, ** P<0.01.
Discussion
The pleiotropic biological and immunological activities of TNFa are determined by its cellular 
localization (transmembrane or soluble) [20-23] and the cell-specific relative abundance of its 
respective receptors, TNFR1 and TNFR2 [9,12,24,25]. The role ofTNF as pivotal mediator of the cytokine 
cascade in inflammation and RA pathogenesis has been unequivocally established, but the relative 
contribution of specific cell types and TNF receptors has not been fully elucidated. Delineating the role 
of TNF and its receptors in different tissues and cell types relevant to disease may contribute to a better 
and safer TNF-targeting strategy in RA patients. While a number of studies using TNFR1-deficient 
mice have established the global contribution of signal transduction through this receptor in CIA 
[8,9,11,26], cell-specific functions ofTNFR1 have thus far only been studied in SFs, bone marrow derived
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macrophages, and radiosensitive hematopoietic cells [10,12,27,28]. In this study we have demonstrated 
that after local treatment in the knee-joint only the synovial lining cells were transduced and that there 
was no spill over to other organs. Gouze et al. [29] have shown that after intra-articular adenovirus 
delivery 75-90% of the transduced cells are positive for fibroblast markers (CD90, CD29,VCAM-1) and 
no transduced cells were positive for the macrophage marker CD11b. Ten percent of the transduced 
cells are positive for the APC marker CD86. After systemic delivery predominantly liver and spleen 
were transduced, while synovium remained negative. It is well documented that systemic intravenous 
delivery of adenoviruses targets the Kupffer cells in the liver [30] and marginal zone macrophages in 
spleen [31]. Stone et al. demonstrated that adenoviruses in the circulation become opsonized by blood 
platelets and that these aggregates are sequestered in the reticuloendothelial system [32]. Interestingly, 
depletion of synovial tissue macrophages [33] or the macrophages in spleen and liver [34] after local or 
systemic administration of clodronate-encapsulated liposomes demonstrates the crucial role of both 
the local and systemic macrophages in mediating experimental arthritis. For this, we can conclude that 
TNFR1-mediated signaling in joint, liver and spleen RES compartments contributes to the local joint 
inflammation and the development of autoimmunity during experimental arthritis.
The contribution of TNFR1-mediated signaling in SLCs to joint inflammation was investigated after 
SCW challenge. In the acute phase, SCW arthritis represents an innate immune response against SCW 
fragments that is driven by direct activation of macrophages [35,36]. TNFR1 silencing in SLCs resulted in 
a significant reduction of secreted IL-6 and IL-1P levels in the joint, which indicates an inhibition of the 
local cytokine cascade. The reduction of IL-6 is most likely a direct effect ofTNFR1 silencing in SLCs, since 
previous studies demonstrated that TNF-induced IL-6 secretion in human RASF is mediated exclusively 
through TNFR1 [37,38]. In contrast, hematopoietic (neutrophils, monocytes), but not mesenchymal 
cells (SFs) were identified as the main source of IL-1 in TNF-driven joint pathology [39]. The observed 
reduction of IL-1P suggests that TNF signaling in SLCs plays an important role in chemoattraction 
of inflammatory cells. Indeed, histological analysis of HpTNFR1-treated joints in CIA showed almost 
complete prevention of IL-1-induced cartilage proteoglycan loss, which was accompanied by an 
impressive reduction of inflammatory cell influx. In line with the study of Armaka et al. [10] we have 
revealed a dominant role of TNFR1-mediated signaling in SLCs in joint inflammation.
Remarkably, we found that TNFR1 silencing in knee joints also protected the ipsilateral ankle joints 
in CIA mice. While such distal effects have been described before in local gene therapy approaches 
[40-42], the underlying mechanism is still not fully understood. However, such an effect might point 
toward a role of local TNFR1-mediated signaling in development of autoimmunity. In support of this, 
previous investigations using periarticular delivery of secreted transgenes, vIL-10 and TNFR, in CIA 
showed that distant anti-arthritic effects coincided with a reduction of specific collagen antibody 
titers and modulation of T-cell responses, respectively [42-44]. Notably, the beneficial systemic effects 
of periarticular TNFR gene therapy correlated well with circulating levels of the transgene [42]. In 
absence of transgene spillover to the circulation, distal effects have been attributed to antigen-primed 
APCs exposed to the therapeutic transgene traveling from treated to untreated joints [44-46]. In our 
approach, TNFR1-silencing was restricted to SLCs which would exclude transgene spillover or direct 
modulation of APCs as a causative for systemic effects. However, local TNFR1-treatment reduced local
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levels of IL-6 and IL-1P. Both cytokines are implicated in APC function, which is in turn a prerequisite 
for induction of auto-reactive CD4+ T-cells and autoimmunity. Eriksson et al. demonstrated that 
IL-1 receptor type I is required for efficient activation of dendritic cells (DCs) [47]. IL-6 switches the 
differentiation of monocyte-derived APCs from DCs to macrophages [48]. The observed reduction of 
both IL-1P and IL-6 synthesis in the inflamed joint may result in the development of immature DCs, 
a differentiation state associated with a tolerogenic function of these cells. Alternatively, tolerogenic 
DCs can be induced by IL-10, a cytokine which inhibits the synthesis of IL-1 and IL-6 in monocytes 
and other cell types [49]. Alternatively, TNFR1-treatment might have affected the APC-like function of 
SLCs. Although SF are not considered to be professional APCs, approximately 60-70 percent of SF in 
the rheumatic joint expresses major histocompatibility complex (MHC) class II molecules and have the 
capacity to serve as accessory cells for superantigen-mediated T-cell activation [50-52]. Importantly, the 
interaction between cytokine-activated T-cells and SF was found to be dependent on transmembrane 
TNFa on the surface of T-cells and resulted in increased production of IL-6 and chemokine IL-8 [53]. 
Indeed, we found strongly decreased IL-6 production in HpTNFR1-treated joints, which may abrogate 
the ability of SLCs to present auto-antigens found within joint tissues.
Strikingly, systemic treatment with HpTNFR1 ameliorated CIA almost to the same extent as local 
treatment. We have previously shown that suppressor of cytokine signaling-3 (SOCS3) overexpression 
in splenic APCs ameliorates CIA via a general suppression ofThelper subsets [15]. Similarly, we observed 
a reduction in the number of Th1 (IFNy, T-bet), Th2 (IL-4, GATA-3), and Th17 (IL-17, RoRyT) cells upon 
TNFR1 in splenic APCs after antigen booster injection. In line with these similar findings, it has been 
demonstrated that TNFR1-deficient murine myocardiocytes show increased expression of SOCS3 
and reduced IL-6 secretion upon TNF infusion [54]. We have confirmed that the splenic APCs from 
HpTNFR1-treated mice produce markedly less IL-6 and IL-1P after TNF stimulation. As these cytokines 
are crucially involved in Th17 differentiation [18,19], the observed large reduction of Th17 numbers in 
spleen is not unexpected. Thus, TNFR1 modulation in the reticuloendothelial system has a clear-cut 
effect on immunity in CIA.
In a side by side comparison, we have demonstrated equal efficacies oflocal and systemic RNAi-mediated 
TNFR1-targeting gene therapy in alleviating CIA. Importantly, cell-specific gene therapeutic targeting 
of TNFR1 clearly modulated pro-inflammatory effects of TNFa, without interfering with protective 
effects of TNF signaling that have been described in hematopoietic cells [11,12]. It will be interesting to 
investigate whether TNFR1 knockdown in a therapeutic rather than a prophylactic regimen will be as 
effective and similar for local and systemic treatment.
Conclusions
Specific silencing of TNFR1 in synovial lining cells, hepatic and splenic reticuloendothelial system 
using an adenoviral-based RNAi approach revealed a dominant and clear pro-inflammatory role 
of TNF signaling in these cells during CIA. Systemic treatment dampened the liver acute phase 
response and reduced proliferation of T-helper subsets in spleen. Local treatment inhibited the 
pro-inflammatory cytokine cascade in the joint. Gene therapeutic targeting of TNFR1 may be a 
promising and safer approach for TNFa-blockade in RA patients.
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Materials and methods 
Animals
Male 10-12 week old DBA/1J and C57BL/6 mice were obtained from Janvier (Le Genest Saint Isle, 
France). During viral experiments, mice were housed in HEPA-filtered individually-ventilated 
cages. The animals were fed a standard diet with food and water ad libitum. All in vivo studies 
complied with national legislation and were approved by the local authorities of the Care and 
Use of Animals.
Induction of collagen-induced arthritis
Bovine collagen type II (bCII) was dissolved in 0.05 M acetic acid to a concentration of 2 mg/ml 
and was emulsified in equal volumes of Freund's complete adjuvant (2 mg/ml of Mycobacterium 
tuberculosis strain H37Ra, Difco Laboratories, Detroit, MI, USA). DBA1/J mice were immunized 
intradermally at the base of the tail with 100 l^ of emulsion (100 ^g of bCII). On day 21, the mice 
were given an intraperitoneal booster injection of 100 ^g bCII dissolved in phosphate buffered 
saline (PBS). Mice were killed on day 31 by cervical dislocation.
SCW preparation and induction of SCW arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. Cell 
walls were prepared as described previously [55]. The resulting supernatant obtained after 
centrifugation at 10,000 g contained 11% muramic acid. Unilateral arthritis was induced by 
intra-articular injection of 5 ^g of streptococcal cell wall (SCW) fragments (rhamnose content) 
in 6 l^ of PBS.
Cell culture
Mouse embryonic fibroblasts (NIH-3T3) stably transfected with a 5xNF-kB luciferase reporter 
were cultivated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 mM 
pyruvate, penicillin-streptomycin (Lonza, Basel, Switzerland) and 5% fetal calf serum (FCS). Cells 
were kept at 37 °C in a humid atmosphere containing 5% CO2.
Plasmids
For cloning we used Pfu DNA polymerase (Stratagene, La Jolla, CA) and T4 DNA Ligase 
(New England Biolabs, Ipswich, MA). All generated constructs were verified by sequencing. 
The U6 promoter was PCR cloned from mouse genomic DNA into XbaI/SalI sites of pShuttle 
(kind gift of Bert Vogelstein, Howard Hughes Medical Institute, Baltimore, MD) to give 
pShuttle-U6 using primers FW 5'-TCTAGAGATCCGACGCCGCCATCTCTA-3'and RV 5'-GTCGACGT- 
TAACAAGGCTTTTCTCCA-3'. The target sequence for silencing the Tnfrsf1a gene was 
ATCTTCGGTCCTAGTAACT (bp 1170-1188, NM_011609.3) and as scrambled control sequence 
we used ACTCATGTCTTGATCAGCT (no complementary sequence in murine genome). The 
silencing cassette was constructed using following oligonucleotides: FW 5'-TG-target-TTCAA-
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GAGA-target reverse complimentary-TTTT-TGCA-3' and RV 5'-AAAA-target-TCTCTTGAA-target 
reverse complimentary-CA-3' where the loop and polyA sequences are underlined and bold, 
respectively. Oligonucleotides (4.5 nM) were mixed in annealing buffer (100 mM potassium 
acetate, 2 mM magnesium acetate, 30 mM HEPES pH 7.4), heated for 5 minutes at 95 °C, and 
gradually cooled to room temperatures. Annealed DNA fragments were ligated in HpaI/SalI 
sites of pShuttle-U6.
Adenoviral vectors
Replication-deficient adenoviral vectors (E1/E3 deleted) Ad5.U6-HpTNFR1, Ad5.U6-HpNS 
(scrambled control) were prepared according to the AdEasy system [56], with the exception that 
replication-competent recombinant free viral particles were produced in E1 transformed N52E6 
amniocyte cells [57]. Ad5.CMV-eGFP was a kind gift of Jay K. Kolls (Department of Pediatrics, 
Children's Hospital of Pittsburgh, Pennsylvania).
Viruses were purified by two consecutive CsCl2 gradient purifications and stored in small 
aliquots at -80 °C in buffer containing 25 mM Tris, pH 8.0, 5 mM KCl, 0.2 mM MgCl2, 137 mM 
NaCl, 730 ^M Na2HPO4, 0.1% ovalbumin and 10% glycerol. The infectious particle titer (ffu) was 
determined by titrating vector stocks on 911 indicator cells and measuring viral capsid protein 
immunohistochemically 20 hours after transduction.
Study design and histology
To study which organs are transduced after systemic or local treatment, Ad5.CMV-eGFP was 
injected into naive DBA/1J mice intravenously (i.v.) or intra-articularly (i.a.) with 3x108 or 107 ffu 
adenovirus, respectively. One day later liver, spleen, lung, knee joints and draining lymph nodes, 
blood and bone marrow cells (BMCs) were isolated. They were fixated in 4% paraformaldehyde 
for 4 days for immunohistochemistry. After decalcification in 5% formic acid, specimens were 
processed for paraffin embedding. Tissue sections (7 ^m) were stained with anti-GFP antibody. 
For mRNA measurement with RT-qPCR all parts were isolated.
DBA/1J mice were injected intravenously (i.v.) or intra-articularly (i.a.) one day after bCII booster 
(day 22) with 3x108 or 107 ffu adenovirus, respectively. For the siRNA hairpin treated mice, three 
days post-transduction mice were sacrificed and synovium (i.a.) spleen, and liver (i.v.) were isolated. 
Development of arthritis in front and hind paws was macroscopically monitored (scores between 
0-2) until day 31. The macroscopic arthritis score is based on the clinical signs of inflammation 
in each paw and ankle with a maximum score of 8 (1 for each hind paw and 1 for the ankle). 
Mice were killed at day 26 or 31 by cervical dislocation. At day 26, synovial tissue explants (i.a.), 
spleen and liver (i.v.) were removed. At day 31, ankle and knee joints (all groups) were removed 
and fixed in 4% paraformaldehyde for 4 days. After decalcification in 5% formic acid, specimens 
were processed for paraffin embedding. Tissue sections (7 nm) were stained with haematoxylin 
and eosin (cell influx) or safranin-0 (cartilage proteoglycan depletion). Histological changes were 
scored in the patella/femur region on five semi-serial sections of the knee joint, spaced 70 nm 
apart. Scoring was performed by two observers without knowledge of the group as described
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before. Histopathological changes were scored using the following parameters. Cartilage depletion, 
defined as the loss of proteoglycan content, was scored on a scale ranging from 0-3 per region, 
depending on the intensity of staining in the cartilage. Infiltration of cells was scored on a scale of 0-3 
(0 = no cells, 1 = mild cellularity, 2 = moderate cellularity, 3 = maximal cellularity) , depending on the 
amount of inflammatory cells in the synovial cavity (exudate) or synovial tissue (infiltrate). Cartilage 
erosion was graded on a scale of 0-3, ranging from no damage to compete loss of articular cartilage.
Immunohistochemistry
Paraffin sections were stained with rabbit-anti-GFP (1:800) (#2555, Cell Signaling Technology, Beverly, 
MA) o/n at 4oC. After washing sections were incubated for 1 hour with biotinylated secondary 
antibody goat-anti-Rabbit-BIOT (1:400) (Vector Laboratories, Burlingame, CA). After washing, sections 
were incubated for 30 minutes with Vectastain (1:400) (Vector Laboratories). Thereafter sections were 
stained with 3,3'-diaminobenzidine and counterstained with haematoxylin, embedded in Permount 
(Thermo Fisher, Rockford, Il).
Spleen cell isolation and APC stimulation
Spleens were mashed and filtered, and erythrocytes were removed by osmotic shock. After washing, 
the splenic cell fraction was incubated in RPMI 1640 (Invitrogen, Carlsbad, CA) at 37°C in 5% CO2 for 
1 hour in order to separate adherent cells from nonadherent cells. The adherent cell fraction mainly 
consisting of macrophages is termed APC. Splenic APCs were stimulated for 24 hours with 10 ng/ml 
TNFa (Abcam, Cambridge,UK). Cytokine production was analyzed by Luminex.
Flow cytometry analysis
Total spleen cells obtained as described above, were cultured (106/ml) for 2 hours in RPMI 1640 
(Invitrogen) supplemented with 10% FCS, penicillin-streptomycin, 1 mM pyruvate, 1 nl/ml Golgiplug 
inhibitor (BD Biosciences, San José, CA), 10 ng/ml PMA, 1 ng/ml ionomycin.Thereafter cells were labeled 
for 30 minutes at 4 °C with antibody TCRP-FITC (1:200) and CD4-APC (1:100) or their respective isotype 
control antibodies. Cells were washed and consecutively fixed and permeabilized using cytofix/ 
cytoperm solution (BD Biosciences). Thereafter, cells were incubated with phycoerythrin-labeled (PE) 
antibodies IFNy-PE (1:200), IL-4-PE (1:200), IL-17-PE (1:500) (Biolegend, San Diego, CA) or appropriate 
isotype controls for 30 minutes at 4°C in PBS containing 1% bovine serum albumin (BSA), 2% FCS, 
0.1% saponin. Analyses were performed on a BD FACSCalibur (BD Biosciences).
Cytokine measurements
Synovial tissue explants were incubated for one hour at RT in 200 nl RPMI 1640 supplemented with 
0.1% BSA, penicillin-streptomycin and 1% pyruvate. Subsequently, supernatant was harvested and 
centrifuged for 5 minutes at 1000g. Murine IL-1P, IL-6 and TNFa levels were determined using the 
Luminex multianalyte technology, using the BioPlex system in combination with BioPlex Mouse 
Cytokine Assays (Bio-Rad, Hercules, CA). Cytokines were measured in 50 nl washout medium. The 
sensitivities were 5, <3 and 5 pg/ml for IL-1P, TNFa and IL-6, respectively.
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Luciferase measurements
NIH-3T3-5xNF-KB-luciferase cells were seeded at 5 x 104 cells per well in a Krystal 2000 96-wells plate 
(Thermo Labsystems, Brussels, Belgium). The day after, cells were transduced with adenovirus at 
indicated multiplicity of infection (MOI) in 50 nl DMEM for 4 hours at 37 °C. Two days post-transduction 
cells were stimulated with 10 ng/ml recombinant murine TNFa or IL-1P (R&D Systems, Abingdon, UK) 
for 6 hours and subsequently lysed in ice-cold lysis buffer (0.5% NP-40, 1 mM DTT, 1 mM EDTA, 5 mM 
MgCl2, 100 mM KCl, 10 mM Tris-HCl pH 7.5). Alternatively, TNFa was antagonized by pre-incubating 
cells for one hour with 10 ng/ml Enbrel (Wyeth Pharmaceuticals, Hoofddorp, Netherlands). Luciferase 
activity was quantified using the Bright-Glo luciferase assay system (Promega, Madison, WI, USA) by 
adding an equal volume ofBright-Glo to the cell lysate. Luminescence was quantified in a luminometer 
(Lumistar, BMG, Offenburg, Germany), expressed as relative light units (RLU) and normalized to total 
protein content of the cell/tissue extracts using BCA protein assay kit (Thermo Fisher, Rockford, Il).
RNA isolation
Synovial and liver tissue was snap-frozen in liquid nitrogen and homogenized using a MagNa 
Lyser (Roche). Total RNA was extracted using TRI reagent (Sigma, St. Louis, MO). Isolated RNA 
samples were treated with RNase-free DNase I (Qiagen, Venlo, the Netherlands) for 15 minutes. 
Synthesis of cDNA was accomplished by reverse transcription PCR using an oligo(dT) primer and 
Moloney murine leukemia virus Reverse Transcriptase (Invitrogen).
Quantitative PCR
QPCR was performed using SYBR Green PCR Master mix and the ABI 7000 Prism Sequence Detection 
system (Applied Biosystems Inc., Foster City, CA) according to the manufacturer's instructions. 
Primers were designed over exon-exon junctions in Primer Express (Applied Biosystems Inc.) and 
used at 300 nM in the PCR reaction. PCR conditions were as follows: 2 minutes at 50 °C and 10 
minutes at 95 °C, followed by 40 cycles of 15 seconds at 95 °C and one minute at 60 °C. Gene 
expression (cycle threshold, Ct) values were normalized using glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) as a reference gene (ACt = Ctgene -  CtGapdh). Primer sequences are available 
on request.
Statistical analysis
Data are represented as means+SEM. and significant differences were calculated using Student's 
t-test, one-way analysis of variance (ANOVA) or Mann-Whitney U-test, as indicated (GraphPad 
Prism 5.02, San Diego, CA). P-values of less than 0.05 were regarded as significant.
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Abstract
Objective
Activated synovial fibroblasts are key players in the pathogenesis of rheumatoid arthritis 
(RA) by driving inflammation and joint destruction. Numerous molecules including cytokines 
and toll-like receptor (TLR) ligands induce pro-inflammatory signalling and gene expression 
through a hierarchical network of kinases. Upstream mitogen-activated protein kinase kinase 
kinases (MAP3Ks) represent an attractive target for RA treatment. In this study we sought to 
determine the role of the MAP3K transforming growth factor-p activated kinase 1 (TAK1) in 
cytokine and TLR-mediated signalling.
Methods
TAK1 activity was inhibited using either a small molecule inhibitor or lentivirally-overexpressed 
kinase-inactive TAK1-K63W mutant in murine embryonic and human dermal and synovial 
fibroblasts. Fibroblasts were stimulated with IL-1, TNF, TLR2 or TLR4 agonists and responses 
were evaluated using transcriptional reporters and analysis of gene expression of collagenases 
(MMP3,13), cytokines (IL-1p,-6) and chemokines (IL-8, MCP-1).
Results
TAK1 inhibition abrogated cytokine- and TLR-induced activation of NF-kB and Saa3-promoter 
reporters in murine and human dermal fibroblasts. In synovial fibroblasts, TAK1 crucially 
regulated IL-1 and TNF-mediated NF-kB, but not Saa3-promoter activation. Furthermore, TAK1 
was required for inducible mRNA expression of IL-1P, IL-6, IL-8, MMP3 and MMP13, but not 
MCP-1, in response to IL-1, .TNF and TLR2 agonist. Unexpectedly, TLR4-induced NF-kB activation 
and gene expression was fully TAK1-independent.
Conclusion
In general, TAK1 plays a prominent role in regulation of IL-1- and TNF-mediated signalling 
in fibroblasts. Interestingly, TLR4 signalling is specifically TAK1-independent in synovial
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fibroblasts. Consequently, therapeutic TAK1 inhibition in arthropaties may not dampen the 
damage-associated molecular pattern-mediated TLR4 activation of synovial fibroblasts.
Introduction
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease that mainly affects 
the synovial joints that ultimately leads to joint destruction. Prior to and during joint 
inflammation the synovial lining tissue, consisting of synovial fibroblasts and macrophages, 
becomes activated and hyperplastic resulting in invasion and degradation of adjacent 
cartilage and bone. In both experimental and human arthritis, synovial fibroblasts have 
been identified as cells that actively drive inflammation and joint destruction [1,2]. 
Moreover, transmigration of activated RA synovial fibroblasts has been implicated in 
mediating the spreading of destructive arthritis to unaffected joints [3]. Due to their key 
role in RA pathogenesis, synovial fibroblasts are major target cells for treatment of disease. 
Synovial fibroblasts are potently activated by cytokines, such as IL-1 and TNF [4-6], and 
toll-like receptor (TLR) ligands [7-9]. TLRs 2, 3 and 4 are predominantly expressed in 
synovial fibroblasts and their expression is increased in RA patients [8,10]. Although 
TLRs are primarily activated by exogenous pathogens, they also recognize endogenous 
damage-associated molecular patterns (DAMPs) that are abundantly present in arthritic 
joints [7,11]. In experimental arthritis, it has been demonstrated that TLR4 activation 
promotes the onset and severity of disease [12]. Moreover, DAMP-mediated activation of 
TLR4 specifically in synovium has been found to be crucially involved in joint destruction 
[13].
After ligation of their respective receptors, expression and secretion of pro-inflammatory 
mediators including cytokines, chemokines and matrix metalloproteinases (MMPs) is 
induced through multiple signalling cascades including nuclear factor-KB (NF-kB) and the 
mitogen-activate protein kinase (MAPK) families p38, c-Jun-N-terminal kinase (JNK), and 
extracellular-signal regulated kinase (ERK) (reviewed in [14]). These kinases are regulated 
through phosphorylation by their upstream kinases IkB kinase (IKK) and MAPK kinase 
(MAPKK), respectively. In turn, MAPKK kinases (MAP3Ks) control the activation of IKK and 
MAPKK and are activated through interactions with receptor-associated proteins, such as 
IL-1R-associated kinases (IRAKs) and TNFR-associated factors (TRAFs). The MAP3K family 
comprises numerous members of which MEK kinase-1, -2 (MEKK1,-2) and transforming 
growth factor-p activated kinase 1 (TAK1) are most abundantly expressed in RA synovial 
fibroblasts [15].
TAK1 has been identified as the key regulator of IL-1, TNF and TLR-induced activation of 
NF-kB and MAPK pathways in mice [16-18]. Inhibition of TAK1 catalytic activity prevented 
chemical-induced inflammation in mice [19]. However, studies using cell-type specific 
TAK1-deficient mice have also revealed that TAK1 is a crucial regulator of homeostasis 
in cartilage, skin, epithelium and liver [20-23]. Therefore, insight into the cell-specific
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Figure 7.1
TAK1-dependent signalling in murine fibroblasts
TAK1-dependent NF-kB activation in murine fibroblasts. TAK1 inhibition by an inhibitor 
and LV-K63W (a). NIH-3T3-5xNF-KB-luciferase cells were either transduced with indicated 
p24gag equivalents LV-K63W (triangles) and control lentivirus (PGK-empty) or pre-treated 
with indicated concentrations inhibitor (squares) and vehicle. Two days post-transduction 
or one hour after pre-treatment, cells were stimulated with IL-1p (1 ng/ml) for 6 hours. (b) 
NIH-3T3-5xNF-KB-luciferase fibroblasts were pre-treated with 500 nM inhibitor or vehicle and, 
stimulated for 6 hours with murine IL-1p, TNFa, TLR2 and TLR4 agonists. NF-kB activation was 
measured by luciferase assay and data are expressed as relative activity compared to controls 
(mean±SEM, n=3). TAK1 inhibition significantly (P<0.05, ANOVA) reduced NF-kB activation 
though all stimuli. (c) Induction of Saa3 mRNA expression by IL-1p or TLR4 agonist in NIH-3T3 
stably transduced with LV-K63W or PGK-empty. Data are represented as fold induction 
(means+SEM, n=3)) over untreated cells. *** P<0.001 by ANOVA.
regulation of signalling pathways by TAK1 is indispensable for developing a treatment 
based on its inhibition.
Until now, it has been shown that TAK1 regulates the IL-1-induced JNK pathway and 
activator protein-1 (AP-1) transcription factor in synovial fibroblasts [24]. Here, we 
investigated the role of TAK1 in TNF-, TLR2-, and TLR4-mediated signal transduction and 
induction of pro-inflammatory gene expression in murine embryonic and primary human 
dermal and synovial fibroblasts. The present study reveals that TLR4 signalling is specifically 
TAK1-independent in synovial fibroblasts.
Results
TAK1 regulates cytokine- and TLR-induced NF-kB activation in murine fibroblasts 
TAK1 has been identified as the crucial mediator of IL-1- and TNF-induced activation of NF-kB, 
JNK and p38 MAPK signal transduction pathways in NIH-3T3 fibroblasts [25]. Using a 3T3 NF-kB 
reporter cell line, we investigated TAK1-inhibitory efficiency of a small molecule inhibitor [19] 
and lentivirally-overexpressed kinase-inactive TAK1-K63W mutant (LV-K63W) (Figure 1a).
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Figure 7.2
TAK1-dependent signalling in human dermal fibroblasts
TAKI-dependent NF-kB and Saa3-promoter activation in human dermal fibroblasts. Dermal 
fibroblasts were co-transduced with 150 ng LV-K63W / PGK-empty and 25 ng LV-Saa3/ 
NF-kB-Luc, serum-starved for two days and thereafter stimulated with human IL-1p, TNFa and 
LPS (TLR4) for 6 hours. NF-kB (a) and Saa3-promoter (b) activation were determined using 
a luciferase assay. Data are expressed as relative activity compared to controls (mean+SEM, 
n=4). Induction of IL-1p, IL-6 and IL-8 mRNA expression by IL-1p was determined by RT-PCR (c). 
Data are represented as fold reduction compared to PGK-empty (2-AACt, AACt= ACt K63W - ACt 
control). Statistical differences were determined using ANOVA. ** P<0.01, *** P<0.001
Maximal inhibition of IL-1 P-induced NF-kB activity was achieved at 500 nM inhibitor 
(66.2±8.6%) or 150 ng p24gag equivalents LV-K63W per 5x104 cells (65.4±6.2%), respectively. 
There were no significant differences in maximal inhibition between inhibitor and LV-K63W, 
and aforementioned concentrations were applied throughout following experiments. Next, we 
analysed TAK1-mediated regulation of TLR-induced signal transduction (Figure 1b). Treatment 
of fibroblasts with inhibitor resulted in a significant reduction in NF-kB activation (~60%, P < 
0.05) induced by TLR2 (Pam3Cys) and TLR4 (LPS) agonists. As a control, IL-1- and TNF-induced 
NF-kB activation were also potently suppressed by inhibitor. Finally, we evaluated the effect 
of TAK1 inhibition on the inducible expression of serum amyloid A3 (Saa3), which has been 
identified as a strictly TAK1-dependent TNF target gene [25] (Figure 1c). Stable transduction 
with LV-K63W also completely prevented induction of Saa3 expression by IL-1 P and LPS. 
These results confirm the crucial role of TAK1 in mediating cytokine- and TLR-mediated signal 
transduction in murine fibroblasts.
TAK1-dependent signalling in primary human dermal fibroblasts 
Since activated fibroblasts play an important role in the pathogenesis of chronic inflammatory 
diseases [1,26], inhibition of inflammatory signal transduction represents a straightforward 
treatment strategy. Therefore, we assessed the contribution of TAK1 to pro-inflammatory signal
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Figure 7.3
Inflammatory signalling in synovial fibroblasts
Induction of transcriptional reporters and pro-inflammatory gene expression in synovial 
fibroblasts. Fibroblasts were transduced with 25 ng LV-Saa3/NF-KB-Luc, serum-starved 
for two days and thereafter stimulated with indicated ligands for 6 hours. NF-kB (a) and 
Saa3-promoter (b) activation were determined using a luciferase assay. Data are represented 
as fold induction over basal levels (mean+SEM, n=4). Induction of pro-inflammatory gene 
expression was determined by RT-PCR (c-f). Synovial fibroblasts were serum-starved for two 
days, pre-incubated for one hour with vehicle, and either left untreated or stimulated for 6 
hours with IL-1p (c), TNFa (d), LPS (TLR4, e), and Pam3Cys (TLR2, f). Data are represented as fold 
induction (2-AACt) compared to untreated cells (means+SEM, six donors).
transduction in primary human dermal and synovial fibroblasts. Overexpression of TAK1-K63W 
in dermal fibroblasts completely abrogated IL-1-induced NF-kB activation (Figure 2a). Also 
NF-kB activation through TNF- (66.2±2.5%) and TLR4- (68.5±4.6%) was strongly reduced. Since 
SAA3 is a pseudogene in humans and TAK1 directly regulates the transcriptional activity of the 
Saa3 promoter [25], we additionally used a Saa3-promoter luciferase reporter for studying the 
effect of TAK1 inhibition in human fibroblasts (Figure 2b). TAK1 crucially regulated IL-1, TNF- and 
TLR4-mediated activation of Saa3-promoter reporter as revealed by an approximately eighty 
percent reduction of luciferase activity. Reduction of NF-kB and Saa3-promoter activation 
through TAK1 inhibition correlated with a suppression of IL-1P, IL-6 and IL-8 gene expression 
(Figure 2c). These data identify TAK1 as a pivotal regulator of pro-inflammatory signalling in 
dermal fibroblasts.
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Figure 7.4
TAK1-independent TLR4 signalling in synovial fibroblasts
TAK1-independent TLR4 signalling and Saa3-promoter activation in synovial fibroblasts. 
Fibroblasts were transduced with 25 ng LV-Sgg3/NF-kB-Luc and consecutively serum-starved 
for two days, pre-treated with 500 nM inhibitor or vehicle for one hour, and either left untreated 
or stimulated with human IL-1p, TNFa, and LPS (TLR4) for 6 hours. NF-kB (a) and Saa3-promoter
(b) activation were measured using a luciferase assay and data are represented as relative 
activity (mean+SEM, four donors, quadruplicate measurements) compared to untreated cells. 
Statistical differences were determined using ANOVA. ** P < 0.001.
Cytokine- and TLR-mediated induction of transcriptional reporters and pro-inflammatory 
genes in synovial fibroblasts 
In order to identify TAK1-dependent signalling pathways in synovial fibroblasts, we first 
validated whether cytokines and TLR ligands induced NF-kB and Saa3-promoter transcriptional 
reporters (Figure 3a,b) and pro-inflammatory gene expression (Figure 3c-f). We found strong 
upregulation of both reporter activities upon IL-1, TNF and TLR4 stimulation, whereas TLR2 
stimulation only led to marginal induction. Accordingly, expression of NF-kB target genes 
IL-1P, IL-6 and IL-8 was strongly upregulated upon cytokine and TLR stimulation. Moreover, the 
magnitude of upregulation seemed to correlate with the extent of NF-kB and Saa3-promoter 
activation. Additionally, we detected significantly induced expression of AP-1 (MMP3/13) [27] 
and interferon regulatory factor-3 (MCP-1) [28] transcription factor target genes.
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Figure 7.5
Effects of TAK1 inhibition on induction of pro-inflammatory gene expression in 
synovial fibroblasts
Effects of TAK1 inhibition on induction of pro-inflammatory gene expression in synovial 
fibroblasts. Fibroblasts were serum-starved for two days, pre-treated with 500 nM inhibitor 
or vehicle for one hour, and left untreated or stimulated with human IL-1p (a), TNFa (b), LPS 
(TLR4, c) and Pam3Cys (TLR2, d) for 6 hours. Expression of indicated genes was measured 
using RT-PCR. Data are represented as fold reduction (2-AACt) compared to DMSO-treated cells 
(mean+SEM, six donors). Statistical differences were determined using Repeated Measures 
ANOVA. * P < 0.05, ** P < 0.01.
TLR4-mediated signalling is TAK1-independent in synovial fibroblasts 
Next, we repeated experiments as described above in the presence of TAK1 inhibitor. Consistent 
with our previous results in murine and human dermal fibroblasts, IL-1 (47.9±7.9%) and 
TNF-mediated (48.4±6.2) NF-kB activation was significantly reduced through TAK1 inhibition 
(Figure 4a). In contrast, induction of Saa3-promoter activation was unaffected by treatment 
with TAK1 inhibitor (Figure 4b). Surprisingly, both NF-kB and Saa3-promoter activation through 
TLR4 triggering demonstrated TAKI-independent, as indicated by a complete lack of inhibition 
of transcriptional reporters upon inhibitor treatment.
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To corroborate these data, we analysed the effect of TAK1 inhibition on the induction of 
pro-inflammatory genes by cytokines (Figure 5a,b) and TLR agonists (Figure 5c,d). In line 
with promoter reporter measurements, induction of NF-kB target genes IL-1P, IL-6 and IL-8 
through IL-1 and TNF was significantly reduced by TAK1 inhibitor treatment. Corresponding 
with the established regulation of JNK-AP-1 pathway by TAK1 [24], IL-1 and TNF-induced 
MMP3 expression was also clearly reduced. The IRF3-target gene MCP-1 demonstrated 
TAK1-independent for all applied stimuli. Whereas TAK1 inhibition resulted in suppression of 
TLR2-induced IL-1P, IL-6 and MMP3 expression, TLR4-induced gene expression was completely 
unaffected by inhibitor treatment. Together these data reveal TAK1-independent TLR4 signal 
transduction that is specific for synovial fibroblasts.
Discussion
Given the multitude of activating molecules and redundancy and complexity of MAPK signalling 
[29,30], upstream MAP3Ks are of particular interest as therapeutic targets as they potentially 
couple multiple receptors to downstream signalling pathways. In this study, we investigated the 
role of the MAP3K TAK1 in mediating pro-inflammatory signalling in fibroblasts and uncovered 
TAK1-independent TLR4 signalling specifically in synovial fibroblasts.
Although there is substantial evidence that IL-1 signals through both TAK1 and MEKK3 [31,32] 
information on a physiological role of these two kinases in synovial fibroblasts is limited. In 
two studies, analysis of MAP3K expression on mRNA and protein level in synovial fibroblasts 
revealed abundant expression of TAK1 and trace amounts of MEKK3 [15]. Knock down of MEKK3 
did not affect IL-1p-induced MAPK activation and TAK1 was identified as the crucial mediator 
in JNK, but not ERK or p38 MAPK pathways. siRNA-mediated suppression of TAK1 did not 
significantly inhibit NF-kB nuclear translocation and DNA binding, but suppressed IL-6, a typical 
NF-kB target gene [24]. Hence, our results, using transcriptional reporter systems confirm that a 
significant portion of NF-kB activation through IL-1R and TNFR is mediated by TAK1, while p38 
and ERK pathways maybe regulated independently from TAK1.
Unexpectedly, we discovered that TAK1 plays no role in TLR4-induced NF-kB activation and 
pro-inflammatory gene expression in synovial fibroblasts. Several studies have emphasized a 
central role for TAK1 in LPS/TLR4-mediated NF-kB activation in murine macrophages, embryonic 
fibroblasts, B-cells, and human HEK293 cells [16,17,33,34]. In addition, we have revealed that 
TAK1 regulates NF-kB in murine NIH-3T3 fibroblasts and primary human dermal fibroblasts. 
TLR4 activates signal transduction through TRIF- (TIR-domain-containing adapter-inducing 
interferon-p) and MyD88-dependent pathways. Upon ligand binding MyD88 is recruited, 
which subsequently leads to the recruitment and phosphorylation of IRAK proteins, which then 
interact with TRAF6. The activated complex activates downstream IKK and MAPKKs through an 
interaction with TAK1. The TRIF-dependent pathway activates the interferon regulatory factor-3 
(IRF3) pathway through TANK binding kinase-1 (TBK1). NF-kB and MAPK pathways are activated 
through interaction with receptor interacting protein-1 (RIP1), which consecutively interacts 
with TRAF6 and TAK1 [35]. Maximal induction of inflammatory cytokines such as TNFa and IL-6
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is dependent on the activation of both TRIF and MyD88 pathways [36]. Based on these studies, 
we expect TAK1-dependent regulation of MyD88- and TRIF-dependent NF-kB and MAPK 
activation, but not the IRF3 pathway. The latter was confirmed by our RT-PCR analysis results, 
which indicated indeed that regulation of the IRF3 target gene MCP-1 [28] was not inhibited 
by treatment of synovial fibroblasts with TAK1 inhibitor. Inhibition of IL-1p-induced NF-kB 
activation by inhibitor treatment suggested a MyD88-TAK1-IKK pathway in synovial fibroblasts. 
Based on the latter, and our observations that TAK1 does not mediate TLR4 signal transduction 
in synovial fibroblasts, at least two mechanism might underlie these remarkable results.
First, the TLR4-MyD88-IKK/MAPK pathway can be regulated by a MAP3K other than TAK1. 
Recent investigations have unravelled a TAK1-independent and MEKK3-dependent mechanism 
for TLR8-mediated IKK and JNK activation [37], and a similar pathway was discovered for IL-1 
mediated NF-kB activation [38]. As in our study, NF-kB activity is not completely inhibited by the 
TAK1 mutant or the TAK1 inhibitor, and knowledge on regulation of MEKK3 in synovial fibroblasts 
is very limited. Therefore, MEKK3 is a likely candidate that accounts for TAK1-independent 
signalling in synovial fibroblasts. Thus, a divergence of IL-1R/TLR MyD88-dependent pathways 
into IL-1R-TAK1- and TLR4-MEKK3 routes could be a possibility.
Second, TLR4 signalling through the MyD88-dependent pathway might be less dominant 
or even ablated in synovial fibroblasts. A possible mechanism for such phenomenon has 
been described for LPS-tolerance induction in human monocytes and dendritic cells [39,40]. 
Upon restimulation with a TLR4 ligand tolerized cells show decreased TLR4-MyD88 complex 
formation, which results in impaired IRAK-1 phosphorylation [41]. Moreover, it has been shown 
IRAK-M was upregulated in RA synovial fibroblasts and which is a negative regulator of the 
MyD88-dependent pathway and is associated with tolerance induction [42,43]. If this were to 
take place in synovial fibroblasts, we would expect predominant signal transduction through 
TRIF. However, in the case of pre-dominant TRIF signalling we would still expect activation of 
the TRIF-TRAF6-TAK1 pathway, unless TAK1 can be bypassed for NF-kB and MAPK signalling in 
this route.
Circumventing TAK1 in TLR4 mediated NF-kB activation can be achieved by TANK, which was 
shown to slightly induce NF-kB transcription after overexpression [44]. Another pathway 
without involvement of TAK1 mediated NF-kB activation has been discovered in IL-1 signalling 
[45]. In this pathway, TRAF6 is associated with p62, which activates atypical protein kinase C 
and this subsequently leads to NF-kB activation.
Besides TLR4 signalling, Saa3-promoter activation demonstrated specifically TAK1-independent 
in synovial fibroblasts. This promoter is synergistically activated through cooperation of 
NF-kB and CAAT/enhancer-binding protein (C/EBP) transcription factors [46,47]. Therefore, 
TAK1-independent Saa3-promoter activity, despite TAK1-dependent NF-kB activity could point 
towards differential regulation of C/EBP transcription factors by TAK1 in synovial versus dermal 
fibroblasts.
In conclusion, using a previously characterized dominant-negative mutant or small molecule 
inhibitor of TAK1, we have found a more restricted role for this MAP3K in mediating
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pro-inflammatory signalling in synovial fibroblasts. In the light of the recently established role of 
TLR4 in experimental arthritis [12,13,48], insight into TLR4 signalling in synovial fibroblasts is of 
particular interest for understanding pathogenesis and treatment. The underlying mechanism 
for TAK1-independent regulation of TLR4 signalling, potentially TLR4 tolerance or involvement 
of an alternative MAP3K, remains to be addressed in future research.
Materials and methods 
Patients and samples
Human dermal fibroblasts were obtained from skin biopsies of healthy volunteers at the 
Radboud University Nijmegen Medical Centre (kind gift from J. Schalkwijk, Department of 
Dermatology). Synovial tissue was obtained from open joint replacement surgery or arthroscopic 
synovectomy at the Clinic of Orthopedics, Waldkrankenhaus "Rudolf Elle', Eisenberg, Germany 
(kindly provided by R.W. Kinne, University of Jena). Patients with RA or osteoarthritis were 
classified according to the ACR criteria. Synovial fibroblasts were purified from synovial tissue 
as previously published [49]. Briefly, the tissue samples were minced, digested with trypsin/ 
collagenase p (Sigma, St. Louis, MO), and the resulting single cell suspension was cultured for 
seven days. Non-adherent cells were removed by medium exchange. Fibroblasts were obtained 
by negative isolation using Dynabeads M-450 CD14 MACS purification.
Cell culture
Mouse embryonic fibroblasts (NIH-3T3) DMEM supplemented with 1 mM pyruvate, 40 ng/ml 
gentamicin, and 5 or 10% fetal calf serum (FCS), respectively. Stable transcriptional reporter 
cell line NIH-3T3-5xNF-KB-luciferase was described before [50]. Human dermal and synovial 
fibroblasts were cultivated in DMEM supplemented with 1mM pyruvate, 80 ng/ml gentamicin, 
and 10% FCS. Cells were kept at 37 °C in a humid atmosphere containing 5% CO2.
Plasmids
For generation of recombinant lentiviral vectors we used of the third-generation 
self-inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) containing the 
human phosphoglyceratekinase (PGK) promoter (kind gift from J. Seppen, AMC Liver Center, 
Amsterdam, The Netherlands). For cloning we used cloned Pfu DNA polymerase (Stratagene, 
La Jolla, CA, USA) and T4 DNA Ligase (New England Biolabs, Ipswich, MA, USA). All generated 
constructs were verified by sequencing. A lentiviral transcriptional luciferase reporter 
containing four tandemly-arranged NF-kB binding sites (pTRH2-NF-KB-Luc) was purchased 
from System Biosciences (Mountain View, CA, USA). Construction of the Saa3-promoter 
luciferase reporter is described in Chapter 3. The cDNA sequences of a non- and EGFP-tagged 
kinase-inactive mutant of TAK1 (K63W) were PCR cloned from pEGFP-C1-TAK1-K63W (kind 
gift from M. Kracht, Rudolf-Buchheim-Institute for Pharmacology, Giessen, Germany) into
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NheI/NsiI sites of PGK-SIN using the following primers: RV 5'-ATGCATTCATGAAGTGCCTTGT- 
CAG-3; FW 5'-GCTAGCGCCACCATGTCGACA GCCTCCGCCGCC-3' (non-tagged, Kozak sequence 
for enhanced translation introduced), and FW 5'-GCTGGTTTAGTGAACCGTCAG-3'(EGFP-tagged).
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was performed by transient 
transfection of 293T cells. One day prior to transfection, 293T cells were seeded in a T75 flask 
at 1x105 cells/cm2 in DMEM supplemented with 10% FCS, 1 mM pyruvate, 40 ng/ml gentamicin 
and 0.01 mM water-soluble cholesterol (Sigma). Cells were co-transfected with 19 ng transfer 
vector, 14 ng gag/pol packaging plasmid (pMDL-g/p-RRE), 4.7 ng rev expression plasmid 
(RSV-REV) and 6.7 ng VSV-G expression plasmid (pHIT-G) by calcium phosphate precipitation. 
Transfections were performed in 6 ml DMEM without antibiotics and cholesterol and proceeded 
for 16 hours. Thereafter medium was replaced with fully supplemented DMEM and supernatant 
harvested after 24 and 48 hours. Cell debris was removed by centrifugation at 1500 rpm for 5 
minutes at 4 °C, followed by passage through a 0.45 nm pore polyvinylidene fluoride Durapore 
filter (Millipore, Bedford, MA, USA). For concentration by ultracentrifugation 28 ml supernatant 
was overlaid on 4 ml 20% sucrose solution and centrifuged at 25.000 rpm for four hours in a 
Surespin 630 rotor (Thermo Fisher Scientific, Waltham, MA). Pelleted viruses were resuspended 
in sterile PBS and stored at -80 °C. Viral titers were determined by assaying p24gag values with a 
commercial enzyme-linked immunosorbent assay (ELISA) kit (Abbott Diagnostics, Hoofddorp, 
the Netherlands) and expressed as ng p24gag/nl.
Luciferase measurements
For in vitro reporter studies, cells were seeded at 5 x 104 cells per well in a Krystal 2000 96-wells 
plate (Thermo Labsystems, Brussels, Belgium). The next day, cells were transduced with 
25 ng p24gag equivalents lentivirus in 50 nl medium supplemented with 8 ng/ml polybrene 
(Sigma) for 4 hours at 37 °C and subsequently serum starved (1% FCS) for two days. Cells were 
pre-incubated for one hour with indicated concentrations TAK1 inhibitor (11,12-dihydro-5Z- 
7-oxozeaenol, AnalytiCon Discovery, Potsdam, Germany) or dimethyl sulfoxide (DMSO) as 
vehicle control. Followed by stimulation with recombinant murine or human IL-1ß (1 ng/ml, 
R&D Systems Europe, Oxford, UK), TNFa (10 ng/ml, Abcam, Cambridge, UK), E. Coli LPS (1 ng/ml, 
Sigma), Pam3Cys (1 ng/ml, EMC Microcollections, Tübingen, Germany) for indicated hours and 
subsequently lysed in ice-cold lysis buffer (0.5% NP-40, 1 mM DTT, 1 mM EDTA, 5 mM MgCl2, 100 
mM KCl, 10 mM Tris-HCl pH 7.5, 1x protease inhibitor cocktail (Roche, Mannheim, Germany)). 
Luciferase activity was quantified using the Bright-Glo luciferase assay system (Promega, 
Madison, WI, USA) by adding an equal volume of Bright-Glo to the cell lysate. Luminescence 
was quantified in a luminometer (Lumistar, BMG, Offenburg, Germany), expressed as relative 
light units (RLU) and normalized to total protein content of the cell extracts.
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RNA isolation
Cells were seeded at 90% confluency in 24-wells plates and serum starved (1% FCS) for forty 
eight hours. Consecutively, cells were pre-incubated with TAK1 inhibitor or DMSO for one hour 
and stimulated as mentioned above. Thereafter, cells were washed in ice-cold PBS and total RNA 
was extracted using TRI reagent (Sigma). Isolated RNA samples were treated with RNase-free 
DNase I (Qiagen, Venlo, the Netherlands) for 15 minutes. Synthesis of cDNA was accomplished 
by reverse transcription PCR using an oligo(dT) primer and Moloney murine leukemia virus 
Reverse Transcriptase (Invitrogen).
Quantitative PCR
QPCR was performed using SYBR Green PCR Master mix and the ABI 7000 Prism Sequence 
Detection system (Applied Biosystems Inc., Foster City, CA) according to the manufacturer's 
instructions. Primers were designed over exon-exon junctions in Primer Express (Applied 
Biosystems Inc.) and used at 300 nM in the PCR reaction. PCR conditions were as follows: 2 
minutes at 50 °C and 10 minutes at 95 °C, followed by 40 cycles of 15 seconds at 95 °C and one 
minute at 60 °C. Gene expression (cycle threshold, Ct) values were normalized using glyceral- 
dehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene (ACt = Ctgene - CtGAPDH). 
Primers sequences are available on request.
Statistics
Data are represented as means+SEM and significant differences were calculated using a one-way 
analysis of variance (ANOVA) or Repeated Measures ANOVA followed by Bonferroni's Multiple 
Comparison test (GraphPad Prism 5.02, San Diego, CA, USA), where appropriate. P-values of less 
than 0.05 were regarded significant.
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Introduction
Over the past decades gene therapy has emerged as a promising approach for treatment of 
a variety of diseases including monogenic diseases, cancer, neurodegenerative disorders, 
autoimmune and inflammatory diseases. However, efficacy and safety remain the major 
challenges for turning gene therapy into a clinical reality. Several advances in vectorology have 
provided opportunities to address these issues including transductional and transcriptional 
targeting of viral vectors. The prior involves the modification of the virus tropism in order to 
increase the efficiency and specificity of target cell transduction. The latter comprises the use 
of cis-regulatory elements, such as promoters and enhancers (Figure 1), to restrict transgene 
expression to specific tissues or patho-physiological conditions. Here we focus on recent 
developments and applications of endogenously-regulated promoter systems in gene therapy 
for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).
Disadvantages of constitutively active promoters
The vast majority of pre-clinical gene therapy studies rely on high levels of therapeutic proteins 
using viral promoters derived from cytomegalovirus (CMV), Rous sarcoma virus (RSV) or cellular 
promoters such as the human phosphoglycerate kinase-1 (PGK), elongation factor 1a (EF1a) 
or chicken p-actin promoter. Despite their short-term effectiveness in animal models, the 
applicability of these promoters for long-term therapy is hampered by a number of issues. First, 
transgene expression in vivo is often transient due to promoter attenuation. A comprehensive 
study of Chen and co-workers demonstrated a dramatic drop in CMV-driven transgene 
expression in liver and spleen starting from 3 days after intravenous delivery of adenovirus [1]. 
Upon intramuscular injection, expression levels decreased between 100- and 1000-fold within 
three weeks using both CMV, p-actin and EF1a promoters. A similar study, describing a rapid 
loss of CMV-driven transgene expression from muscle tissue, demonstrated rapid and extensive 
methylation of CpG sites in the promoter abolishing its transcriptional activity [2] (Figure 1). In 
synovial tissue, which represents the target site of local gene therapy for RA, rapid silencing of 
the CMV promoter is frequently observed [3-7]. Second, strong constitutive promoters might 
transactivate endogenous (onco)genes upon integrating in the genome. Weber et al. established
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a cell-type specific correlation between transcriptional strength and transactivation potential 
of promoters, including PGK, EF1a and CMV [8]. A second study by Zychlinski and co-workers 
confirmed the transactivation potential of retroviral enhancer-promoters. Additionally, they 
demonstrated that the genotoxic risk of integrating vectors is considerably reduced using 
constitutive cellular promoters (PGK, EF1a) in combination with a self-inactivating vector 
design [9]. Third, systemic or local overexpression of biologicals regardless of the physiological 
demand can elicit serious transgene-induced side effects. Our group has demonstrated several 
undesired side effects in cytokine-based gene therapy approaches, arising from the pleiotropic 
nature of these proteins. Intra-articular gene therapy for experimental arthritis and osteoarthritis 
using respectively interleukin-4 (IL-4) [5,10] and transforming growth factor-p (TGFP) [11], led to 
a protection against cartilage destruction. However, constitutive TGFP expression also induced 
synovial fibrosis and osteophyte formation [12]. The chemotactic properties of IL-4 gave rise 
to a massive joint inflammation when this transgene was overexpressed in non-arthritic joints. 
Taken together, the development of long-term and safe gene therapeutic treatment requires 
a careful consideration of promoter selection. While strong ubiquitous promoters represent 
seemingly obvious candidates for gene therapy, tightly-regulated expression of transgene 
appears a key feature towards an effective and safe mode of gene therapy.
Transcriptional targeting
Transcriptional targeting strategies that are either based on cell-specificity or reactivity to 
physiological changes are explored extensively in cancer due to their unique expression 
of tumor specific (onco)genes and regional enriched expression of genes created by the 
hypoxic environment in tumors (reviewed by Robson and Hirst [13]). Although hypoxia and 
related processes such as neovascularisation also occur in the inflamed tissue, promoters of 
these genes or artificial promoters bearing consensus sequences of response elements for 
the hypoxia-inducible transcription factor (HIF-1a) have thus far not been explored in gene 
therapeutic approaches for chronic inflammatory of autoimmune diseases. Other strategies 
utilized in cancer gene therapy as radiation-, chemotherapy- and hyperthermia-inducible 
expression vectors make use of existing anti-cancer therapies [14] and are for this reason not 
used for transcriptional targeting of inflammation. Several chronic inflammatory diseases 
including RA, lupus and inflammatory bowel disease are characterized by a disease course 
which displays spontaneous periods of exacerbations and remission. Most ideally, expression of 
a therapeutic protein meets the variable demand during these diseases: high during a relapse 
and low during remission of the disease. For this, transcriptional targeting in these diseases is 
now based on the use inflammation-responsive rather than cell-specific promoters.
Acute phase gene promoters
The acute phase response (APR) is part of the innate immunity and comprises an early set of 
inflammatory reactions induced by infection or tissue injury [15]. The APR is accompanied 
by a rapid increase in acute phase protein (APP) levels in plasma including serum amyloid A
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Figure 8.1
(SAA), complement factor 3 (C3) and C-reactive protein (CRP). The augmentation in serum 
SAA and CRP levels are sensitive biological laboratory markers in RA patients that correlate 
with disease activity [15]. The dramatic increase in APP levels are due to a strongly induced 
transcriptional rate arising from cytokine-mediated synergistic activation of APP promoters. 
Varley and co-workers pioneered the inflammation-inducible expression of recombinant 
proteins in vivo from APP promoters. Using intravenous administered adenoviral reporters 
harboring the firefly luciferase cDNA under transcriptional control of murine Saa3 (-306/+33) 
or C3 (-397/+45) promoters they demonstrated a strong response upon systemic injection of 
lipopolysaccharide (LPS). Burke and co-workers applied the human CRP (-122/+672) promoter 
to generate transgenic-mice showing inflammation-inducible expression of granulocyte
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Figure 8.1
Typical TATA-dependent promoter, its cis-regulatory sequences and interactions 
between regulatory proteins and the transcription initiation complex
Schematic overview of a typical TATA-dependent promoter, its cis-regulatory 
sequences and interactions between regulatory proteins and the transcription 
initiation complex. The lower part displays the core promoter region which 
is the essential sequence for transcription initiation. In eukaryotes, the most 
common type core promoter is the TATA box that is the binding site for the 
transcription factor TATA binding protein (TBP). After TBP binds the TATA box, a 
number of TBP-associated factors (TAFII) and RNA polymerase (Pol II) combine 
around the TATA box to form the preinitiation complex (PIC). The TAFII, TFIIH 
has helicase activity and is involved in opening the double helical DNA strands.
The PIC only drives a low rate of transcription. The transcriptional rate is 
further enhanced or inhibited by regulatory factors along with any associated 
co-activators or co-repressors. The cis-regulatory elements that drive tissue- or 
context-specific expression are predominantly located in the proximal-promo- 
ter region, depicted in the left part of the diagram.
Regulatory factors consist of protein complexes, often hetero- or homodimers, 
that bind on their cognate binding sites (TFBS). Transcription factors (TF) 
can transactivate or repress the activity of the PIC and work cooperatively by 
stabilizing each other when forming DNA-protein complexes. Co-activators 
mediate the influence of regulatory factors through protein-protein 
interaction between a TF and the PIC. Additional fine-tuning of transcription 
is accomplished via more distal DNA elements as enhancers, displayed on the 
right part. These sequences exert their activating effects independently from 
position or orientation and are obtained by accomplishing a specific DNA 
formation. Extensive methylation of CG-rich regions in promoter sequences 
(CpG Islands), e.g. viral promoters, compromises the binding of regulatory 
factors and leads to inactivation of the promoter. The Kozak sequence (GCCRCC) 
is frequently placed directly upstream of the translation start codon (ATG) for 
enhanced translation of transgenes in gene therapy approaches.
macrophage colony-stimulating factor (GM-CSF) [16]. Upon systemic administration LPS, 
GM-CSF levels were increased approximately 150-fold within 6 hours and protein levels were 
100-500 fold higher compared to endogenous GM-CSF. Transgenic Saa1-Luc mice harboring 
a 7.7 kB promoter of murine Saa1 demonstrated strong induction of luciferase activity in 
multiple tissues after systemic LPS and tumor necrosis factor-a (TNF-a) treatment [17]. The 
strongest induction of luciferase activity, approximately 5000-fold, was observed in the liver 
whereas brain and spleen showed a less than two fold induction. During an acute arthritis 
induced by intra-articular injection of zymosan, luciferase levels were induced approximately 
twenty fold within four hours and declined to seven and six fold induction at one and five days 
after arthritis induction, respectively.
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Pro-inflammatory cytokine and enzyme gene promoters
Apart from APR genes, the promoter regions of genes that are differentially regulated in 
chronic inflammatory processes such as cytokines, chemokines and matrix degrading enzymes, 
represent attractive candidates for development of disease-specific gene therapeutic vectors. 
Experimental arthritis models showed that the pro-inflammatory cytokines TNFa, IL-1, IL-6, 
IL-18 belong to early-responsive genes, which are upregulated at the primary onset and 
secondary flare-ups of experimental arthritis [18]. Especially IL-6 is identified as a marker of 
disease activity and the principal cytokine responsible for the acute phase response in RA 
patients. Serum IL-6 levels correlated with serum CRP levels and erythrocyte sedimentation rate 
(ESR) [19,20]. Also the synovial fluid levels of IL-6 correlate with serum CRP and ESR in patients 
with RA [21]. The synovial fluid concentration of IL-6 are higher than in serum with the synovial 
fibroblasts as the source of IL-6 with the highest production in the presence of lymphocytic 
follicles in the synovial tissue [19,20,22]. IL-6 is strictly regulated at the transcriptional level and 
several transcription factors, including NF-kB, activator protein-1 (AP-1) and CCAAT/enhancer 
binding protein (C/EBP) contribute to the complex regulation of this gene. For NF-kB and AP-1 
factors a pivotal role has been implied in human RA, murine collagen-induced arthritis (CIA) 
and immunity [23-27]. Enhanced expression and DNA binding activity of C/EBPp in synovial 
tissue of RA patients has been implicated in the pathology [28] and chronicity [29] of disease. 
Therefore, the IL-6 promoter appeared a prominent candidate to achieve disease-regulated 
gene therapy. While the minimal promoter of human IL-6 (-163/+12) showed only little 
responsiveness, the upstream addition of the human IL-1fi enhancer (-3690/-2720) mounted 
a robust response towards pro-inflammatory stimuli in vitro and in vivo [7]. A comparison of 
in vivo performance between the hybrid (IL-1E/IL-6) and C3-Tat/HIV promoters revealed a 
comparable responsiveness and transcriptional strength. Geurts and co-workers exploited 
the properties of this hybrid promoter to enable the use of an otherwise disputable biological, 
IL-4 [5]. They demonstrated effective protection against cartilage erosion in CIA by injection 
of knee joints with adenoviral vector containing IL-1E/IL-6P-driven murine IL-4. Perhaps even 
more importantly, restriction of IL-4 expression to inflammatory conditions minimized the 
deleterious effects of this transgene under non-diseased conditions, effectuating a safer mode 
of IL-4 gene therapy for RA. Adriaansen, Khoury and co-workers constructed adeno-associated 
viral vectors encoding human soluble p55 TNF receptor coupled to the Fc part of murine IgG1 
under control of a minimal CMV promoter containing six upstream NF-kB binding motifs 
derived from the HIV-LTR promoter. Using a local intra-articular gene therapy approach, this 
construct delayed onset and decreased the incidence of CIA in mice [30]. The NF-KB-responsive 
promoter demonstrated a transient responsiveness to repetitive LPS injections at one and eight 
weeks post-transduction, respectively. In addition, the same vector was used to for local gene 
therapeutic treatment of adjuvant arthritis in rats [31]. Adriaansen and co-workers found a 
superior therapeutic effect for disease-regulated expression of transgenes and suggested his 
phenomenon to arise from a more favorable expression profile during the disease course.
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Nitric oxide (NO) is produced by many cell types and has been implicated in host defense and 
immunity, including modulation of inflammatory processes. The compound is synthesized 
via nitric oxide synthases (NOS) and the inducible isoform (iNOS) is predominantly expressed 
after exposure to pro-inflammatory stimuli. The induction of iNOS is not a disease-specific 
event and has been demonstrated in several autoimmune and inflammatory diseases such 
as sepsis, arthritides, systemic lupus erythematosus and type I diabetes [32]. Transgenic 
iNOS-luciferase mice showed a transient upregulation of luciferase activity in knee joints 
upon injection with zymosan. Luciferase expression peaked at four hours after the challenge, 
showing six fold upregulation, and returned to basal levels after 24 hours [33]. This group also 
created a transgenic luciferase-reporter mouse for imaging of angiogenesis using the murine 
vascular endothelial growth factor receptor 2 (Vegfr2) [34]. Since angiogenesis is a hallmark 
of a variety of inflammatory diseases, including RA, Vegf (receptor) promoters can serve as 
disease-regulated promoters for gene therapy. Considering the co-dependence of angiogenesis 
and chronic inflammation [35], for warranting a rapid response to acute inflammatory processes 
angiogenesis-specific promoters may not be most suitable. Prostaglandins (PGs), particularly 
PGE2 and prostacyclin (PGI2), are potent mediators of pain and inflammation. PGs are derived 
from arachidonic acid metabolism through constitutive and inducible cyclooxygenases: 
COX-1 and COX-2, respectively. An interesting development is the use of the COX-2 promoter 
for the replication control of conditionally replicating adenoviruses (CRAds)[36]. CRAds 
are based on placement of essential early adenoviral E1 genes under specific promoters to 
mediate oncolytic potency on tumor cells. The COX-2-dependent CRAds might be applied 
for genetic synovectomy in a regulated fashion by killing the synovial cells when becoming 
active during inflammation. Rachakonda and co-workers used the canine COX-2 (-1145/+93) 
promoter for cytokine-inducible expression of canine IL-4 in articular chondrocytes [37]. For 
the development of disease-specific gene therapy for canine osteoarthritis, Campbell and 
colleagues applied the matrix metalloproteinase-9 (MMP9) (-1984/-1) promoter [38]. In a human 
chondrosarcoma cell line this promoter responded strongly to TNFa but not IL-10. Interestingly, 
the transcriptional strength of the promoter was significantly enhanced by addition of three 
or five tandem-arranged NFkB binding sites. However, the basal promoter activity increased 
accordingly indicating leakiness of the hybrid promoter in vitro.
Bioinformatics-driven promoter design
Undoubtedly, the availability of endogenous or artificial promoters that confer a range of 
transcriptional activities in an inflammation-regulated fashion would contribute substantially 
to tailor-made gene therapy. While the aforementioned studies have provided compelling 
evidence for the value of disease-regulated gene therapy, the number of experimentally-verified 
promoters is fairly low. In addition, the actual choice of promoter identity and region has been 
mostly an educated guess. The latter issues can be addressed by exploiting recent advances in 
bioinformatics that aid in inferring transcription regulatory networks [39-42] and understanding 
promoter architecture [43,44]. Computational analyses of promoter regions from genes
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specifically expressed in human cartilage or nematode muscle successfully identified the 
relevant regulatory DNA elements [42,45]. Using gene expression profiling of target tissues 
for gene therapy, computational analyses can provide useful information for promoter 
design. Our laboratory has pursued this approach and performed a gene expression profiling 
study of synovial tissue from murine CIA to elucidate disease-regulated genes. The proximal 
(-500/+200) promoter regions of these genes were analyzed with motif scanning algorithms 
to identify relevant DNA regulatory elements. Transcription factor binding sites for NF-kB, 
AP-1 and C/EBPp were significantly enriched and evolutionary conserved in the promoters 
of arthritis-induced genes. The corresponding promoter regions that contained these motifs 
conferred inflammation-inducible expression in vitro and in vivo (unpublished observations). 
The strength of these approaches have additionally been demonstrated by the Pleiades 
promoter project, which is aimed at designing well-defined human promoters for brain region 
or cell type-specific gene therapy [46-48]. These studies focused on profiling region-enriched 
gene expression within seventeen key areas of the adult mouse brain and used bioinformatics 
tools to elucidate the transcription factor combinations governing expression profiles. Li and 
co-workers managed to elucidate a regulatory network comprising fifteen transcription factors 
and 153 target genes within the mouse brain, whose promoters or DNA regulatory elements 
will be tested for promoter design in brain-specific gene therapy [49].
Transcriptional amplification strategy
In the above computational approach promoter selection is based on their expression profile 
and promoter strength as determined by the level of their inducibility to obtain an efficacious 
gene therapy strategy. However, to obtain a side effect-free physiological response the basal 
expression of candidate promoters must be low and show no leakiness. To reach all these 
prerequisites a transcriptional amplification strategy might be necessary to integrate in the 
inflammation-responsive system. In order to couple inflammation-inducibility with sufficiently 
high expression levels required to achieve biological effects, Varley and Munford developed 
a 2-component expression system in which the C3 promoter regulates the production of the 
human immunodeficiency virus-1 (HIV) transactivator of transcription (Tat) protein, which in 
turn regulates the HIV-1 long terminal repeat (LTR) promoter to express the gene of interest 
[50]. This system was highly responsive towards various inflammatory stimuli as TNFa, 
IL-1 p, IL-6, and LPS/turpentine-induced peritonitis. The HIV-LTR is also directly responsive 
to nuclear factor-kappaB (NF-kB) activating cytokines (IL-1/TNF) and other factors such as 
LPS. More importantly it was demonstrated that this 2-component construct responded 
to an inflammatory reaction in a similar fashion in different organs as liver, spleen, kidney, 
lung and heart. We found that this system was also highly responsive in the joint towards 
a zymosan-induced joint inflammation in an IL-6-dependent fashion [51]. Miagkov and 
coworkers and our laboratory independently demonstrated the feasibility of this 2-component 
system for auto-regulated expression of therapeutics in experimental arthritis models [51,52]. 
Intra-articular injection of adenoviruses containing the C3-Tat/HIV-hIL-10 construct in arthritic
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paws of rats completely prevented reactivation of arthritis by an intravenous challenge with 
group A streptococcal peptidoglycan-polysaccharide (PG-APS) [52]. We used this system for 
adenoviral overexpression of human interleukin-1 receptor antagonist (IL-1Ra) in knee joints of 
murine collagen-induced arthritis (CIA) and compared this with the effect of IL-1Ra expression 
under direct control of the conventional CMV promoter. In a prophylactic regimen we could 
demonstrate superior effectiveness of this 2-component IL-1Ra expression system in CIA. While 
the in vivo studies using the Tat/HIV based-approach provided proof of principle of the efficacy 
of local disease-regulated gene therapy for arthritis, side effects of Tat expression in host cells 
including dysregulation of cytokine expression [53,54] and promotion of chemotaxis [55] limit 
its applicability for a safe and long-term gene therapeutic treatment.
There are several new drug-inducible expression systems developed based on tetracycline, 
rapamycin and ecdysone that allows reversible and adjustable expression by an exogenous 
stimulus (extensively reviewed in [56]). These regulatable systems can be combined with 
cell-specific or physiologically responsive promoters for regulation of their respective 
transactivating proteins. Despite their robustness and specificity, long-term application of these 
systems might be hampered due to an immune-response against the artificial transactivators as 
has been described for tetracycline-regulated systems in larger animals [57,58]. Regulating the 
transactivator expression using inducible promoters with low basal activities may delay or even 
prevent this immune-response and prolong the in vivo life time of these systems. Furthermore, 
these drug-controlled systems provide an additional safety switch to shut-down the system in 
case of malfunction or deleterious effects.
Conditional RNA interference-based gene therapy
Until now we reviewed the transcriptional targeting strategy for tunable expression of proteins 
but we envisage the application of inflammation-controlled promoters for development of a 
gene therapeutic treatment relying on conditional RNA interference-mediated gene silencing. 
Gene knockdown in experimental models of arthritis has been shown to be therapeutically 
efficacious [59,60] but a systemic mode of treatment gives rise to the risk of impairing the 
normal physiological responses required to combat pathogens and injuries. Therefore, 
conditional knockdown of endogenous genes using inflammation-responsive promoters 
would be advantageous. However, viral systems for temporal and conditional knockdown are 
almost exclusively based on drug-controllable (tetracycline) expression of RNA polymerase (Pol) 
III promoter-driven short hairpin (sh) RNAs [61]. Due to tight restrictions for transcriptional start 
sites and the termination signal only a relative small number of RNA Pol II promoters are able to 
produce effective silencing (si) RNAs using the shRNA system. In contrast, microRNA-adapted 
shRNA systems, in which mature miRNA sequences are replaced with gene-specific 
duplexes, have no such limitations and therefore can accommodate Pol II-dependent cell- or 
conditions-specific promoters. Stegmeier and co-workers developed a sophisticated lentiviral 
platform for simultaneous production of a miR30-adapted shRNA and transgene [62], which 
could be adapted for developing a dual-approach gene therapy. However, attempts for
-------------------------------------------------------------------------------  Disease-regulated local gene therapy for rheumatoid arthritis —
131
—  Disease-regulated local gene therapy for rheumatoid arthritis
conditional expression of miRNAs using other than exogenously-controlled systems have been 
rarely undertaken. Yang and Paschen used the human heat shock protein 70 (HSP70) promoter 
for heat shock-induced silencing of genes [63]. Since the expression of HSP70 is up regulated 
in almost all inflammatory diseases [64], this represents a strong candidate promoter for 
inflammation-induced gene silencing. Alternatively, Yoshizaki and co-workers used the human 
E-selectin (-160/+1) promoter for conditional knock down of the SELE gene [65]. The promoter 
showed a two-fold increase in activity upon stimulation with TNFa, which proved sufficient for 
effectively reducing E-selectin expression.
Future perspectives
The efficacy of gene therapy for RA has been demonstrated extensively in animal models 
of disease using a variety of vectors and transgenes. These promising pre-clinical results 
have until now led up to the initiation of five human phase I clinical trials in RA [66]. Without 
exception, these trials relied on strong constitutive viral promoters e.g. the Moloney 
murine leukemia LTR [67,68] and CMV promoter [69] . This indicates that the selection 
of an appropriate promoter remains an underestimated aspect in the development of 
gene therapeutic treatment for arthritis. In contrast, transcriptional targeting has been 
recognized as an essential prerequisite towards safe human gene therapy in other 
diseases, predominantly cancer. Gene therapy for inflammatory diseases is, however, 
not based on gene correction as in monogenic diseases but on restoring the balance 
by up-regulating therapeutic - or down regulating disease-process implicated genes. In 
general, the latter genes often have important regulatory roles in normal physiology and 
immunity that needs to be maintained. For instance, current systemic anti-TNF-treatment 
in RA has been shown to cause side effects such as opportunistic infections, particularly 
tuberculosis, in a number of patients [70,71]. For this, local and transcriptionally targeted 
gene therapy may circumvent the current problems seen with systemic delivery of protein 
biologicals. We have reviewed that hijacking the local inflammatory gene regulation is a 
feasible approach for transcriptional targeting, which has demonstrated efficacy in animal 
models. These studies are summarized in Table 1. Together with transductional targeting 
via vector modification or detargeting transgene expression from non-target tissues using 
miRNA-regulatory elements [72,73], inflammation-responsive promoters will develop into 
a safer and efficient mode of gene therapy that is essential for treatment of non-lethal 
diseases.
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Table 1. Inflammation-responsive promoters used in gene therapy approaches
Promoter Vector Inflammation model Species Ref.
Saa3 Adenovirus LPS i.p. & turpentine s.c. Mouse [74]
C3 Adenovirus LPS i.p. & turpentine s.c. Mouse [50-52,74]
CRP Transgenic LPS i.p. Mouse [16]
Saal Transgenic LPS/TNFa i.p. & zymosan i.a. Mouse [17]
IL-IE/IL-6P Adenovirus SCW/zymosan i.a. & CIA Mouse [5,7]
6xNFkB/mCMV Adeno-associated virus Adjuvant arthritis Rat [31]
Adeno-associated virus CIA Mice [30]
iNOS Transgenic LPS/IFN" i.p. & zymosan i.a. Mice [33]
Vegfr2 Transgenic Oxazolone topical Mice [34]
cCox2 Plasmid In vitro, TNFa/IL-1# Dog [37]
cMMP9 Plasmid In vitro, TNFa/IL-1# Human [38]
HSP70 Plasmid In vitro, heat shock Mouse/Rat [63]
SELE Plasmid In vitro, TNFa Human [65]
LPS, lipopolysaccharide; SCW, streptococcal cell wall; CIA, collagen-induced arthritis; 
i.a., intra-articular; i.p., intraperitoneal; s.c., subcutaneous
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Summary
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints and mainly 
targets the joint capsule, articular cartilage and bone. Key features of the disease include 
autoimmunity, chronic inflammation and connective tissue destruction. Despite improved 
understanding of its pathology in the last decades, the etiology remains to be elucidated. 
Correspondingly, treatment strategies for RA aim at alleviating disease symptoms and halting 
its progression. The identification of pro-inflammatory cytokines interleukin-1 (IL-1) and tumor 
necrosis factor-a (TNFa) as crucial mediators of cartilage destruction and inflammation, has 
led to novel treatment strategies in the clinic based on neutralizing these cytokines using 
antibodies or soluble receptors. Despite therapeutic efficacy of these so-called biologicals, the 
required continuous and systemic mode of treatment has led to several issues, including serious 
side effects, limited clinical remission and high costs. To tackle these issues, local and sustained 
delivery of biologicals to arthritic joints appears an ideal treatment alternative. Gene therapy 
has emerged as a promising approach for achieving these goals. An additional advantage of 
gene therapeutic treatment of RA includes the opportunity to achieve fine-tuned regulation 
of therapeutic transgene expression using a transcriptional targeting strategy. Ideally, such 
a strategy results in gene therapeutic vector that serves as a "doctor within" by providing 
transgene expression in an offer-meets-demand fashion with respect to disease activity in the 
arthritic joint. The aim of the research presented here was to rigorously design a transcriptional 
targeting strategy for RA and to evaluate its application for gene therapeutic treatment and 
diagnostics. Additionally, we have sought to validate novel gene therapy approaches based on 
targeting of intracellular signal transduction pathways.
To this end, we first reviewed the current status of different viral vectors for in and ex vivo 
transduction of resident cells of the arthritic joint in Chapter 2. These studies revealed that 
synovial fibroblasts are considered as primary target cells for local RA gene therapy and they 
can be efficiently transduced using adenoviral (Ad) and lentiviral (LV) vectors. We corroborated 
these findings by investigating the transduction efficiency of murine synovium in vivo by LV and 
Ad vectors in Chapters 4 and 6, respectively. Immunohistochemistry analyses of joints injected 
intra-articularly with green fluorescent protein (GFP) expressing Ad or LV viruses, demonstrated 
predominant transduction of the lining layer of the synovium. Using cholesterol-optimized LV 
we managed to enhance transduction efficiency of synovium four-fold (Chapter 4). Moreover, 
we demonstrated that LV vectors can transduce human synovial fibroblasts ex vivo up to nearly
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hundred percent. This feature was exploited in Chapter 7, which analyzed pro-inflammatory 
signal transduction in synovial fibroblasts from RA patients using LV-based transcriptional 
reporters.
In Chapter 3 we focused on the development of a transcriptional targeting strategy for RA. We 
hypothesized that suitable promoters for this strategy could be deduced from gene expression 
analyses of inflamed synovial tissue. Using gene expression profiles from synovial tissues from 
joints with progressing stages of collagen-induced arthritis (CIA), we detected 201 genes whose 
expression was at least ten-fold upregulated from the onset of disease. Bioinformatic analyses 
of corresponding promoter regions indicated that transcription factor (TF) binding sites of 
nuclear factor-KB (NF-kB), activator protein-1 (AP-1) and CAAT/enhancer-binding protein p (C/ 
EBPP) were significantly over-represented. Using an in-house developed filtering algorithm, 
based on TATA-box position and presence of over-represented TFs, we reduced the number 
of candidate human and murine promoters from 382 to 66. Ten promoters were incorporated 
into LV luciferase reporter vectors and nine showed inducible expression by lipopolysaccharide 
(LPS) in murine macrophages and fibroblasts. The serum amyloid A3 (Saa3) promoter, which 
showed strong inducibility and transcriptional strength, was applied for disease-regulated 
expression of IL-1 receptor antagonist (IL1Ra) and demonstrated capable of neutralizing effects 
of IL-1 in vitro. These results highlighted the value of a bioinformatics approach for designing a 
transcriptional targeting strategy and suggested the Saa3-promoter as candidate promoter for 
IL1Ra gene therapy.
The diagnostic value of Saa3- and Cxcl7-promoters identified in Chapter 3 was the research 
topic of Chapter 4. First, LV luciferase reporters were used to evaluate promoter activities 
during two flares of joint inflammation induced by streptococcal cell wall (SCW) fragments. 
We found that specifically Saa3-promoter activity correlated with histological and technetium 
uptake measurements of joint inflammation. A comparison of the conventional technetium 
uptake with assessment of Saa3-promoter activity revealed an increased sensitivity of the 
latter for detecting joint inflammation. These findings led to the hypothesis that this method 
also might discriminate between high and low inflammatory synovial tissues from arthritis 
patients. Indeed, the relative Saa3-promoter responses to IL-1, TNFa and LPS were significantly 
increased in synovial fibroblasts with a high inflammatory expression profile. Taken together 
the transcriptional Saa3-promoter reporter demonstrated to be a robust, sensitive and feasible 
method for distinguishing molecularly distinct inflammatory subtypes both in experimental 
arthritis and synovial fibroblasts from a heterogeneous patient population.
Having designed and evaluated transcriptional targeting strategies in the aforementioned 
chapter, we demonstrated the important proof of principle for enhanced safety of gene therapy 
using transcriptional targeting in Chapter 5. For this, we compared the effects of constitutively 
versus disease-regulated intra-articular expression of IL-4 under healthy and arthritic conditions.
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Disease-regulated expression was achieved using a hybrid promoter consisting of the IL-1 
enhancer fused to the IL-6 promoter (IL-1E/IL-6P). Regulated expression of IL-4 demonstrated 
successful protection against cartilage erosion in CIA. More importantly, restriction of IL-4 
expression in healthy joints significantly decreased inflammation, which occurs as a side effect 
of sustained IL-4 expression. These results definitely showed that transcriptional targeting is 
safer mode of gene therapy by retaining therapeutic potential of transgenes under arthritic 
conditions while effectively minimizing transgene-induced side effects during disease 
remission.
In Chapters 6 and 7, we sought to validate novel gene therapy approaches based on 
targeting of signal transduction pathways in synovial fibroblasts. The central role of TNFa in 
RA pathogenesis, led to the development of an Ad vector that mediated knockdown of TNF 
receptor-1 (TNFR1) via RNA interference (Chapter 6). When applied for local gene therapy, this 
vector markedly reduced IL-1 and IL-6 mRNA and protein expression in SCW-induced arthritis. 
Local treatment of CIA led to a significant amelioration of disease as characterized by reduction 
of joint inflammation and cartilage proteoglycan depletion. Notably, systemic gene therapy, 
which targeted TNFR1 in the reticulo-endothelial system of liver and spleen, also effectively 
ameliorated CIA. The underlying mechanism for this appeared to be a reduction of activated 
T cells in spleen and a dampening of the acute phase response in liver. Since besides TNF 
signaling numerous signal transduction pathways contribute to RA pathology, we evaluated 
transforming growth factor-p-activated kinase 1 (TAK1) as a target for simultaneously inhibiting 
multiple signaling pathways (Chapter 7). TAK1 catalytic activity could be efficiently inhibited 
using LV-mediated overexpression of a TAK1 kinase-inactive mutant. Using LV transcriptional 
NF-kB and Saa3-promoter reporters we confirmed the central position of TAK1 in mediating 
IL-1, TNF and toll-like receptor 2/4 (TLR) signaling in murine fibroblasts and human dermal 
fibroblasts. However, we uncovered a more limited role for TAK1 in synovial fibroblasts since, 
contrastingly, TLR4 signaling and IL-1/TNF-induced Saa3-promoter activation were independent 
of this kinase. Nonetheless, cytokine-induced NF-kB activation could be dampened by TAK1 
inhibition. The combined data from Chapters 6 and 7 suggests that targeting of intra-cellular 
signal transduction holds promise for novel gene therapeutic treatment strategies for RA.
In Chapter 8 we finally returned to transcriptional targeting strategies and reviewed its recent 
developments and future perspectives.
Future perspectives
The initial optimism surrounding the emergence of gene therapy as a cure for disease has 
been severely tempered by cases of vector-induced fatalities in clinical trials [1-3]. These 
serious adverse events have shifted the emphasis of vector design from efficacy to safety. 
Transcriptional targeting has been introduced as suitable strategy to increase both efficacy 
and safety of gene therapy approach by strictly controlling spatial and temporal expression of 
transgenes. The most common strategies include the use of endogenously (Chapters 3-5) or
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Figure 9.1
Future expression cassette for RA gene therapy
exogenously-controlled promoter systems [4]. Noteworthy, Brown and colleagues developed 
an intriguing novel approach that exploited endogenous microRNAs (miRNAs) for regulation 
of transgene expression [5]. Introduction of miRNA target sequences at 3' untranslated regions 
of transgene cDNAs resulted in strong suppression of its expression in cells expressing the 
corresponding miRNA. Adaptation of the miRNA-controlled system for RA gene therapy would 
require the identification of a miRNA whose expression inversely correlates with disease 
activity. Interestingly, comparison of miRNA profiles in synovial fibroblasts have revealed that 
miR-124a is significantly underexpressed in RA, which stimulates proliferation and chemokine 
secretion [6]. Based on these findings, miR-124a might be applicable for transgene regulation, 
provided that its expression level increases during RA remission. In terms of safety, regulation 
of transgene expression by a combination of endogenous inflammation-regulated promoters 
and miRNA-based suppression in remission appears an ideal combination. Another major 
advantage of using physiologically-regulated promoters is that their application leads to a 
strongly reduced risk of insertional mutagenesis [7]. Additionally, unpublised results from our 
laboratory suggested that the longevity of transgene expression might be elongated through 
transcriptional targeting. Whereas local adenoviral gene therapy using a constitutive promoter 
normally results in rapid loss of transgene expression within three weeks (Chapter 5), we 
were able to induce strong expression from such a vector at three months after transduction 
(unpublished observations).
Chapters 6 and 7 convincingly demonstrated that intracellular targeting of signal transduction 
pathways could be a valid strategy for gene therapy. Notably, selective knockdown of genes 
using short hairpin RNA interference (shRNA) appeared a powerful method for targeting signal 
transduction (Chapter 6). Ideally, shRNA-based gene therapy strategies would also incorporate
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transcriptional targeting to ensure safety. However, due to tight restrictions for transcriptional start 
sites and the termination signal only a relatively small number of endogenous cellular RNA polymerase 
II-dependent promoters are able to effectively produce shRNA. Recently, Stegmeier and colleagues 
managed to address this issue by an miRNA-adapted shRNA design [8]. This design mimics a natural 
miRNA-30 primary transcript, which is naturally driven by a polymerase II-dependent promoter [9]. 
Yang and Paschen used this design in combination with a Hsp70 promoter for heat shock-induced 
silencing of genes [10]. Importantly, these studies suggest that transient induction of miRNA-adapted 
shRNA is sufficient for temporal knockdown of genes. The development of inflammation-inducible 
RNAi gene therapy might therefore be feasible and has been pursued as a pilot experiment in our lab 
(unpublished results).
In Chapter 3 we demonstrated that a computational approach on expression profiling data is a 
powerful strategy for developing transcriptional targeting for gene therapy. In principle, this approach 
can be applied to any expression profiling study as evidenced by D'Souza and coworkers, who followed 
an analog method to design brain region-specific gene therapy [11]. With respect to human gene 
therapy, computational analysis on expression profiles of synovial tissues could pave the way towards 
a personalized therapy. Supporting evidence for this hypothesis has been demonstrated in Chapter 
4, in which we described that a Saa3-promoter shows a more potent response, and thus therapeutic 
transgene production, in synovial tissue from RA patients a high inflammatory profile. Therefore, in 
depth analyses of synovial tissue expression profiles of RA patients with different disease subtypes are 
warranted.
The differential transcriptional properties of the promoters identified in Chapter 3 equip us with 
convenient tools for tailor-made gene therapy approaches. In addition, we demonstrated that 
transcriptional reporters could be of value for diagnostic imaging in arthritis (Chapter 4). Apart from 
feasibility, promoter-reporters could have several prominent advantages over present methods such 
as magnetic resonance imaging, ultrasound biomicroscopy and scintigraphy. First, several reporter 
genes are available that allow both ex vivo (Chapter 4) and non-invasive and real-time in vivo imaging 
[12]. Second, using standard molecular cloning techniques it would be possible to generate a diverse 
range of promoter-luciferase reporters for monitoring specific cell types, transcription factors or disease 
processes. Recently we have made promising advances towards real-time bioluminescence imaging 
of SCW-arthritis using promoter-reporters constructed in Chapter 3 (unpublished results).
A future gene expression cassette for RA gene therapy, based on the perspectives sketched above, is 
illustrated in Figure 1.
Finally, recent glimpses of therapeutic efficacy of gene therapy in clinical trials have indicated that gene 
therapy still holds a great promise [13-17]. The search for the optimal vector for RA gene therapy is still 
ongoing [18]. This thesis shows that transcriptional targeting represents a valuable strategy towards a 
successful clinical application of gene therapy for RA.
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Reumatoïde artritis (RA) is een chronische ontstekingsziekte die voornamelijk de gewrichten 
aantast. RA wordt getypeerd door aanhoudende ontsteking van het synoviale membraan 
(synovitis), het weefsel dat de gewrichtsruimte van het gewrichtskapsel en ligamenten afsluit. 
Continue synovitis leidt tot onomkeerbare destructie van het bot en kraakbeen en uiteindelijk 
ernstige invaliditeit. Omdat deze ontstekingen voortkomen uit een immuunrespons tegen 
lichaamseigen factoren uit het gewricht, wordt RA tot de autoimmuunziekten gerekend. In de 
laatste decennia is onze kennis wat betreft de onderliggende mechanismen sterk toegenomen, 
echter de oorzaak blijft tot op de dag van vandaag onbekend.
Hierdoor richt de behandeling van RA zich niet op het bestrijden van de bron, maar op bestrijding 
van symptomen en remming van ziekteprogressie. De ontdekking dat de pro-inflammatoire 
cytokines interleukine-1 (IL-1) en tumor necrose factor (TNF) een cruciale rol spelen bij de inductie 
van kraakbeendestructie en gewrichtsonsteking, hebben geleid tot de ontwikkeling van een 
nieuwe generatie medicijnen welke gebaseerd zijn op het wegvangen van deze cytokines met 
behulp van antilichamen of vrije receptoren. Ondanks de therapeutische effectiviteit van deze 
zogenaamde biologicals heeft de vereiste continue en systemische behandelmethode enkele 
kritische beperkingen. Ten eerste wordt klinische remissie, ofwel meer dan zeventig procent 
afname van ziektesymptomen, slechts bereikt in twintig procent van de patiënten. Ten tweede 
spelen cytokines een belangrijke rol in dagelijkse afweer tegen bacteriën, waardoor patiënten 
een verhoogde kans op opportunistische infecties hebben. Ten derde zijn de jaarlijkse kosten 
voor biologicals hoog, tussen de tien en twintigduizend euro per patiënt, mede omdat deze 
continue toegediend moeten worden.
Om deze punten aan te pakken, lijkt een langdurige, lokale en afgestemde productie van 
biologicals in aangedane gewrichten een goed alternatief. Gentherapie heeft zich inmiddels 
ontwikkeld tot een veelbelovende methode om dit doel te bereiken. Een bijkomend voordeel 
van gentherapie is de mogelijkheid om de productie van het biological strikt te reguleren. In 
het ideale geval namelijk functioneert de gentherapie vector als een "dokter van binnenuit" en 
wordt de biological geproduceerd naar gelang de behoefte van het ontstoken gewricht. In dit 
proefschrift beschrijven we de ontwikkeling van een methode om tot ontstekingsafhankelijke 
productie van een biological te komen. De toepassing van deze methode in gentherapie en 
diagnostiek hebben we uitgebreid getest in RA diermodellen en patiëntenmateriaal. Tenslotte 
hebben we de toepasbaarheid onderzocht van nieuwe biologicals, welke gebaseerd zijn op het 
van binnenin blokkeren van pro-inflammatoire cytokine-geïnduceerde signaaltransductie in 
cellen van het synoviale membraan.
Allereerst hebben we een literatuuronderzoek uitgevoerd om inzicht te krijgen in de huidige 
mogelijkheden wat betreft het gebruik van verschillende virus vectoren voor het doelgericht 
inbrengen van genetisch materiaal in cellen van het ontstoken gewricht. Hieruit bleek dat 
fibroblasten uit het synoviale membraan gezien worden als primaire doelwitcel en deze
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efficiënt genetische gemodificeerd kunnen worden door adenovirale en lentivirale vectoren. 
Deze bevindingen hebben we bevestigd in onze onderzoeken naar de toepasbaarheid van 
adenovirale (Hoofdstuk 4) en lentivirale (Hoofdstuk 6) vectoren voor genetische modificatie 
van het synoviale membraan in muizen. Hiertoe hebben we gebruik gemaakt van virussen die 
in plaats van een biological een groen fluorescent eiwit (GFP) produceren. Na injectie van deze 
virussen in het gewricht vonden we vrijwel uitsluitend GFP productie in de synoviale cellen 
aan de binnenkant van de gewrichtsholte. Daarnaast hebben we aan weten te tonen dat 
lentivirussen zeer efficiënt zijn in het inbrengen van genetisch materiaal in in vitro gekweekte 
human synoviale fibroblasten. Deze eigenschap hebben we benut in hoofdstuk 7 waarin we de 
effecten van een nieuwe biological op signaaltransductie door cytokines bestudeerd hebben 
met behulp van lentivirale reporters .
Hoofdstukken 3-5 beschrijven, in chronologische volgorde, de ontwikkeling, diagnostische 
en therapeutische waarde van een gentherapie vector als "dokter van binnenuit" voor RA. 
Om te komen tot ontstekingsafhankelijke productie van een biological hebben we gebruik 
gemaakt van een zogenaamde induceerbare promoter, een DNA element welke genexpressie 
in respons op omgevingsfactoren reguleert. Geschikte promoters hebben we afgeleid uit 
een bioinformatische analyse van het genexpressieprofiel van ontstoken synovium van 
muizen met collageen-geïnduceerde artritis. Uit deze analyse bleek dat de promoters van 
ontstekingsafhankelijke genen een specifieke verrijking kennen van bepaalde transcriptie 
factor bindingsplaatsen. Transcriptie factoren (de)activeren genexpressie door binding aan de 
promoter. Bindingsplaatsen voor de activerende factoren nuclear factor-KB (NF-kB), activator 
protein-1 (AP-1) en CAAT/enhancer-binding protein p (C/EBPP) waren verrijkt in promoters 
van ontstekingsafhankelijke genen. Mede op basis van aanwezigheid van bindingsplaatsen 
voor deze factoren konden wij het aantal kandidaatpromoters terugbrengen van 382 naar 66. 
Negen van tien uiteindelijk geteste promoters gaven een respons op een ontstekingsprikkel 
in gekweekte cellen, waarbij de promoter van het serum amyloid A3 gen (Saa3) het meest 
waardevolle profiel toonde: lage basale activiteit, welke tot wel twintigmaal toenam tijdens 
ontsteking. Hieruit blijkt dat bioinformatica analyses van toegevoegde waarde zijn voor het 
selecteren van promoters voor gereguleerde gentherapie.
Het diagnosticeren van gewrichtsontsteking is een essentieel onderdeel voor een afgestemde 
behandeling van RA. Daarnaast bestaat in preklinisch dierexperimenteel onderzoek naar 
nieuwe medicaties de vraag naar een accurate en minimaal-invasieve uitlees van synovitis. De 
hypothese in hoofdstuk 4 luidde dat een ontstekingsafhankelijke promoter met een lichtgevend 
reporter eiwit in plaats van een biological mogelijk toepasbaar zou zijn in bovengenoemde 
toepassingen. Metingen van Saa3-promoter activiteit in het synoviale membraan van muizen 
tijdens twee opeenvolgende episodes van gewrichtsontsteking bleken specifiek en uitstekend 
te correleren met de mate van ontsteking gemeten aan de hand van histologie en technetium
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opname methode. In vergelijking met technetium opname bleek de meting van Saa3-promoter 
activiteit zelfs gevoeliger met betrekking tot de detectie van ontsteking. In de humane situatie, 
bleek daarnaast de mate van cytokine-geïnduceerde Saa3-promoter activatie in gekweekte 
synoviale fibroblasten overeen te komen met het ontstekings-genexpressieprofiel. Tezamen 
suggereren deze data dat een Soo3-promoter reporter ontwikkeld zou kunnen worden tot een 
eenvoudige en gevoelige methode voor het diagnosticeren van synovitis.
Tenslotte hebben we de toepasbaarheid van ontstekingsafhankelijke promoters voor 
gentherapeutische behandeling van RA getest. In hoofdstuk 3 toonden we aan dat de 
specifieke eigenschappen van de Soo3-promoter, met name snelle en sterke toename 
onder ontstekingscondities, ruim voldoende waren om in vitro de effecten van het cytokine 
IL-1 te neutraliseren met een receptor antagonist. In hoofdstuk 5 bestudeerden we de 
effectiviteit en veiligheid van ziektegereguleerde gentherapie in een diermodel van RA. Als 
biological gebruikten we interleukine-4 (IL-4), een kraakbeenbeschermend cytokine dat 
bij langdurige expressie in het gewricht schadelijke bijwerkingen heeft. Zowel continue als 
ontstekingsafhankelijke productie van IL-4 tijdens artritis leidde tot succesvolle bescherming 
tegen kraakbeendestructie. Maar van groter belang was de bevinding dat in niet-ontstoken 
gewrichten de schadelijke bijwerkingen van IL-4 zeer sterk verminderd waren ten opzichte 
van continue expressie. Deze resultaten bewijzen namelijk onomstotelijk dat toepassing van 
ontstekingsafhankelijke promoters leidt tot een veiligere manier van gentherapie.
Hoofdstukken 6 en 7 beschrijven het onderzoek naar de toepasbaarheid van nieuwe 
biologicals, welke gebaseerd zijn op het van binnenin blokkeren van cytokine-geïnduceerde 
pro-inflammatoire signaaltransductie in cellen van het synoviale membraan. De eerste 
strategie is gebaseerd op vermindering van TNF receptor-1 (TNFR1) productie door specifieke 
afbraak van TNFR1 mRNA met behulp van RNA interferentie. Het verminderen van TNFR1 
expressie in synoviale cellen leidde uiteindelijk tot een reductie van gewrichtsontsteking 
en kraakbeenschade in muizen met artritis. Noemenswaardig was het feit dat vermindering 
van TNFR1 productie in cellen van de milt en lever ook leidde tot een verbetering van artritis 
via een demping van immuunresponsen. Omdat naast TNF meerdere cytokines, waaronder 
IL-1, bijdragen aan de pathologie van RA hebben we blokkering van transforming growth 
factor-p-activated kinase 1 (TAK1) onderzocht als mogelijk doelwit. Dit eiwit speelt een 
centrale rol in pro-inflammatoire signaaltransductie door meerdere cytokines en toll-like 
receptor liganden in verschillende celtypen. In hoofdstuk 7 hebben we onderzocht welke 
betrokkenheid TAK1 heeft bij pro-inflammatoire signaaltransductie in synoviale fibroblasten. In 
muis embryonale fibroblasten en humane huidfibroblasten bleek TAK1 een cruciale mediator 
van IL-1, TNF en TLR2/4 signaaltransductie. In synoviale fibroblasten daarentegen bleek 
de betrokkenheid van TAK1 meer gelimiteerd, met als meest opmerkelijke bevinding een 
complete TAK1-onafhankelijkheid van signaaltransductie door TLR4. Desondanks kon door het 
blokkeren van TAK1 de activatie van transcriptie factor NF-kB door IL-1 en TNF geremd worden. 
Deze gegevens suggereren dat het van binnenin blokkeren van cytokine-geïnduceerde
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pro-inflammatoire signaaltransductie in cellen van het synoviale membraan een haalbare 
strategie zou kunnen zijn voor gentherapeutische behandeling van RA.
We eindigen met een overzicht van recente ontwikkelingen en toekomstperspectieven met 
betrekking tot het gebruik van reguleerbare promoters voor gentherapie in hoofdstuk 8.
Tot slot lijkt gentherapie haar grote belofte langzaam in te gaan lossen, gebaseerd op succesvolle 
behandeling van enkele humane ziekten in klinische trials. Hoewel de zoektocht naar de ideale 
virale vector voor RA gentherapie nog gaande is, hebben we in dit proefschrift aangetoond dat 
gereguleerde productie met behulp van ontstekingsafhankelijke promoters een waardevolle 
toevoeging kan zijn om te komen tot een veilige en effectieve gentherapeutische behandeling 
van rheumatoïde artritis.
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„It only ends once. Everthing that happens before that, is justprogress."
De wijze uitspraak van Jacob uit Lost verwoordt perfect hoe ik nu terug kan kijken op mijn 
promotieonderzoek: Het eindigt met dit proefschrift, de weg er naartoe was er één van 
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concentreren op risicovol onderzoek, maar ook oog te hebben voor de eenvoudige 
vragen. Ik waardeer de vrijheid die ik gekregen heb - en rijkelijk genomen heb - om 
eigen onderzoekslijnen op te zetten, waarbij je op subtiele wijze zorgde dat deze toch één 
geheel zouden vormen. Gelukkig delen we ook de eigenschap om wetenschap en 
humor te kunnen combineren, zodat we ook een goede "samenwerking" hadden 
tijdens borrels en verre congresvluchten. Zoals wij Brabanders zo mooi kunnen 
zeggen: Da ge bedanktzijt, da witte!
Beste John, vier jaar geleden mocht ik jou als paranimf bijstaan bij jouw promotie. 
Voor mij was het meteen duidelijk dat jij dezelfde eer zou krijgen bij mijn promotie. 
Tijdens mijn stage bij jou is mijn weggezakte enthousiasme voor het onderzoek 
aangewakkerd, mede door onze werkbesprekingen in de Aesculaaf. Dit heeft 
zeker bijgedragen tot mijn keuze om na mijn studie te kiezen voor een AIO positie.
Beste Renoud, in 1999 begonnen we samen aan de studie scheikunde (Huukske!). 
Via heel verschillende wegen zijn we uiteindelijk beiden terechtgekomen bij lab 
Reuma. Jouw passie naast onderzoek, organiseren, heeft mij ontzettend geholpen om 
vanuit Zwitserland mijn proefschrift af te ronden. Ik wens je veel succes met het afronden 
van jouw proefschrift en wens je een net zo behulpzame paranimf toe.
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kwijt mocht.
De overige collega's: Esmeralda, Wouter, Bas, Genoveva, Lilyanne, Lenny, Twan, Calin, Mieke, 
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Mini neui Arbeitskollegä / mes nouvelles collègues / miei nuovi colleghi, thanks for all your 
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en stimulerende uitspraken!
Lieve Ger en Marion, Frank en Suus bedankt voor jullie interesse en steun de afgelopen jaren. 
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tussen ons. Als trotse oom geniet ik van jullie gezinnetje en wens jullie al het beste voor 
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jij weet precies wat ik nodig heb. Met jouw steun en liefde is werkelijk alles mogelijk, HVJ !
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